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Summary 
 
Malaria is major public health problem in Tanzania and increasing trends have been observed 
in the last two decades. A significant consequence of repeated malaria infections in high 
transmission areas is anaemia in very young children. The control of malaria in Tanzania 
includes both preventive and curative strategies. On the preventive side insecticide treated 
bed nets (ITNs) are a promising tool. ITNs have been shown to be effective in reducing 
malaria morbidity and mortality in controlled trials. Large-scale implementation of the 
technology is currently being initiated in many African countries. We report the impact of a 
large social marketing programme of ITNs on malaria morbidity through a series of studies, in 
a population of about 55,000 people in Tanzania.  
 
The ITNs social marketing programme resulted in a rapid increase in any net ownership (from 
58 to 83%) and an increase in ITNs ownership (from 10 to 61%) in children under two years 
of age within 2 years of implementation. As a result the overall mean haemoglobin levels  
increased (from 8.0 to 8.9 g/dl) in the study children during the successive surveys. The 
prevalence of anaemia in the study population decreased from 49% to 26%. Comparison 
between children with ITNs and those without nets showed that ITNs had a protective efficacy 
of 63% (95% CI: 38 to 77) on the prevalence of parasitaemia, and 63% (95% CI: 27 to 82) on 
anaemia (haemoglobin £ 8 g/dl).  These results endorse the wide scale implementation of 
ITNs in Tanzania.   
 
ITNs can only reduce the risk of malaria disease but cannot eliminate it. Hence, appropriate 
effective treatment is required. Chloroquine is a cheap and safe antimalarial and it was until 
recently the first line drug of choice in the National Malaria Treatment Policy. Resistance to 
chloroquine has been reported with increasing frequency in Tanzania and has been linked to 
the increasing admissions with severe disease in hospitals.  A comparative randomised,  
open clinical trial of chloroquine against Co-artemâ (fixed combination of Artemether + 
Benflumetol) an alternative new antimalarial, showed seven-day parasitological cure rates of 
94% for Co-artemâ and only 35% for chloroquine. Generally, Co-artemâ showed a superior 
clearance rate, successfully cleared higher parasite densities and suppressed new infections 
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over a longer period of time. Furthermore, Co-artemâ suppressed more effectively 
gametocytes in these children, indicating a potential benefit for reducing malaria transmission.  
The unacceptably high chloroquine failure rates call for an urgent review of the National 
Malaria Treatment Guidelines. 
 
The decision to change the first line antimalarial and the choice of a new drug depend on a 
number of factors that include the clinical, epidemiological and social-economical factors, as 
well as the health infrastructure. Considering all of these dimensions, sulphadoxine-
pyrimenthamine (SP) was identified as a good interim replacement for chloroquine. Further 
Phase IV evaluation of Co-artemâ and other combination therapy regimens are required 
before considering their inclusion in the national treatment policy. Much work is also needed 
to identify suitable compounds to be used for home management of malaria, within the 
national treatment guidelines.  
 
Experience gained with these studies gives a description of the different methodologies and 
tools that can be used to evaluate different components of the National Malaria Control 
Programme. For example, it was difficult to assess the impact of the ITNs programme using 
the case-control approach. Repeated cross-sectional assessments were found to be more 
suitable for assessing the impact of ITNs under programme conditions, especially on malaria-
related anaemia in this area of high transmission. Specific indicators for programme 
evaluation may need to be identified for specific interventions. These may be different from 
the ones used in randomised controlled trials. The use of molecular markers for monitoring 
and evaluation of antimalarial intervention programmes illustrate the need to develop and 
validate novel tools and approaches for programme evaluation.   
 
Better malaria control is expected by combining ITNs and an effective antimalarial, especially 
combination therapy. The evaluation, implementation, and monitoring of all these control 
activities requires a partnership between researchers, policy makers, health managers, in 
close collaboration with other stakeholders in the public and private domain, including the 
beneficiaries - the community. 
Zusammenfassung 
 
vi 
Zusammenfassung 
 
Malaria ist ein schwerwiegendes öffentliches Gesundheitsproblem in Tansania. In den 
vergangenen 20 Jahren hat sich ein Trend zunehmender Ausbreitung der Krankheit 
beobachten lassen. Eine symptomatische Hauptfolge wiederholter Malariainfektionen in 
Gebieten mit hohen Übertragungsraten ist Anämie in Kleinkindern. Die Malariakontrolle in 
Tansania umfasst sowohl präventive als auch kurative Strategien. Auf der Seite der 
Prävention haben sich insektizidimprägnierte Bettnetze (IIB) als vielversprechendes 
Instrument erwiesen. In ‚kontrollierten Versuchen’ zeigte die Verwendung von IIB eine 
effektive Reduzierung malariabedingter Morbidität und Mortalität . Ein erweiterter Einsatz 
dieser präventiven Massnahme findet derzeit in zahlreichen afrikanischen Ländern statt.  
Die vorliegende Arbeit zeigt die Wirkung eines grossangelegten sozialen 
Marketingprogramms für IIB auf Malaria Morbidität auf. Eine Serie von Studien in einer 
Population von 55'000 Menschen wurden hierfür durchgeführt. 
 
Das soziale Marketingprogramm in Tansania für imprägnierte Bettnetze hatte in einem 
Zeitraum von 2 Jahren eine rapide Steigerung des Besitzes von Mückennetzen bei 
Erwachsenen (von 58 % auf 83 %) und der Nutzung bei Kindern unter zwei Jahren 
Lebensalter zur Folge. Als Konsequenz hieraus stieg der Gesamtmittelwert des 
Hämoglobinlevels (von 8,0 g/dl auf 8,9 g/dl). Die Prävalenz für Anämie sank in der 
Untersuchungspopulation von 45 % auf 26 %. Vergleiche zwischen Kindern, die mit und ohne 
imprägnierte Netze schliefen, zeigten eine Schutzwirkung der imprägnierten Netze von 63 % 
(95 % CI: 38 bis 77) in bezug auf die Prävalenz von Parasitämie, und 63 % (95 % CI: 27 bis 
82 %) bezüglich der Anämieprävalenz (Hämoglobin > 8 g/dl). Diese Ergebnisse unterstützen 
eine Befürwortung einer grossräumigen Einführung insektizidimprägnierter Bettnetze in 
Tansania. 
 
Imprägnierte Bettnetze können jedoch das Risiko an Malaria zu erkranken nur reduzieren, 
nicht völlig aufheben. Folglich ist eine effektive Behandlung ebenso notwendig wie die 
Prävention. Chloroquine war lange Zeit ein kostengünstiges und sicher wirkendes 
Antimalariamedikament und es war bis vor kurzem das Medikament der Wahl in der 
nationalen Politik der Malariabehandlung. Es ist jedoch in Tansania mit zunehmender 
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Häufigkeit von Chloroquineresistenzen berichtet worden und es wurde ein Zusammenhang 
zwischen Spitalkonsultationen mit schwerer Malaria und Chloroquineresistenzen festgestellt. 
Ein vergleichender randomisierter klinischer Versuch zur Wirkung von Chloroquine und Co-
artem®, einem neuartigen Antimalariamedikament (Kombination aus Arthemether und 
Benflumetol), zeigte nach siebentägiger Anwendung eine Effizienz von 94 % bei Co-artem® 
und nur 35 % bei Chloroquine. Insgesamt zeigte Co-artem® eine höhere ‘clearance rate’, d.h. 
es beseitigte eine höhere Parasitendichte und verminderte Neuinfektionen über einen 
längeren Zeitraum als Chloroquine. Weiterhin unterdrückte Co-artem® die 
Gametocytenbildung in Kindern wirkungsvoller, woraus ein weiterer Nutzen in Form einer 
verminderten Malariaübertragung resultiert. Die nicht akzeptierbar hohe Ausfallrate von 
Chloroquine erfordert eine umgehende Aenderung der nationalen Richtlinien zur 
Malariabehandlung. 
 
Die Entscheidung, ein etabliertes Antimalariamedikament durch ein neues zu ersetzen, hängt 
von vielerlei klinischen, epidemiologischen, sozio-ökonomischen Faktoren, als auch den 
infrastrukturellen Bedingungen ab. Unter in Betrachtziehung all dieser Komponenten wurde 
Sulphadoxine-Pyrimenthamine (SP) als adäquater interimistischer Ersatz für Chloroquine 
identifiziert. Es sind weitere Phase IV evaluationen von Co-artem® und anderen 
Kombinationstherapien erforderlich, bevor deren Einbezug in die nationale 
Antimalariabehandlungspolitik avisiert werden kann. Ebenso sind noch Anstrengungen 
erforderlich um adäquate Präparate zur ‚Heimbehandlung’ von Malaria zu identifiziern und  
sie in den  nationalen Richtlinien  zu verankern. 
 
Die durch die verschiedenen Studien gewonnen Erfahrungen zeigen eine Palette 
verschiedener Methoden und Instrumente auf, die verwendet werden können, um die 
verschiedenen Komponenten nationaler  Kontrollprogramme zu evaluieren. So war es 
beispielsweise schwierig den Einfluss imprägnierter Mückennetze im Rahmen einer ‚Fall-
Kontroll Studie’ zu ermitteln. Wiederholte ‚Querschnittstudien’ erwiesen sich dagegen unter 
Programmbedingungen als geeigneter, v.a. in bezug auf malariabedingte Anämie in Gebieten 
mit hohen Übertragungsraten. Zur Evaluation von Interventionsprogrammen werden 
spezifische Indikatoren benötigt, die sich von denen, die in „randomisiert kontrollierten 
Studien“ verwendet werden unterscheiden. Die Verwendung molekularer Marker für 
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Monitoring und Evaluation von Antimalariainterventionen zeigt neue Wege in dieser Richtung 
auf. 
 
Eine verbesserte Malariakontrolle ist durch die Kombination von imprägnierten Bettnetzen 
und wirkungsvollen Antimalariamedikamenten, v.a. von Kombinationspräparaten, zu 
erwarten. Die Evaluation, das Monitoring und die Implementierung dieser 
Kontrollmassnahmen erfordert Partnerschaften zwischen Forschern, Politikern und 
Gesundheitsmanagern in enger Zusammenarbeit mit anderen Vertretern öffentlicher und 
privater Bereiche, sowie der Bevölkerung. 
 
List of Tables 
 
ix 
List of Tables 
 Page 
 
CHAPTER 5 
Table 1: Characteristics of children surveyed in 3 cross-sectional surveys (1997-1999) 68 
Table 2: Predictors of bed nets ownership  69 
Table 3: Impact of nets on the prevalence of any parasitaemia  71 
Table 4: Impact of nets on prevalence of anaemia  72 
Table 5: Impact of treated nets materials on anaemia in Sub-Saharan Africa  75 
 
CHAPTER 6 
Table 1: Risk factors for being a case of malaria at Idete dispensary  88 
Table 2: Attendance rates for different reasons at Idete dispensary  89 
Table 3: Characteristics of children in Idete village: cross-sectional assessment  90 
Table 4: Risk factors for parasitaemia in the cross-sectional survey  91 
 
CHAPTER 7 
Table 1: Characteristics of mapped and unmapped households in Idete village  103 
Table 2: Characteristics of children living within different coverage areas (C100)  
 in Idete village  105 
Table 3: Risk factors for anaemia (Hb < 8 g/dl) in children in Idete village  106 
 
CHAPTER 8 
Table 1: Demographic and baseline data  128 
Table 2: 7 day and 14 day cure rates  129 
Table 3: Percentage parasite reduction on days 1, 2 and 3  130 
Table 4: Gametocytes on day 0, 1, 2, 3 and 7  131 
Table 5: Haemoglobin levels  132 
 
List of Tables 
 
x 
CHAPTER 9 
Table 1: Patients with microscopically detectable parasites on follow-up days  147 
Table 2: Mean multiplicity of initial infections in patients with recrudescent  
 or new parasites, by treatment group  148 
Table 3: Representative example of infection dynamic with recrudescent  
 and new infections after chloroquine or CGP 56697 treatment   149 
Table 4: Initial geometric mean density in patients with recrudescent  
 or new parasites, by treatment group  150 
 
CHAPTER 10 
Table 1: Comparison of advantages and disadvantagess of three commonly used 
antimalarials   164 
Table 2: Source of antimalarials among 1263 interviewed people  
 from different parts of Tanzania  166 
 
List of Figures 
 
xi 
List of Figures 
 
 Page 
CHAPTER 1 
Figure 1: Distribution of stable malaria transmission  4 
Figure 2: Antimalarial drug resistance –Tanzania 12 
 
CHAPTER 4 
Figure 1: The KINET programme area in Morogoro, Region,south-western Tanzania. 
Shading indicates Phase 1 area (under demographic surveillance).  
 The town of Ifakara is approximately 37 oE and 8 oS.  43 
Figure 2: The logo used for Zuia Mbu brand used by the KINET programme 46 
Figure 3: One of the 3 posters developed for the treated net promotion campaign 50 
 
CHAPTER 7 
Figure 1A: Spatial distribution of houses in Idete village  108 
Figure 1B: Spatial distribution of ITNs in Idete village  109 
Figure 1C: Spatial distribution of parasitaemia in Idete village  110 
Figure 1D: Spatial distribution of anaemia in Idete village  111 
Figure 2: Age specific malaria-parasite prevalence in the Kilombero Valley 114 
 
CHAPTER 8 
Figure 1: Number of patients with positive or negative blood films   133 
 
CHAPTER 9 
Figure 1: Calculated recrudescence rates and new infection rates   151 
 
  
1 
 
 
 
 
 
 
 
 
 
 
PART I : BACKGROUND, OBJECTIVES AND METHODS
Chapter 1: Introduction 
 
2 
 
CHAPTER 1 
 
Introduction: 
 
Burden of Malaria disease 
Malaria is major public health problem in the world. In 1997, more than 40% of the world 
population lived in areas with a risk of malaria trasmission. Furthermore, in the last few 
decades there has been a resurgence of malaria transmission in areas where it was 
previously under control in the Central Europe, Southern Asia and the Pacific (Trigg & 
Chondrachine 1998). Malaria contributes to a considerable burden in endemic communities 
with premature deaths, disability from illness and it impedes on social and economic 
development. Each year about 300 million episodes of clinical malaria disease and about one 
million malaria deaths occur in the world (WHO 1999). 
 
The majority (90%) of the burden of disease is in Sub-Saharan Africa. It is estimated that 
malaria contributes to a loss of 39 million disability-adjusted life years (DALYS), of which 34 
million are in Africa alone (WHO 1999). The problem of malaria is also increasing in Africa. In 
parts of Eastern and Southern Africa malaria has extended into previously non-endemic or 
low transmission areas. The climatic conditions existing in many parts of Sub-Saharan Africa 
favour high malaria transmission potential (Snow et al. 1999).  Furthermore, Plasmodium 
falciparum is the predominant parasite species, and it is associated with high virulence, 
severe morbidity and high mortality.  
 
In Tanzania, malaria accounted for about 33% of all outpatient attendance and hospital 
admissions in 1996 and it is the leading cause of deaths (34%) in hospital admissions in 
children under five years (MOH 1998). Health facility reports indicate that there are an 
increasing number of admitted cases of malaria since 1982 (Kilama & Kihamia 1991, MOH 
1998). Reliable data on mortality burden caused by the disease are not available as most 
deaths occur at home and there is no adequate vital event registration system in place 
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(Kitange et al. 1996, Snow et al. 1999). Demographic surveillance data from Morogoro rural 
district indicate that malaria is a major cause of death in children and even among adults 
(Kitange et al. 1996).   
 
Plasmodium falciparum is the main parasite species in Tanzania and it accounts for more 
than 90% of all infections. Other malaria species found are P. ovale and P. malariae. These 
frequently occur as mixed infections with P. falciparum . P. vivax is very rare in Tanzania 
(Kilama & Kihamia 1991). 
 
Malaria transmission in Tanzania has been described by Clyde (1967) as a sea of stable and 
high transmission with islands of low or no transmission, especially at high altitudes (Fig1). 
Estimates of population at risk in Tanzania indicate that 28 million people live in malaria 
endemic areas, 1.3 million in epidemic malaria areas and only about 0.6 million in very low 
risk areas (MARA/ARMA: http: /www.mrc.ac.za/maracrt). The main vectors are Anopheles 
gambie complex and Anopheles funestus . The climatic and environmental factors favour the 
existence of an abundance of these vectors resulting in high vectorial capacity for malaria 
transmission. This makes malaria control difficult in many areas of Tanzania.   
 
The burden of malaria and the consequence of the disease in the health of the population has 
been characterised in detail in an area in the Kilombero valley, Southwest Tanzania (Tanner 
et al. 1991). It has been estimated that on average there are about 0.7 and 0.6 episodes per 
child per year of clinical malaria and severe anaemia in children under five years living in the 
area (Menendez et al. 1997) . 
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Figure 1:  Distribution of stable malaria transmission in Tanzania 
  (source: MARA/ARMA Collaboration) 
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It is widely accepted that transmission intensity influences the prevalence and incidence of 
malaria infection and associated complications. Severe anaemia and cerebral malaria are the 
two major forms of severe disease leading to death. It has been observed that in areas of 
lower transmission the incidence of clinical disease is much more spread out in early 
childhood and cerebral malaria predominates as severe disease presentation. In areas of 
high transmission, the burden of morbidity and mortality is concentrated in the very young 
children and is much less in older children and adults. This is due mainly to early acquisition 
of functional immunity to clinical disease.  In these areas severe anaemia predominates as 
the severe disease presentation (Marsh & Snow 1999, Schellenberg et al. 1999). These 
differences in cerebral versus anaemia patterns may therefore be important in monitoring 
changes of transmission intensity over time and may be valuable indicators for assessing 
impact of control measures. 
 
Several studies have shown a positive correlation between parasitaemia and anaemia, and 
further demonstrated that parasitaemia is the primary cause of anaemia in very young 
children in Africa (Kitua et al. 1997, Newton et al. 1997). The pathogenesis of malarial 
anaemia is complex and includes the process of haemolysis, sequestration of red cells, and 
dyserythropoiesis (Weatherall & Abdalla 1982). Malarial anaemia may develop rapidly 
following an acute malaria attack or may develop insidiously over a period of time; many 
patients fall in between these two extremes (Abdalla et al. 1980). 
 
 The emergence and spread of parasite resistance to commonly used antimalarials has 
exacerbated the problem of anaemia in Sub-Saharan Africa, since persisting parasites 
contribute to the occurrence of anaemia (Bloland et al. 1993). In the Kilombero, 60% of 
children treated with chloroquine (the recommended first line antimalarial), fail to respond 
within 14 days (Hatz et al. 1998). Hospital management of the severe forms anaemia involves 
blood transfusion (Newton et al. 1997 , Schellenberg et al. 1999) and there is an increasing 
concern that the transfusions are a potential risk for HIV transmission in children (Greenberg 
et al. 1988 , Holzer et al. 1993). In addition, most children at risk of severe anaemia live 
beyond reach of hospitals able to provide such blood transfusions (Font & Nathan, 
unpublished data). Furthermore, severe anaemia is a silent disease that is less recognised in 
the community and therefore not easily treated (Menendez et al. 1997). Hence, there is an 
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urgent need to implement effective malaria control strategies in the Kilombero valley and 
Tanzania as whole. 
 
Malaria control strategies 
The World Health Organisation (WHO) has identified malaria as a priority health issue in the 
world and initiated the Roll Back Malaria Cabinet Project (RBM) in 1998. In this new initiative 
the WHO, United Nations Children’s Fund (UNICEF), United Nations Development 
Programme (UNDP), World Bank (WB) and various collaborators join forces to fight malaria. 
RBM aims at achiving a 50% reduction of the malaria burden by 2010. The initiative has 
identified six elements to achieve the objective: (1) early detection of malaria illness, (2) rapid 
treatment of those who are ill, (3) multiple means for prevention of infection, (4) strengthening 
of health sector and intersectorial activities, (5) a powerful sustained social involvement and 
movement, and (6) focused research for new tools and better implementation (Nabaro 1999). 
These main elements are an elaboration of the basic elements of the global malaria control 
strategy devised in 1993. The main strategy for malaria control is still early diagnosis and 
treatment of clinical cases (WHO 1993). Since, the increasing incidence of antimalarial drug 
resistance is undermining the effectiveness of this strategy, alternative cost-effective and 
sustainable control measures are urgently required. 
 
Malaria prevention strategies in Tanzania  
Environmental modification to control the scourge of malaria in Tanzania has a long history. In 
the 50’s several programmes were implemented in the more populated urban areas (mainly 
Dar-es salaam and Zanzibar). But this is only feasible in urban areas and requires functional 
administrative and implementation structures (Kilama 1991). People in urban areas use 
several mosquito repellent measures, including aerosol insecticides and mosquito coils. In 
rural areas those who can afford use these insecticides and many more use more traditional 
preventive measures, such as burning of leaves. These mosquito repellent measures have 
doubtful benefits in preventing malaria. In semi-immune population chemoprophylaxis  with 
effective antimalarials is only recommended for pregnant women (WHO 1984). 
Chemoprophylaxis in children is not recommended for fears of interference with the 
development of protective immunity and the acceleration of drug resistance. Furthermore, it 
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may be impossible to achieve continuous suppression in a significant proportion of the 
population and it may then be better to use the scarce resources for treatment. Malaria 
vaccines will go a long way in reducing the burden of malaria in people in endemic areas, 
especially children. However, there is limited hope for a vaccine in the near future. A recent 
trial of SPf66 in infants in Tanzania did not show any protection (Acosta et al. 1999). 
 
Vector control by insecticides has been implemented in both urban and rural areas in 
Tanzania. In rural areas, the Pare-Taveta project in Northeast Tanzania was the most 
elaborated control effort. Spraying of households was conducted from 1955 to 1959 and the 
impact of these control measures was monitored (Bradley 1991). Both urban and rural 
spraying programmes were successful in reducing the burden of malaria in short periods. In 
the Pare-Taveta project, the infant mortality rate was reduced by about 20% and haemoglobin 
levels increased about 26% during the intervention period, compared to before the 
intervention (Bradley 1991). Unfortunately, problems in sustaining the spraying in these areas 
clearly demonstrated the difficulties of such a strategy.  The programmes required high 
financial and human resource inputs, which could not possibly be maintained. These were 
mainly “vertical” programme with specialised spraying teams and had limited community 
involvement, hence there was also a growing reluctance of the population to co-operate with 
the spraying activities. Although transmission was significantly reduced in the programmes, it 
was not interrupted.  
 
Currently, preventive malaria control is being re-considered using insecticide treated nets 
(ITNs), including treated bed nets and curtains, which do not require a large national 
programme infrastructure for implementation. Studies in Muheza indicate that ITNs have 
similar efficacy to indoor spraying and are cheaper to implement (Curtis et al. 1998). 
 
ITNs in Tanzania 
The use of protective measure similar to bed nets can be traced to traditional behaviours in 
some tribes in Tanzania. Examples are the use of ‘MTUTI’, a sleeping bag made of thatched 
palm leaves in the Rufiji delta (Mayombana et al. unpublished data) or the use of nets made 
of cloth ‘baba kalala wapi’ in the Kilombero Valley (Minja H. pers. Comm). Only a small 
proportion of people in the Kilombero Valley used bed nets in the 1980’s and early 1990’s 
Chapter 1: Introduction 
 
8 
(Fraser-Hurt & Lyimo 1998). The main reason for using bed nets in this setting was protection 
against mosquito nuisance rather than protection against malaria disease.  
 
The treatment of these bed nets with insecticide is a revival of an old idea that was started in 
the Second World War with the treatment of soldiers’ uniforms to prevent malaria and other 
vector borne diseases (Lindsay & Gibson 1988). The ITNs act by both being a physical barrier 
protecting those sleeping under them, and by killing and repelling mosquitoes hence reducing 
their survival and infection rates (Lines 1996). Hence those using ITNs properly have a 
reduced exposure to malaria infecting mosquitoes and as a consequence have a reduced 
malaria disease burden. Different types of insecticide on the net have been shown to have 
slightly different killing and repellency effects although they mostly belong to the class of 
synthetic pyrethroids (Curtis et al. 1996) 
 
After the initial success in experimental hut trials (Lines et al. 1987) and small scale studies, 
large trials were implemented in Tanzania as in many other parts of Africa (Premji et al.. 
1995). Large randomised controlled trials were also conducted in many parts of Africa to 
establish the efficacy of ITNs in reducing morbidity and mortality. A summary of the results of 
these randomised controlled trials showed an average protective effect on mild malaria 
episodes of 46% in stable malaria areas when controls did not use nets, and a protective 
effect of 37% when controls used untreated nets. Moreover, protective effects were shown on 
the prevalence of high parasitaemia (31%). A modest improvement in packed cell volume 
(2%) and weight gain was also observed in children sleeping under treated nets (Lengeler, 
1998). Most importantly, the regular use of ITNs under trial conditions prevents approximately 
6 deaths for every 1000 children protected every year across a large range of transmission 
intensities. Hence, there was a recent call by African leaders to protect 60% of African 
children by 2005 and large-scale pilot programmes are underway in several areas in Africa 
(Anonymous 1999).  
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ITNs implementation strategy 
The translations of promising research results into effective public health action, is a huge 
task. There are at least 60 million children living in areas at risk for malaria in Africa and their 
nets, once provided, will need to be treated regularly (every 6-12 months) over many years 
(although there is currently hope for development of permanently treated nets). Various 
options for financing and implementation of ITNs have been tried, most of them on a relatively 
small scale (up to 10 villages). There are three main traditional implementation models 
(Feilden 1996): (1) the integration of ITNs distribution into a community pharmacy network 
(eg. the Bamako initiative programme in western Kenya: Hill (1991)),  (2) sales through local 
health units (eg. Fraser-Hurt and Lyimo 1998) or the existing PHC system (D'Alessandro et al. 
1995), and (3) distribution through community groups (eg. Premji et al.  1995). Despite these 
various programmes which contributed much useful operational experience, we do not yet 
have sufficient experience to recommend specific large-scale ITNs implementation strategies 
for all the varied social, cultural and economic conditions in Africa. Hence, launching a 
number of large programmes (population of over 100,000) using different pragmatic 
approaches will allow locally-relevant implementation approaches to be found. 
 
Social marketing is a flexible implementation model that has proved successful in resource-
poor countries for interventions such as oral rehydration salts (ORS) and condoms.   In this 
approach commercial marketing methods are applied to a product which has a social benefit, 
with the main motivation being social improvement rather than financial gain to the marketer 
(Andreasen 1986, BASICS 1998). Much attention is paid to the main target group (i.e. for 
malaria: children and pregnant women) and much effort goes into understanding the 
perception, knowledge, attitudes and practices of this group in order to optimise promotion 
and distribution. Social marketing entails an effective public -private partnership which may be 
particularly useful for ITNs: unlike drugs and vaccines, ITNs may be seen as a commercial 
commodity rather than a medical product. Social marketing of ITNs has recently been started 
in various African countries, for example the Central African Republic (in 1996), Tanzania, 
Rwanda, Kenya and Zimbabwe.  
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Lastly, the social marketing programmes are also not large enough to allow coverage of 
whole countries. Hence, different strategies for up-scaling the implementation to national 
scale need to be developed involving public-private partnerships. 
 
Impact of ITNs under programme conditions 
It is still unclear whether social marketing can be used to distribute ITNs in the community 
while retaining the benefits of the nets seen in randomised control trials.  Usually one can not 
assume that the results of the controlled trials are directly translated or replicated in 
programme settings (Lengeler & Snow 1996). Experience with the Gambian national bed net 
programme that concentrated on treatment of already available bed nets showed that the 
coverage, compliance and percentage re-treatment of the nets were well below the level 
achieved in an earlier controlled trial. The estimated impact on overall mortality was only 25% 
(D'Alessandro et al.1995) as compared to 42% in the earlier controlled trial (Alonso et al. 
1991).  
 
Moreover, it is not known what impact the pattern of distribution will have on the occurrence of 
disease in the community.  Earlier work indicated that there are short range (within the same 
room) protective effects of ITNs on unprotected people sleeping nearby (Lines et al. 1987) but 
this has not been shown everywhere (Rowland et al. 1996). Work conducted in Ghana 
supports the claims of short distance protective effects on those without bed nets. Among 
non-users the mortality risk increased by 6.7% with every 100 meters shift away from the 
nearest compound with treated bed nets (Binka et al. 1998). More recent work in Kenya 
indicated the presence of a ‘mass effect’ due to ITNs that confers protection to nearby non-
users. While this spatial phenomenon is very important from the public health point of view, it 
also has bearing on the estimated effectiveness of ITNs in programme evaluations. If 
deflection of mosquitoes to those without ITNs occur, with a resulting increase of disease in 
this group (Rowland et al. 1996), then there will be an overestimation of the protective 
effectiveness. On the other hand, if the killing effect is predominant with a reduced risk for 
those near the ITNs (Lines et al. 1987) then the measured effect will be biased toward zero, 
as has been demonstrated in some areas (Binka et al. 1998, Howard et al. 2000). Further to 
these distance effects, coverage was also shown to be an important parameter as the efficacy 
was observed to be highest with high compliance. The distribution pattern and coverage 
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levels attained in these programmes may determine the level of protection observed in those 
who use them (Binka et al. 1998) 
  
 
Treatment of uncomplicated malaria in Tanzania 
The use of ITNs as a preventive measure is not going to interrupt transmission in many of the 
areas in Africa and therefore cannot eliminate the need for effective treatment of cases. 
Indeed after the collapse of the few major preventive programmes in the 1950 and 60’s, early 
diagnosis and prompt treatment with an effective antimalarial was adopted as the main stay of 
the control effort in most African countries (WHO 1993). However, the implementation of this 
strategy also faces many challenges. Most people who fall sick with malaria-like symptoms 
are given antimalarial drugs stored at home and frequently in sub-optimal or incorrect drug 
dosage (Mwenesi et al. 1995, Nyamongo 1999, Nsimba et al. 1999). Many factors contribute 
to the preference for shops and drug stores rather than existing health services. These 
include lack of drugs in public sector facilities and convenience. There are more shops and 
drug stores than health facilities, and they may be more easily accessible, in terms of time to 
reach them, time spent waiting for service, and opening times.    
 
There are concerns that the wide scale use of antimalarial drugs encourages the 
development and spread of Plasmodium falciparum resistance and threatens the 
effectiveness of the early diagnosis and treatment strategy in many parts of the world. 
Resistance to chloroquine, the cheap and safe antimalarial, has been reported with increasing 
frequency in Tanzania (Kilimali & Mkufya 1985a, 1985b, Mshinda et al. 1996). Work 
conducted as part of the National malaria control programme, showed that on average half of 
the children treated with chloroquine ended up with inadequate clinical response within 14 
days (Figure 2). The work also demonstrated the presence of resistance at a lower level of 
the second line drug Sulphadoxine/pyrimethamine (MOH 1999). 
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When treatment is not successful, patients often look for alternatives. For malaria, 
treatment-seeking behaviour patterns vary a great deal, with constant interchange 
between formal and traditional providers.  Studies in Ifakara and Rufiji found that only a 
quarter of the mothers and caretakers came back for  re-treatment, if there was no 
improvement after initial treatment at a formal health facility (Bjorkman 1991, Muela-
Hausmann et al. 1998). Treatment failure increases the risk of development of complicated 
malaria, with convulsive episodes in children or severe anaemia.  
 
Perceptions of malaria disease severity vary and they reflect the perceptions of 
effectiveness of different treatments and services (Snow et al. 1992, Mwenesi 1995, 
Nsimba et al. 1999). Convulsive illness (degedege) is often regarded as a separate 
disease, for which traditional healers are considered to be a superior source of care 
(Makemba et al. 1996, Mwenesi et al. 1995, Minja et al. 2000). Perceptions of disease 
causation are of significance also for uptake of other interventions including ITNs (Minja et 
al. 2000). 
 
Different levels of health care necessitate the consideration of the choice of drugs to be 
promoted at particular level. The wide availability of chloroquine for home treatment was 
advantageous in facilitating early treatment but its indiscriminate use has lead to rapid rise 
of resistance. The reliance on presumptive treatment rather than diagnostic microscopy at 
dispensary level, and the use of diagnostic strategies such as those of the Integrated 
Management of the Childhood Illnesses (IMCI) have clear benefits in terms of ease and 
cost of implementation. But they also increase drug pressure and the risk of resistance 
developing in the drugs being used. Together all these factors make it necessary to 
develop new alternative drugs and evaluate the optimal strategies for their introduction in 
the community.  
 
Evaluation of the Control tools and programmes: 
The description of the main malaria prevention and treatment strategies given above, 
highlights the continued need of developing and testing new tools and strategies to combat 
the increasing problem of malaria in many parts of Africa. On the preventive side, this will 
involve the development of new tools like malaria vaccines, which will take some time to 
accomplish. The curative side will involve the identification of new drug targets, as the 
current armoury of antimalarial drugs are based on very few targets in the parasite 
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(Winstanley 2000). Once these tools have been identified, rigorous testing of the identified 
compounds or tools should be done, to demonstrate their safety and efficacy in humans.  
 
Thereafter, operational research to explore better ways of introducing the intervention in 
the community should be carried out. With ITNs much effort had gone into try out different 
delivery channels, as described above. Previously, much emphasis has been laid on the 
demonstration of efficacy of interventions in randomised controlled trials. Once efficacy 
was demonstrated the interventions were implemented in large programmes. Recently, 
more emphasis has also been laid on demonstrating that the expected benefits of the 
intervention are realised when the interventions are delivered in a programme setting 
(Lengeler & Snow 1996, Habicht et al. 1999). These evaluations aim to encourage the 
allocation of resources to sustain and expand the programmes to cover whole populations 
in endemic countries (Bryce et al. 1994 , Lengeler & Snow 1996) . The programme 
evaluations are further complicated by the fact that in most situations it is not possible to 
have a proper control group. Also there is often limited opportunity for establishing an 
elaborate evaluation system that is required to accurately assess exposure and outcome 
events in the target population (Habicht et al. 1999, Mohr 2000) . Therefore, relatively 
cheap and easy evaluation tools are required. 
 
Summary  
A large part of Tanzania has high malaria transmission and the burden of disease is 
increasing. The disease is concentrated in young children and frequently presents as 
malaria anaemia, especially in very high transmission areas. The emergence and spread 
of drug resistance are undermining the current strategy of early diagnosis and treatment. 
Therefore there is an urgent need to investigate and evaluate new appropriate tools for the 
control of malaria in Tanzania. This thesis describes a series of studies conducted in the 
Kilombero Valley to assess the value of a new preventive tool (insecticide treated nets) 
and a new curative tool (Co-artem®) to combat malaria. These studies also explored 
issues on the design and methodologies for the evaluation of malaria control. Lastly, the 
experience gained from this work is used to highlight the many factors that influence the 
translation of research results into public health policy.  
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CHAPTER 2 
 
Goal and objectives 
 
Goal 
To evaluate the value of preventive (insecticide treated nets) and curative (Co-artemâ) 
interventions in reducing malaria morbidity in an area of intense perennial malaria 
transmission. 
 
Objectives: 
 
§ To determine the effect of insecticide treated nets on anaemia (Hb below 8 g/dl) in 
children under two years of age living in the IC-KINET DSS area by means of annual 
cross-sectional surveys. 
 
§ To determine the effectiveness of insecticide treated nets in reducing mild malaria 
episodes in children aged under five years in one village in the Kilombero Valley by 
means of cohort and nested case-control studies. 
 
§ To compare the performance of a case-control versus a cross-sectional approach for 
assessing the impact of insecticide treated nets in reducing the malaria morbidity in 
children under five years of age in one village in the Kilombero Valley. 
 
§ To determine the effect of spatial patterns of distribution of insecticide treated nets on 
malaria morbidity in children under five years in one village in the Kilombero Valley. 
 
§ To determine the efficacy of the new antimalarial Co-artemâ compared to chloroquine 
in the treatment of uncomplicated malaria in children under five years of age. 
 
§ To investigate issues and determinants that are important in the development of a 
national antimalarial treatment policy.  
Chapter 3: Design and Methods 
22 
CHAPTER 3 
 
Design And Methods 
 
Study area and population: 
The flood plains of the Kilombero river extend 250kms from Southwest to Northeast, and 
are bordered by the Udzungwa range of mountains in the Northeast and Mahenge 
Mountains in the Southeast. Alluvial soils that are flooded every year support grassland 
vegetation. Diverse ethnic groups inhabit the plains and the majority are either subsistence 
farmers cultivating rain fed rice, maize cassava and/or fish from the Kilombero River and 
its tributaries. Several studies have been done to describe the disease patterns and 
assess their impact on health indicators of the communities living in these areas (Tanner 
et al. 1987, Tanner et al. 1991). These studies identified malaria and malarial-anaemia as 
a major public health problem in this area of high malaria transmission (Tanner et al. 
1987).  There is intense year-round malaria transmission (Charlwood et al. 1998). On 
average every person receives above 300 infective bites per year (Smith et al. 1993). The 
main vectors are Anopheles gambiae ss, Anopheles arabiensis and Anopheles funestus. It 
has been estimated that on average there are about 0.7 and 0.6 episodes per child per 
year of clinical malaria and severe anaemia in children under five.  The main malaria 
control measure is prompt diagnosis and treatment of clinical cases. Chloroquine is still the 
first line antimalarial and its consumption is high. There are reports of rising chloroquine 
resistance in the area with only 80% of children responding to treatment within 7 days  
(Mshinda et al. 1996). Further detailed studies where conducted in Idete village (08o 5’ S; 
36o 30’ E), which has features representative of the rural villages in the valley. The village 
is one of 18 in the Kilombero valley under demographic surveillance (DSS) (Schellenberg 
et al. 1999). 
 
Social marketing and distribution of nets 
The Kilombero bed net project (KINET) was implemented in the Kilombero valley using a 
social marketing approach and aimed to promote and distribute insecticide treated nets and 
insecticide for net treatment on a large scale. “ZUIA MBU” branded nets and insecticides 
were sold and distributed in the community using public and private distribution channels, 
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and a system of community door-to-door distributors. The implementation was staggered, 
with the first phase involving 18 villages. The implementation was expanded progressively to 
cover the whole of the two districts by the end of 1999. Planning and progress meetings 
involving project staff, district authorities and experts were held regularly during the period of 
implementation. 
 
Demographic surveillance 
The health impact assessment was restricted to the 18 villages located in the phase one 
area. In order to facilitate the evaluation of morbidity and mortality a demographic 
surveillance system (IC-DSS) was established. The system was adapted from the 
Navrongo demographic surveillance system (Binka et al. 1999). The IC-DSS covers 18 
villages in the Kilombero Valley: 6 in Kilombero District and 12 in Ulanga District.  The 
system involves visiting every household in the 18 villages once every 4 months. During 
these visits demographic and vital events like births, deaths and migration, are recorded in 
a household record book (HRB). The information is then entered in a relational data-base 
at the Ifakara Health Research and Development Centre (IHRDC) data unit. Using this 
system the study area was assessed to have approximately 55,000 residents and 3533 
children under two years of age in 1997. 
 
Passive case detection at Idete dispensary 
For detailed morbidity assessment a passive case detection system (PCD) was 
established at Idete village dispensary. All children in the DSS database who were under 
the age of five on 1st February 1998 were listed, assigned a study number and provided 
with a special card bearing their name, date of birth, area of residence and DSS identifiers.  
This list was updated every 6 months to include new-borns and those children who had 
migrated into the village and who were therefore classified as new residents in the DSS. 
Children under five who were sick or had a history of illness were seen at the dispensary 
by a Rural Medical Aide. A clinical form was filled and information was entered in a 
database at the IHRDC data unit. The diagnosis, laboratory results and medication given 
were also written on the patient cards. The drug supply and services at the Idete 
dispensary were improved as part of the project to reduce the need of children to seek 
care elsewhere. 
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Case-control study   
Using the PCD at Idete dispensary, a case control study was done between February 
1998 and August 1999, to assess the impact of ITNs on mild malaria episodes. Children 
who were found to have a temperature of more than 37.4 OC and any parasitaemia were 
classified as cases.  Children who had signs and symptoms of severe disease (e.g. 
haemoglobin <5.0 g/dl) were excluded from being cases. 
 
For each case, one age-matched dispensary control was randomly chosen among the 
children who had come for growth monitoring or attended for another cause of disease, 
within two weeks of the attendance of the case. Separate records were kept for all the 
children who were not sick and had attended for growth monitoring. An additional 
community control was randomly chosen from the DSS database matched for age and 
area of residence (hamlet). If a control could not be found, then a child of an adjacent 
hamlet was chosen. Age was matched to within one month for infants, within two months 
for those between 12 - 24 months of age, and within 3 months for those above two years. 
A special Foxpro program was written and was run every week to identify cases and 
controls from the PCD, MCH attendance and DSS databases.  
 
Both cases and controls were then visited at home, individual verbal consent was sought 
from the guardian and a questionnaire applied. The use of ITNs and other risk factors was 
assessed, including age of the child, tribe, religious affiliation, mother’s education, family’s 
social economic status, nutritional status, vaccination status, access to clean water, 
antimalarial and antipyretic use, condition of the net and its use in the previous month.  A 
blood sample was taken from controls who had not given a blood sample at the dispensary 
in the two weeks prior to the day of the interview. Cases and controls were not eligible for 
re-recruitment as either cases or controls for a period of one month.  
 
The sample size was calculated using Epi Info 6 for an unmatched design (matched 
designs need slightly fewer numbers). The sample was estimated to be able to show a 
40% effectiveness against mild malaria episodes (summary estimate is about 46% from 
controlled trials (Lengeler 1998)), assuming a 30 % use of ITNs in the control group, five 
percent significance level and 90% power, giving a total of 454 cases. The sample was 
increased by 10% to allow for incomplete information and refusals, giving a total of 
approximately 500 cases to be recruited in one year. We used a concurrent sampling 
design, i.e. a case could be a control latter, and vice versa. The incidence of clinical 
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episodes of malaria was estimated to be 0.92/child/ year in children aged 12-30 months in 
Idete (Alonso et al. 1996). It was expected that the incidence rate would be slightly higher 
when taking children below 24 months.  
 
Cross-sectional surveys 
The impact of ITNs on the prevalence of parasitaemia and anaemia was assessed using 
annual cross-sectional surveys. Three annual cross-sectional surveys where conducted in a 
sample of children under two years of age living in the DSS area (Schellenberg et al. 1999). 
The first survey was done at the time of launching the social marketing campaign in June 
1997, and two other surveys were carried out at the same period (June to August) in the 
subsequent two years. This period also coincided with the end of the rainy season when 
malaria anaemia is most prevalent (Kitua A. pers. Comm). 
 
A simple random sample was selected from the DSS database for the first survey, and a two-
stage random sampling (sampling 6 villages then sampling children from these) was done for 
the subsequent surveys. Children from Idete village and Kivukoni were not included in the 
subsequent surveys due to participation in other studies. The demographic surveillance data 
provided the sampling frame. For each year a different sample of children was selected from 
the database.  
 
The sample size for the baseline (1st year DSS cross-sectional) was calculated using Epi-6 
to get a sample which could estimate the proportion of children with haemoglobin below 8 
g/dl  to within +/- 2.5% (SE). Estimates from a study in the village of Kiberege (Fraser-Hurt et 
al. 1999) showed that the proportion of children with anaemia (Hb below 8 g/dl) was 30% for 
those without nets. Assuming a 95% confidence level and 2.5% standard error for the 
estimate, 296 children were required. Adding 10% more to account for refusals and non-
availability a total of 325 children was sampled. For the subsequent DSS cross-sectional 
surveys, a review of the sample size was done taking into consideration the prevalence of 
anaemia, as estimated from the baseline survey, and the clustering of sampling. The sample 
size was calculated to estimate a 30% difference in the proportion of anaemic children 
between those who use ITNs and those who don't, assuming a 95% confidence level and 
80% power.  330 children were sampled for each subsequent survey.  
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All the sample children were traced at home, consent from the parent or guardian requested, 
a questionnaire applied, clinical examination and anthropometric measurements performed, 
and a blood sample was taken for microscopy and haemoglobin estimation, as described 
below. 
 
One cross-sectional assessment was also done in Idete village in June-August 1998. All 
children who were under-five years of age on 1st February 1998 were visited at home and 
a questionnaire applied to assess their use of ITNs and other risk factors for malaria 
infection and anaemia (similar to the main cross-sectional surveys). A blood sample (for 
malaria parasites and Hb estimation) was taken for children who had not given a blood 
sample at the dispensary during the two weeks prior the day of the interview.  
 
Mapping of houses in Idete 
The distribution patterns of the ITNs and the effect of high coverage of ITNs was 
investigated in Idete village.  The position of the houses and other important service 
outlets including the dispensary were later determined using a portable Global Positioning 
System (Garmin, Thousand oaks, USA). The geo-referenced points were then used to 
calculate the distance between houses and between the houses of residence and the 
dispensary. Demographic data was collected from the updated DSS database. 
 
Spatial positioning of events and variables was done by linking the mapped households 
with data from the PCD and Idete cross-sectional survey. Coverage of ITNs and untreated 
nets were calculated for each individual child during the cross-sectional survey. The 
number of nets per 1000 population living in houses other than the index child and within a 
specific radius were calculated. The radii of 50m (R50), 100m (R100), 200m (R200) and 400m 
(R400) were chosen considering the indication from studies done elsewhere (Binka et al, 
1998; Hii et al. 2000). Further coverage was categorised as low (0 ITNs/1000 persons), 
moderate (1-300 ITNs/1000 persons) and high (>300 ITNs per/1000 persons) 
 
Clinical trial of Co-artemâ  
The comparative efficacy of Co-artemâ (Artemether + Benflumetol: CGP 56697) and 
chloroquine was assessed in a clinical trial at the 'mother -and-child' out-patient clinic at St 
Francis District Designated Hospital between February 1996 and September 1996 (Hatz et 
al. 2000). Inclusion criteria for selection were: age 1-5 years; body weight >5kg; 
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microscopically confirmed P.falciparum infection, with parasitaemia >5,000/µL blood; fever 
(axillary temp ³37.5oC); living within 5 km of trial site; feasibility of participation and 
informed consent; not participating in any other trial. Exclusion criteria were parasitaemia 
<5,000/µL; absence of fever; intolerance to oral medication; signs/symptoms of 
severe/complicated malaria; severe malnutrition or kwashiorkor; history of other 
antimalarial drugs within 48 hours; known sensitivity to chloroquine; any known chronic 
underlying disease.  
 
Eligible children were randomised to receive either Co-artemâ or chloroquine. The children 
in the Co-artemâ treatment group received 4 doses of paediatric tablets at 0, 8, 24 and 48 
hours.   Trial medication for each child was contained in an individually numbered blister 
pack. Children were assigned treatment upon presentation by allocating the blister pack 
with the lowest available number.  The contents (chloroquine or Co-artemâ) were allocated 
randomly in blocks of 6. Each paediatric Co-artemâ tablet contained 10mg artemether + 
60mg benflumetol (½ the adult tablet level) and 1, 2, 3 or 4 tablets were given at the 4 
dosage times according to body weight (5-10kg body weight, 4 doses of 1 tablet; 10-15kg, 
4 doses of 2 tablets; 15-20kg, 4 doses of 3 tablets; 20-25kg, 4 doses of 4 tablets).  
Children in the chloroquine treatment group similarly received 4 doses over 3 days, 
according to body weight at 25mg per kg body weight as follows: 5-10 kg: ½ tablet, ¼ 
tablet each dose; 10-15kg: ¾ tablet, ½ tablet each dose; 15-20kg: 1 tablet, ½ tablet each 
dose; 20-25kg: 1½ tablets, ¾ tablet each dose (each tablet contains 150 mg chloroquine 
base).   
 
Children were then visited at home for the first 3 days to administer medication and 
monitor side effects.  There were then  followed up at the clinic on day 7,14, 21, 28. 
Clinical examination and screening for malaria parasites was done during follow-up. 
 
Interview and clinical procedures 
A medical officer (the author) saw all study children in the main DSS cross-sectional 
surveys and the Co-artemâ trial. A Rural Medical Aide using similar procedures saw 
children who were sick or had a history of illness when attending Idete dispensary, as well 
as those included in the cross-sectional survey in the village. All parents/guardians were 
asked for consent for children to participate using information sheet prepared specifically 
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for each study. History of illness was recorded using standard forms at the clinic for each 
study.   
 
A standard questionnaire was applied to all children visited at home and who participated 
in all the cross-sectional surveys and the case control study in Idete. A questionnaire was 
used to assess exposure to treated bed nets and other potential risk factors. These factors 
included antimalarial treatment, anthropometric measurement, socio-economic status, 
tribe, religion, travel outside study area, illness in the previous month, history of blood 
transfusion, educational status, fostering and net usage. 
 
All study children had their axillary temperature checked with an electronic thermometer. 
Weight was measured with a hanging scale and height measured with a special tape with 
the child lying down for those under two, and with child upright for those over two years. 
Physical examination was done with the child on the mother’s lap. Splenomegaly was 
palpated on the mother’s lap for those children below 2 years of age, and in an upright 
position for those above 2. Splenomegaly was recorded as palpable or not. Information on 
any other abnormalities was recorded. Finger prick blood samples were made with sterile 
lancets and drops of blood were collected on slides, Hemocueâ micro-cuvette and a 
microtainer. 
 
Treatment of sick children was done following the normal good clinical practice procedures 
of the hospitals in Kilombero and Ulanga Districts. Children with Hb below 8 g/dl were given 
haematenics, folic acid 5 mg once a day for three weeks, and ferrous sulphate 200 mg once 
a day for three weeks. For the home visits, the attending clinical officer treated sick children. 
In the main cross-sectional survey, asymptomatic children with parasitaemia above 2000 per 
microliter were traced and given a standard dose of chloroquine or 
sulphadoxine/pyrimethamine (SP). 
 
Assessment of parasitaemia 
Thick and thin films were stained with Giemsa stain.  All blood films were read twice, 
independently, with the microscopist not knowing the intervention status (either bed net or 
drug treatment) of the child, and a third time if the ratio of densities from the first 2 
exceeded 1.3 or was less than 0.67, or if one was positive and the other negative.  A 
definitive result was based on a majority verdict for positivity and the geometric mean of 
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the 2 closest positive density counts (Alonso et al.1994). 20 thick film fields were examined 
before the slide was declared negative.  If asexual forms of P. falciparum were found, then 
200 thick film fields were screened for the presence of malarial parasite species.  
Identification of P.falciparum was followed by a tally counter count of asexual forms and 
leucocytes. Present gametocytes were counted similarly. A peer review of 282 slides was 
done. There was a 87% agreement in terms of negative/positive results between the 2 
counts.  
  
Measurement of haemoglobin 
 Haemoglobin was measured using the HemoCueâ system (HemoCue AB, Ängelholm, 
Sweden). A drop of blood was placed in a special microcuvette which contained a 
hemolyzing agent (sodium desoxycholate, sodium nitrite, and sodium-azide). The 
erythrocyte membranes are disintegrated by sodium desoxycholate, releasing the 
haemoglobin. Sodium nitrite converts the haemoglobin iron from the ferrous to the ferric 
state to form methaemoglobin, which then combines with azide to form 
azidemethaemoglobin. The meters measured the amount of light absorbed by the sample 
within the microcuvette in the 540nm range, to estimate the haemoglobin level. The 
method has been found to be easy and accurate for measuring haemoglobin (von 
Schenck et al. 1986). 
 
DNA processing and PCR 
Five ml of blood were lysed in 50 ml GTC solution (4 M guanidine-isothiocyanate, 25 mM 
Na citrate pH 7.0, 0.5% Na sarcosylsulphate), 5 ml b-mercaptoethanol, and mixed with 50 
ml TE saturated phenol and 50 ml chloroform. The aqueous phase was separated, 
precipitated with isopropanol and DNA redissolved in 30 ml H20. 
 
A nested PCR was performed for MSP2. 5 ml of DNA were used for the primary reaction 
and 2 ml of PCR product for the nested reaction in a 100 ml reaction composed as follows: 
10 mM Tris pH 8.8, 50 mM KCI, 1.5 mM MgCI2, 0.25% Tween 20, 0.2 mM each NTP, 0.5 
pM each primer, 1.25 U taq polymerase. Primer pairs used were S2 and S3 for the primary 
reaction and S1 and S4 for the nested reaction as published by Foley et al. (1992). Both 
PCR reactions were performed in a Perkin Elmer Thermocycler 480 with the following 
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profile: 5 min at 94 oC and 30 cycles: 1 min at 94 oC, 2 min at 55oC, 2 min at 70 oC. 
Negative controls were included with each set of PCR reactions. 
 
The different MSP2 alleles were genotyped as previously described (Felger et al. 1993). 
20 ml of nested PCR product were subjected to restriction digests with the restriction 
enzymes Ddel, Rsal, Hinfl, ScrF1, respectively, and run on a 10% polyacrylamide gel. All 
digests of one restriction enzyme were loaded side by side for all samples of an individual 
patient and sizes were calculated using a standard commercial size marker. RFLP 
patterns were visualized by ethidium bromide staining and documented electronically. All 
gels were analysed by two independent researchers. 
 
Data processing 
All data collected in the study was double entered into a database (Foxproâ) at the IHRDC 
data center. Consistency and logical checks were done using programs written in Foxproâ 
(Microsoft Corporation, Redmond USA). 
 
Analysis 
In the case-control assessment, cases of mild malaria were compared with controls 
primarily with regard to their exposure to ITNs. Matched pairs were analysed by univariate 
analysis, then by multivariate analysis. Matched pairs multivariate analysis using 
conditional logistic regression was done using STATA® (Stata Corporation, Texas USA). 
Comparison was made of the attendance and incidence of episodes of anaemia and 
parasitaemia at the dispensary among users and non-users of ITNs. The relative rates were 
calculated in STATA®. 
 
Analysis was done for all the three cross-sectional surveys combined. The impact of the nets 
on haemoglobin level, anaemia, parasitaemia and splenomegaly was estimated using 
multiple linear and logistic regression models taking into account the village cluster sampling 
for year 2 and 3, using robust regression approaches in STATA® (Stata Corp. 1999). The 
effect of different time points of observation (surveys) was included as one of the explanatory 
variables.  
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Anaemia was classified as haemoglobin level below 8.0 g/dl since this is the level that has 
been associated with increased mortality (Stoltzfus 1997) and this is consistent with earlier 
studies in the area (Menendez et al. 1997). Parasitaemia and splenomegaly were classified 
as either present or absent. Use of treated nets was categorised based on the respondent’s 
answers on ownership, and if they were “ever treated” or “not treated”. There are currently no 
simple ways to assess insecticide content on the nets in the field. 
 
Other factors considered in the multivariate models included use of the net, condition of 
the net, age, sex, ethnicity, religion, nutritional status, access to the dispensary, shops and 
covered wells. Treatment history and attitudes toward health seeking were also included, 
as were factors related to the family size and income. The cross-sectional surveys in Idete 
was analysed similarly.  
 
The statistical modelling part for neighbourhood or short-distance effects was done using 
generalised linear mixed models (Breslow & Clayton, 1993) to measure the impact of 
categorical explanatory variables on binary outcomes of having anaemia, harbouring 
parasites and owning an ITN, under consideration of spatial correlation. Continuous fixed 
effect variables are discretisized into several categories to check their linear influence. 
Because this analysis showed non-linearity in all cases, they were categorised in the final 
models. 
 
We assume that near observations in space are likely to have the same outcome. To 
adjust for such a spatial dependence structure, the correlation function takes the value of 
one for observations close together and it decreases with increasing distance. 
 
If pi is the probability outcome for observation i, then using a logit link function leads to the 
model: 
    logit (pi) = b t Ci  + ei 
where b is the vector of coefficients and Ci the vector of fixed effects for observation I with 
1 in the first place to include an intercept term. The error term ei has the general form  
Cov(ei, ej) = s 2  f(dij), where dij measures the euklidian distance between location si and sj. 
For f(dij) we choose the exponential type f(dij) = exp(-r • dij), but compared the fit as well 
with models incorporating different choices of spatial covariance types.  In addition to 
better estimates for the fixed effects, this setting allowed us to describe the size and decay 
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of spatial dependency through s 2 and r, respectively. Finally the analysis was done using 
the SAS GLIMMIX macro, which uses iteratively reweighted likelihoods (Wolfinger & 
O'Connel, 1993) to fit the models. To compare the spatial with the non-spatial models, we 
applied likelihood ratio statistics. The macro can only accommodate one observation per 
location, therefore the youngest child was chosen from houses with multiple children. A 
repeat of the analysis using a randomly selected child from these households yielded 
similar results. 
 
Quality control 
The medical officer (the author) did a repeat of 5% of interviews and physical examination 
and observed 5% of all physical examinations and interviews in the Idete surveys. All 
forms were checked for completeness before being accepted into the data room. Clinical 
data entered in the computer was checked for logical errors weekly. Standard quality control 
procedures for IHRDC data center and laboratory were applied. An independent laboratory 
in the United Kingdom did a review of the parasitological results and good agreement was 
observed. Daily Hemocue® calibrations were done. 
 
Regulatory approval 
This thesis describes a series of studies that were conducted in a period of four years and 
included both hospital and community based work. Furthermore, the studies on treated bed 
nets were part of a larger multidiscipline evaluation. All the studies received institutional 
scientific and ethical approval from the IHRDC, and the National Institute for Medical 
Research. The KINET programme evaluation and the Co-artemâ trial had approval from the 
Ministry of Health and the Commission of Science and Technology that has the mandate of 
overseeing all research in Tanzania.  
 
Sensitisation, community and individual consent 
 For the community-based studies a series of meetings were held first at district then ward 
and finally at village level to get consent from the authorities to implement evaluation. After 
the approval of the authorities public village level meetings were held to sensitise and get 
community consent for the programme. For the hospital-based studies approval was sought 
from the hospital board and the staff of the St Francis Designated District Hospital. Idete 
village leadership and dispensary staff were consulted for approval of the dispensary studies.  
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The Idete dispensary studies were further explained at public meetings at hamlet level. At the 
time of implementation of all the studies, individual verbal consent was requested from the 
parent or guardian of the child, and a written or finger printed consent was also asked for the 
hospital-based trial. All children who were sick in the community studies were treated 
according to the good clinical practice of the Kilombero distric t health facilities and 
treatment guidelines of the Tanzania Ministry of Health. 
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Abstract 
We present a large-scale social marketing programme of insecticide-treated nets in 2 rural 
districts in south- western Tanzania (population 350 000) and describe how the long-term 
child health and survival impact will be assessed. Formative and market research were 
conducted in order to understand community perceptions, knowledge, attitudes and 
practice with respect to the products to be socially marketed. We identified Zuia Mbu 
(Kiswahili for 'prevent mosquitoes') as a suitable brand name for both treated nets and 
single-dose insecticide treatment sachets. A mix of public and private sales outlets is used 
for distribution. In the first stage of a stepped introduction 31 net agents were appointed 
and trained in 18 villages: 15 were shop owners, 14 were village leaders, 1 was a parish 
priest and 1 a health worker. For net treatment 37 young people were appointed in the 
same villages and trained as agents. Further institutions in both districts such as hospitals, 
development projects and employers were also involved in distribution. Promotion for both 
products was intense and used a variety of channels. A total of 22 4 10 nets and 8072 
treatments were sold during the first year: 18 months after launching, 46% of 312 families 
with children aged under 5 years reported that their children were sleeping under treated 
nets. A strong evaluation component in over 50 000 people allows assessment of the long-
term effects of insecticide-treated nets on child health and survival, anaemia in pregnancy, 
and the costs of the intervention. This evaluation is based on cross-sectional surveys, and 
case-control and cohort studies. 
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Introduction 
Despite malaria being the largest public health problem in Africa south of the Sahara, with 
over one million associated deaths each year (WHO, 1997), little progress has taken place 
in control during the past decades. Prompt treatment with an effective antimalarial remains 
the basis of malaria control strategies in most African countries (WHO, 1993). Preventive 
transmission control is being reconsidered using insecticide-treated nets (ITNs, including 
treated bednets and curtains) which do not require a large national programme 
infrastructure for implementation. In a meta-analysis of African trials ITNs were found to 
reduce clinical malaria episodes by 48% and to improve anaemia status by an average 0.5 
g/dL (Lengeler, 1998). Most importantly, the regular use of ITNs under trial conditions 
prevents approximately 6 deaths for every 1000 children protected every year across a 
large range of transmission intensities. Many international agencies (e.g., UNICEF, WHO, 
World Bank, Organization of African Unity) have recognized that malaria control is an 
urgent priority in order to improve child survival and are now making plans for 
implementation of ITNs (WHO, 1996; UNICEF, 1998; USAID, 1998). 
 
The translation of promising research results into effective public health action is a 
daunting task. There are at least 60 million children living in areas at risk for malaria in 
Africa and their nets, once provided, will need to be treated regularly (every 6-12 months) 
over many years. Feilden (1996) reviewed various options for financing and 
implementation of ITNs, most of which have been tried on a relatively small scale (up to 10 
villages). These fall into 3 main implementation models: (i) the integration of ITNs 
distribution into a community pharmacy network (e.g., the Bamako Initiative pro- gramme 
in Western Kenya (Hill, 1991), (ii) sales through local health units (e.g., Fraser-Hurt & 
Lyimo, 1998) or the existing primary health care system (D'Alessandro et al., 1995), and 
(iii) distribution through community groups (e.g., Premji et al. 1995). Despite much useful 
operational experience, it seems premature to recommend specific large-scale ITNs 
implementation strategies for the African continent. The launch of a number of large 
programmes (population of over 100 000) using different pragmatic approaches will allow 
these strategies to be optimized. 
 
Social marketing is a very flexible implementation model that has proved successful in 
resource-poor countries for interventions such as oral rehydration salts (ORS) and 
condoms (BASICS, 1998). Social marketing is an approach where the experience and 
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methods of commercial marketing are applied to a product which has a social benefit, with 
the main motivation being social improvement rather than financial gain to the marketer 
(Andreasen, 1995). The approach usually uses a branded product that can be marketed 
and advertised professionally. Much attention is paid to the main target group-sometimes 
called customers-and much effort goes into understanding the perception, knowledge, 
attitudes and practices of this group. Social marketing entails an effective public-private 
partnership which may be particularly useful for ITNs: unlike drugs and vaccines, ITNs 
may be seen as a commercial commodity rather than a medical product. Social marketing 
of ITNs has recently been started in various African countries, for example, the Central 
African Republic (in 1996), Rwanda, Kenya and Zimbabwe (in 1997). 
 
The long-term impact of ITNs on small children in areas with high malaria transmission (an 
arbitrary cut-off being an annual entomological inoculation rate over 100) remains a 
controversial issue. The potential con- sequences of delaying acquisition of immunity are 
worrying in that in such areas it has been suggested that overall survival could be better 
without ITNs (Snow et al., 1997). However, good data on the issue are scant and the 
discussion has been based on indirect evidence. Following the discontinuation of malaria 
control trials in the past no evidence for a delay or a 'rebound' in mortality was found 
(Molineaux & Gramiccia, 1980; Bradley, 1991; Greenwood, 1997). Further, the indirect 
evidence presented to support the idea of a delay in child death in areas of high 
transmission has been questioned (D'alessandro & Coosemans, 1997; Lengeler et al., 
1997; Lines, 1997; Moljneaux, 1997). Only long-term randomized controlled trials could 
answer this question reliably but these would be unlikely to be ethical or acceptable to the 
communities involved. Not many alternative designs remain. One possibility is to compare 
users of ITNs to non-users in the frame of a large-scale programme: combining this 
estimate with information from coverage surveys would allow estimation of community 
effectiveness (Lengeler & Snow, 1996). Although the current debate does not warrant 
delaying the implementation of ITNs programmes the issue needs to be addressed and 
monitored by more than one large-scale ITNs programme. 
 
We present an overview of the KINET (pronounced 'key-net') project in Tanzania. The 
project, based at the non-governmental Ifakara Health Research and Development Centre, 
has developed a social marketing system for getting nets and insecticide to a scattered 
rural population of 350000 people. A strong evaluation component in over 50 000 people 
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allows monitoring of the long-term effects of ITNs on health and child survival, together 
with an assessment of the costs of the intervention. 
 
Background  
Study area 
Kilombero and Ulanga Districts lie in Morogoro Region in south-westem Tanzania, about 
320 km from Dar-es-Salaam (Fig. 1). Much of the area lies in the low- lying flood plain of 
the Kilombero River (average altitude 270 m), which divides the 2 districts. The Udzungwa 
mountains lie to the northwest and there is also an upland area around Mahenge town 
(over 1000 m). The area has a rainy season from November to May, although rain may fall 
in any month of the year. Annual rainfall range is approximately 1200-1800 mm. 'Me 
population is about 350 000, with an average density of about 10 people /km2. There are 
109 villages in the 2 districts, ranging in size from <1000 people to >6000. Average 
household size is about 5-5 people. 
 
There is a wide mix of ethnic groups including Wandamba, Wapogoro, Wabena, Wabunga 
and Wahehe. Many local houses have mud walls and thatched roofs, while up to one-third 
have brick walls and corrugated iron roofs. Rice, maize and cassava are commonly grown 
for home consumption. The main agricultural exports from both districts are rice, timber 
and charcoal. Fishing is also common, both for local consumption and for export as 
smoked fish to the towns of Morogoro and Dar- es-Salaam. Many families have a second 
house known as a shamba (farm) house in low-lying farmland areas where they stay 
during the rice-planting and harvesting seasons. 
 
The public health system has a network of village health workers, health posts, 
dispensaries, health centres and hospitals with varying quality of care. In Ifakara town, the 
capital of Kilombero District, the main hospital is a large well-equipped mission Designated 
District Hospital. The hospital in Mahenge, the Ulanga District capital, has more limited 
facilities. There is a further mission hospital in Malinyi, serving the south-westem part of 
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Fig. 1. The KINET programme area in Morogoro Region, south-westem Tanzania. Shading 
indicates Phase 1 area (under demographic surveillance). The town of Ifakara is 
approximately 37 oE and 8 oS. 
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 Ulanga District. The mother-and-child health (MCH) services are well developed and 
vaccination coverage is high with 78% children receiving all Expanded Programme on 
Immunization (EPI) vaccines by age 1 year (F. Font, personal communication). There are 
no paved roads and some villages are cut off for parts of the year by flooding. Limited 
seasonal bus services run up to 3 times each day between the towns of Ifakara, Mahenge 
and Malinyi. The TAZARA railway links the towns of Ifakara and Mlimba. 
 
Malaria and mosquito net use 
Malaria is the foremost health problem as reported through the health services and as 
perceived by local people, both for adults and children (Tanner et al., 1991). Malaria 
transmission due to Plasmodium falc iparum is intense and perennial, despite marked 
seasonality in mosquito densities with a peak in the rains. Anopheles gambiae and An. 
funestus are the main vectors, with an estimated 200-300 infective bites per person per 
year occurring in rural areas close to Ifakara (Smith et al.,1993). Life-threatening malaria in 
most of the area occurs largely in children, and commonly presents in those aged < 1 year 
(Snow et al., 1994). 
 
A baseline survey conducted in 1996 found that 37% of households (3817/10 299) had at 
least 1 net. The main motivation for their use was mosquito nuisance rather than malaria 
control, with use being widely reported as seasonal. A previous study at the Ifakara Health 
Research and Development Centre allowed preliminary assessment of various ways to 
distribute nets and net treatment in the area close to Ifakara town (Fraser -Hurt & Lyimo, 
1998). 
 
The social marketing programme 
We describe here the background work preparing the social marketing campaign from July 
1996 to May 1997, and then cover the issues of product, price, place and promotion. 
 
Sensitization and market research 
Sensitization meetings with village leaders were held in all the 18 villages of the Phase 1 
distribution area (shaded area in Fig. 1). Each half-day meeting took the form of an open 
discussion between project and community leaders of the health problems of the 
community, ways to prevent malaria including ITNs, and the issues of how to get ITNs to 
the community in a sustainable way. The concepts of sustainability and cost recovery led 
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to long discussions: most community leaders had no previous experience of projects that 
aimed for substantial cost recovery and found the concepts hard to understand. There was 
a common misconception that the Swahili term for 'project' (mradi) involved being given 
things at little or no cost to the consumer. 
 
An initial survey confirmed that virtually all people in the area knew of mosquito nets and 
that round and rectangular white polyester nets manufactured in Tanzania were generally 
available in the towns. Qualitative studies on community preferences for different types of 
net suggested that rectangular, dark green, high-quality polyester nets were likely to be 
popular. They were needed in 2 sizes (180 X 150 X 100 cm and 180 X 150 X 130 cm) in 
order to accommodate local sleeping patterns. People said they would prefer coloured 
nets to white nets since they would not need washing as often. Many people had heard of 
net treatment, owing to a previous UNICEF project in the area and to the avail- ability of 
Rotary-funded treated nets in lfakara (Fraser- Hurt & Lyimo, 1998), but very few had tried 
it. 
 
Further qualitative studies in 2 small villages found that malaria was often not perceived as 
a life-threatening problem, but as a fever-related illness which attacked all ages. This 
finding was confirmed by related work carried out at the same time in Ifakara town 
(Hausmann- Muela et al., 1998). Severe conditions perceived as causing child deaths, 
such as bandama (enlarged spleen), degedege (convuls ions) and homa kali (high fever) 
were not widely thought to be caused by malaria. Consequently, it was decided to highlight 
messages related to malaria as a cause of child deaths, including those seen as bandama, 
degedege and homa kali, in promotion campaigns. Nuisance biting by mosquitoes was 
consistently felt to be a major problem and this was the main reason for people using 
mosquito nets. Few people were aware that malaria-transmitting mosquitoes were more 
likely to bite late at night than in the early evening: without this knowledge it is hard for 
people to understand how nets might prevent malaria. 
 
We identified Zuia Mbu (Kiswahili for 'prevent mosquitoes') as a suitable brand name for 
both treated nets and insecticide treatment. lUs brand name and a logo for Zuia Mbu (Fig. 
2) were developed together with an advertising agency in Dar-es-Salaam and tested 
locally. The brand and logo are used on all products and promotional materials. 
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Fig. 2. The logo used for the Zuia Mbu brand used by the KINET programme.
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Products: nets and insecticide 
Dark green polyester 100-denier 156-mesh nets were obtained from Siamdutch Ltd, 
Thailand. Each net was pre-treated at the factory with 20 mg/m2 deltamethrin, and 
wrapped in a clear plastic bag with an insert containing information about Zuia Mbu. 
The insecticide for net treatment was 2-5% lambda-cyhalothrin CS (capsule suspension), 
a water-based micro-encapsulated formulation produced by Zeneca Ltd (UK). The 
insecticide was re-packaged by a collaborating project in Dar-es-Salaam in individual 6-mL 
sachets, each containing enough to treat a single net of any locally available size (Miller et 
al., 1998). 
 
Price 
Village sensitization meetings and experience from a previous project (Fraser-Hurt & 
Lyimo, 1998) suggested that local people would be willing to pay near cost-recovery price 
for the nets, but rather less than cost- recovery price for the insecticide. Retail prices were 
set at TSh 3000 (~US$5-0) for either size of net and TSh 250 (~US$O.42) for the 
insecticide treatment service. For nets, a commission of TSh 500 per net is paid to each 
retailer and a further commission of TSh 250 is paid to wholesalers. Thus the project 
recovers TSh 2250 (~US$3.75) for each net sold, or about 66% of the replacement cost 
including transport to lfakara and packaging. For insecticide, a commission of TSh 125 per 
sachet is paid to the retailers and a fürther TSh 25 to wholesalers. The project therefore 
recovers TSh 100 (~US$O.17) for each sachet sold, about 17% of the replacement cost. 
Price control for nets, initially a particular worry of the community, is achieved by making 
the selling price clearly visible on the net packaging and by advertising the price widely. 
 
Place: the distribution system 
The social marketing of nets and insecticide was phased-in step-wise in 3 increasingly 
large areas. A flexible distribution system was chosen in conjunction with community 
leaders and community members in a series of open meetings. In the first phase, in each 
village 2 sales agents for nets and a further 2 mobile sales agents for insecticide were 
chosen regardless of the size of the village. The agents were nominated by the villagers 
themselves, and included health workers, parish priests, community leaders and 
shopkeepers. Net sales agents and net treatment agents were both given a 1 -day training 
seminar, where they learnt how to treat nets and how to keep sales records. These 
records show the purchaser's name, balozi (local political leader), sub-village and village, 
and permit checks that the products have been sold within the study area. Twice-yearly re-
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training and review sessions are also held. The net treatment agents were given a 
distinctly painted Zuia Mbu bicycle to assist with door-to-door sales, plastic basins, gloves, 
and plastic boxes for storage of sachets of insecticide. Nets and insecticide were initially 
supplied directly by project staff at weekly intervals, but as the project area enlarged a 
network of wholesalers was developed to keep agents supplied on a regular basis. Each 
agent has a contract with the lfakara Health Research and Development Centre, and is 
paid on a commission basis (see ‘Price' above). A reward system for reaching certain 
sales targets is also used. Agents who do not keep the terms of the contract are replaced. 
 
Promotion and the voucher system for pregnant women and infants 
A range of materials to support an information, education and communication (IEC) 
campaign was developed, including 3 posters (Fig. 3) and a leaflet. These materials, each 
incorporating ideas from the qualitative studies, were drawn by a local artist and pilot-
tested extensively before printing and distribution to health clinics, sales outlets, etc. 
Billboards were posted along the main roads and one local bus had the Zuia Mbu logo 
painted prominently on its side. The project worked together with the District Health 
Management Teams in both districts in preparing the campaign. 
 
A discount system to reduce further the cost of a net for mothers of young children and 
pregnant women was developed for use through health clinics. This system is intended to 
increase use of treated nets in those most at risk of severe effects of malaria. All women 
attending antenatal clinics and those attending for routine immunizations are entitled to a 
discount voucher which gives them a TSh 500 (US$ O.84 or 17% retail value) price 
reduction for a treated mosquito net. Their clinic attendance card is marked to show that 
they have received the voucher. The voucher is then presented by the women to the net 
sales agent in their village. The sales agent then receives a credit from the project to the 
value of TSh 500 plus a TSh 50 handling charge. 
 
Public-Private mix 
KINET uses a pragmatic mix of activities involving the public and private sectors. Such 
mixes have recently been advocated as an effective strategic approach for large- scale 
ITNs projects (USAID, 1998). KINET social marketing involves a collaboration between 
public entities such as the District Health Management Teams and the Ministry of Health, 
the private sector such as international suppliers and local business people, and the 
project social-marketing team. 
Chapter 4: KINET 
49 
 
Launching and expansion 
The treated nets and insecticide treatment service were launched in 2 large villages on 24 
and 25 May 1997 with celebrations including community theatre, songs, a raffle and 
speeches from community leaders. During the following week sales of nets and insecticide 
started in all the 18 Phase 1 villages. The project expanded to cover a further 8 villages in 
December 1997, 35 in June 1998, 18 in December 1998 and will cover the remaining 30 
villages early in 1999. 
 
In order to facilitate this expansion in an efficient way, KINET is working to maximize 
inputs from local project partners such as local employers and mission hospitals. Project 
partners act as local distributors of Zuia Mbu nets and insecticide, using the same 
promotional materials and price structure, and as key players in the IEC campaign. 
 
Project evaluation: the effect of ITNs on child health and survival 
Socio-cultural aspects 
Quantitative and qualitative work is being done, including periodic knowledge, attitude, 
beliefs and practices (KABP) studies, detailed community-based anthropological studies, 
and semi-structured interviews with sales agents and customers. This work allows a 
review of how IEC messages are received in the community and the chance to see which 
new messages might be useful. In addition, it allows evaluation of the discount system and 
the sales agents themselves, with a view to making improvements so that customers are 
served better by the project. 
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Fig. 3. One of the 3 posters developed for the treated net promotion campaign. This 
poster emphasizes the undisturbed sleep with the use of a Zuia Mbu net. 
Translation: (1) Malaria-carrying mosquitoes bite in the middle of the night, (2) Zuia 
Mbu treated nets repel and kill mosquitoes 
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Demographic surveillance system (DSS) 
This system was started in September 1996 and operates in the 18 Phase 1 villages 
covered by the study (shaded area in Fig. 1). This area has a population of some 55000 
people living in 11000 households. A baseline census was carried out from September to 
December 1996. Name, sex, date of birth, and relationships within the household were 
recorded. Household locations were noted on sketch-maps. Rough locations of any 
shamba houses were also recorded. Since January 1997 every household has been 
visited every 4 months by an interviewer who updates the census record by asking about 
in- and out-migrations, pregnancies, births and deaths. The system developed originally in 
Navrongo (Ghana) by BINKA et al. (1998) was used with few modifications. Special 
surveys are added from time to time: for example, the first census round in 1997 was used 
to record socio-economic status in the household, and educational level for each 
household member. The DSS gives a full sampling frame for the Phase 1 area, within 
which vital events are monitored and random samples of households or individuals may be 
chosen for various in-depth studies. 
 
Effect of treated nets on child survival 
Two studies are under way within the DSS. First, a case-control study will assess risk 
factors for child mortality in the area, with a particular focus on use of nets, treated or 
untreated. Cases are children resident in the study area who died of any cause aged 
between 1 month and 5 years. Four controls are chosen for each case from the same area 
of residence and of approximately the same age. The case-control study will give an 
estimate of efficacy of the treated nets among children who use them. This can be 
combined with the coverage estimates from periodic surveys to estimate effectiveness in 
this target group. 
The second study to assess the effect of treated nets on child survival is a birth cohort: all 
children born in 1998 and 1999 will be enrolled. At enrolment a questionnaire is used to 
elicit information on birth-weight, mother's age and educational level, twinning, family size, 
birth order and birth interval. At subsequent routine DSS visits, a further brief questionnaire 
will be used to gather additional information. It is planned to follow these children until their 
5th birthdays. Analysis will compare mortality rates in those using treated nets with those 
using un- treated nets and those using no nets, allowing for any measured potential 
confounders. 
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Effect of treated nets on anaemia and malaria in young children 
Three annual cross-sectional surveys to assess the effect of social marketing of treated 
nets on anaemia will be carried out on a random sample of children aged <2 years from 
the DSS area, one at baseline before the sale of the nets and then after the first and 
second year of implementation. A questionnaire is applied, a physical examination done 
and a blood sample obtained. The prevalence of anaemia will be compared between users 
and non-users of treated nets using logistic regression analysis to control for confounding. 
 
To assess the effect of the interventions on malaria and anaemia episodes, a cohort of 
children aged <5 years residing in the village of Idete is being followed-up and their 
disease episodes documented, using a passive case- detection system at the village 
dispensary. Risk factors including treatment-seeking behaviour, household socio-
economic status, use of treated nets and mother's education are being assessed by short 
questionnaires applied through routine DSS visits. Rate ratios of disease episodes 
(first/only episode) between those using treated nets and those not using them will be 
compared using Poisson regression to control for confounding. More detailed assessment 
of the impact of the interventions on malaria episodes is  being done within this cohort 
using a nested case-control study. 
 
Effect of treated nets on anaemia in pregnancy 
A cross-sectional survey of pregnant women with rolling recruitment over a period of 12 
months is also being carried out using the DSS. The study is designed to determine the 
prevalence of severe anaemia (Hb <8 g/dl) and to identify major risk factors for this 
anaemia, including use of treated nets. 
 
Costing of implementation and willingness and ability to pay.  
Cost of the implementation to the provider is being assessed. Measures of effectiveness 
and costs will be combined in a cost-effectiveness analysis (CEA). The costs involved 
include the initial investment, recurrent costs, capital costs and opportunity costs. Each 
type of cost is identified by associated activities such as brand creation, promotion, 
training, distribution, etc. Willingness and ability to pay were elicited from a sample of 
respondents within and outside the Phase 1 area, who were asked about household 
expenditure patterns. 
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Insecticide resistance: entomological indicators 
With increasing use of ITNs at community level, it is possible that the usual night-biting 
behaviour of the main vector of malaria in the area might change to peak in the early 
evening and early morning, when few people are in bed. Studies to assess changes in 
mosquito biting behaviour are therefore carried out every year together with bio-assays to 
monitor any trend in resistance of wild-caught An. gambiae to lambdacyhalothrin or 
deltamethrin. 
 
First results  
Demography 
The estimated mid-year (1997) population of the Phase 1 area was 54 061 people living in 
10 966 house- holds. Average household size is 4-9 people. Almost half (44%) of the 
population is aged < 15 years, 16% aged <5 years, and the sex ratio (M:F) is 1:1.02. 
During 1997 the infant mortality rate was 95/1000 live births (181/1902), and annual 
mortality in children aged 1-4 years was 14.3/1000 (98/6859 child-years). In children aged 
5-9 years the annual mortality rate was 3.5/1000 (28/7944 child-years). Total fertility was 
estimated at 4.7 births/woman. 
 
Willingness and ability to pay 
Of those interviewed, 69% (128/185) claimed to be willing to pay the price of US$5 per net 
and 88% (163/185) were willing to pay US$O.4 per net for a net treatment service. Ability 
to pay assessed by median overall household expenditure in the month prior to the first 
survey was US$74. Excluding expenditure on food, a median of US$7 was spent on 
capital items and US$ 11 was spent on other small items in the previous month. Many 
households have a bicycle (34%) or radio (11 %). It should be noted that this survey was 
carried out in the harvest season, when expenditures are at their annual maximum. 
Further surveys are ongoing. 
 
Sales 
Thirty-one net sales agents and 37 mobile net treatment agents were appointed in May 
1997 in the 18 villages of the first phase. Among the net agents there were 15 shop 
owners, 14 village leaders, 1 health worker, and 1 village priest. After 10 months, the priest 
and 3 village leaders were replaced: they were inactive, mainly owing to their other 
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commitments. During the same period 10 (27%) net treatment agents were no longer 
active and have been replaced. 
 
The percentage of households with at least 1 net rose from 37% at the end of 1996 to 52% 
(5913/11480) in mid-1 998, by which time 24% (2730/11480) of house- holds had at least 
1 treated net and 48% (4323/9040) nets were treated. Of a random sample of families with 
children aged < 5 years, 46 % reported that their children were sleeping under treated nets 
by April 1998. A total of 22 410 nets and 8072 treatments were sold by the project during 
the first year. Sales records in the Phase 1 area suggest over 80% nets were sold to 
residents. As expected, demand peaked after the rains started, when mosquito 
populations rose dramatically: almost half of the total annual sales were during the months 
of December and January. Most net treatments were sold to owners of ordinary untreated 
nets: 31% of those who owned ordinary nets had treated these by December 1997, 
whereas only 13% of Zuia Mbu net owners who had bought their nets at least 3 months 
previously had re- treated their nets by December 1997. 
 
There was a good response to the discount vouchers, with 26% (1687/6489) of net sales 
to Phase 1 area residents making use of the vouchers. Ongoing surveys will reveal 
whether the target group, i.e., pregnant women and those with young children, are the 
principal users of the discounted nets. 
 
Discussion 
Social marketing is a novel and promising approach to promote and supply effective 
malaria control tools. Its excellent track record for interventions as diverse as ORS, 
condoms and oral contraceptives suggests that it could perform well for the large-scale 
deployment of ITNs (USAID, 1998). So far the KINET project has achieved good coverage 
in a large highly endemic rural area, reinforcing positive experiences with social marketing 
of ITNs in the Central African Republic, Zimbabwe and Rwanda (A. Boner and L. Jamu, 
personal communication). 
 
Large-scale ITNs programmes will always be confronted with the problem of finding agents 
that are both trusted by the community and effective in selling ITNs. The initial choice of 
net and treatment agents rested largely with village leaders and this resulted in a great 
diversity of agents selling KINET products. Our early results suggest that commercial 
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retailers often provide a better service to their communities than village leaders. Retailers 
are used to selling goods and usually have a larger working capital to invest in net and 
insecticide consignments. Further, they are available at most times of day and easy for 
potential customers to find. Future expansion is likely to increase the involvement of the 
private sector. 
 
The issue of whether health facilities should also sell ITNs and treatments remains open, 
and there are no current Ministry of Health guidelines on this matter. With the gradual 
introduction of cost-sharing in Tanzania the selling of ITNs could find a natural place in the 
system but the issue of who should keep commission from the sales deserves careful 
consideration. An interesting contrast is seen in how sales commission is shared between 
2 MCH clinics selling ITNs in the KINET area (see also Fraser-Hurt & Lyimo, 1998). In one 
clinic all the staff participate in the sales and the TSh 500 commission on each sale is 
shared. In contrast, in the second clinic the rural medical aide in charge alone sells nets 
and keeps the commission; this has led to resentment among other staff and to less active 
promotion on their part. 
 
In the interests of sustainability it is important to develop a system of wholesalers that 
follows the existing commercial system. This allows reduction of the intensive investment 
needed when all agents are supplied weekly by the project. The apparently lower cost-
recovery to the project with wholesalers is more than offset by the lower distribution cost. 
Once an efficient wholesale network is established monthly supplies to wholesalers should 
be sufficient and the project can then easily expand to a wider area. 
 
Nets were relatively common in our area before KINET sales started. We therefore started 
to promote and sell insecticide for net treatment as soon as possible so that existing nets 
might be treated. Informal feedback from the community suggests that people are often 
uneasy about bringing their nets out in public, and that they would prefer to treat their nets 
themselves. We have therefore introduced a home-treatment kit developed in Tanzania 
(Miller et al. 1998), consisting of a single- dose sachet of insecticide packaged with 
disposable gloves and locally developed instructions. The relatively high cost of this 
packaging is offset against the problems of deliberate or accidental misuse of larger 
quantities of insecticide, and the advantage that our target group prefer the freedom and 
privacy of treating their nets at home. 
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We chose to sell pre-treated nets rather than untreated nets despite the argument that this 
denies the opportunity of educating people at the time of purchase about the difference 
between a treated and an untreated net and how to treat a net. Pilot studies with the 
home-treatment kit suggest that people do not need special training to treat their nets. 
Selling pre-treated nets may mean that some people will not realize that they have bought 
a treated net, but we feel their lack of knowledge is an issue best tackled through ongoing 
targeted IEC concerning net treatment. For example, our treatment agents can make use 
of net sales records in order to make follow-up visits to those who have bought a net 3 
months previously. They can then offer advice on malaria prevention and a net treatment 
service. 
 
Two key issues remain on the promotion agenda. First, the sales are very seasonal, 
clearly peaking during the time of maximum mosquito densities. No detailed compliance 
measures are yet available but it is very likely that the net usage follows the same 
seasonal pattern. Since malaria transmission is perennial in the Kilombero Valley the all-
year use of ITNs needs to be promoted actively. Secondly, KINET is aiming to reach a 
large and very dispersed rural population with 2 products: nets, for which existing demand 
is high, and insecticide, for which existing demand is much lower. Promotion will therefore 
focus increasingly on re-treatment of existing nets and new distribution channels may have 
to be developed to facilitate this. 
 
An optimal balance between affordability, equity and full cost-recovery is difficult to 
achieve. KINET has a current low level of subsidy on the treated nets (66% cost 
recovered) and a high level of subsidy on the insecticide (17 % cost recovered). These 
costs do not cover a mini- mum programme infrastructure nor the cost of promotion: the 
project loses a substantial amount of money on every sale. As international demand for 
insecticide for net treatment increases it seems likely that cheaper formulations will 
become available and the cost of insecticide will decrease. Once a stable demand for nets 
and net treatment exists, retail prices may be increased towards full cost-recovery levels, 
with subsidies targeted exclusively through the public health sector using vouchers or in 
other ways. 
 
Although full cost-recovery is an important consideration, there is more to sustainability 
than full cost- recovery alone. Many ITNs projects conducted in the past have not survived 
the end of their project status (e.g., Hill, 1991; Premji et al., 1995) despite a certain level of 
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infrastructure and a banked revolving fund. Often procurement and ongoing distribution 
have been beyond the capacity of the local groups. One of the strengths of a public-private 
mix such as that used by KINET is the inherent sustainability of the private sector 
distribution system. The remaining issues of procurement and promotion are likely to need 
special attention at the end of the 'project status' phase. A low-cost social-marketing 
support service at district, regional or even national level could provide such inputs. 
Virtually no other intervention in preventive health is entirely self-supporting: if ITNs 
programmes are (1) feasible on a large scale and (2) efficient through low delivery cost per 
net or per treatment, they should be able to attract sufficient donor support in the context 
of the Roll Back Malaria initiative. 
 
The question of long-term effect of ITNs on survival in highly endemic areas is important. 
Since randomized controlled trials are neither feasible nor ethically acceptable, we have 
chosen observational studies to compare users of ITNs with non-users, both through a 
case- control study and the long-term follow-up of a birth cohort. Problems remaining 
include the difficulty of determining use of treated nets and the influence of potential 
confounders, many of which are difficult to measure. Experience from other areas of 
health, for example the health impact of smoking or the impact of ORS, suggests that 
observational studies can make a useful contribution. However, our results will need 
careful interpretation. Ideally, such long-term follow- up should be carried out in a number 
of sites. Other African projects are attempting to do this in Ghana and in Burkina Faso 
where the population formerly involved in the scientific trials (Binka et al., 1996; Habluetzel 
et al., 1997) is being followed-up for a further 3 years in order to detect a possible delayed 
increase in mortality in the former intervention group compared to the former control group 
(F. Binka, personal communication; E. Sanogo, personal communication). A similar study 
is planned in Western Kenya (P. Phillips-Howard, perso- nal communication). 
 
The KINET project represents an attempt to see to what extent social marketing is a useful 
tool in the fight against malaria in a rural African setting. Data are being collected on the 
key issues of cost and effectiveness of ITNs on child survival, but the results are some 
time away. In the mean time, the information available to date suggests that social 
marketing is a useful approach for ITNs, being innovative, popular and sufficiently 
adaptable to address the varied challenges of a malaria control programme in a rural 
African setting. 
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 Abstract: 
 
Objective: 
 To assess the impact of social marketing (an approach using marketing techniques to 
promote and distribute socially beneficial interventions) of insecticide treated nets on 
malaria parasitaemia and anaemia in children under two years of age in an area of high 
malaria transmission.  
 
Design: 
Annual cross-sectional data were collected at the beginning of the social marketing 
campaign and subsequent two years. Net ownership and other risk and confounding 
factors were assessed using a questionnaire. Blood samples were taken from the children 
to assess prevalence of parasitaemia and haemoglobin levels. 
 
Study participants: 
A sample of children under two years of age living in 18 villages in the Kilombero river 
plain, Southwestern Tanzania. 
 
Main outcome measures: 
The presence of any parasitaemia in the peripheral blood sample, and anaemia classified 
as haemoglobin of less than 8 g/dl. 
 
Results: 
There was a rapid increase in net ownership (from 58 to 83%) and treated net ownership 
(from 10 to 61%). There was an overall increase in the mean haemoglobin (from 8.0 to 8.9 
g/dl) of the study children in the successive surveys. Overall, the prevalence of anaemia in 
the study population decreased from 49% to 26% in two years of implementation. Treated 
nets had a protective efficacy of 63% (95% CI: 38, 77) on the prevalence of parasitaemia, 
and 63% (95% CI: 27, 82) on anaemia.  
 
Conclusions 
 These results demonstrate that insecticide treated nets have a substantial impact on 
morbidity parameters when distributed in a public health setting.  
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Introduction 
Several studies have shown a positive correlation between malaria parasitaemia and 
anaemia, and  that parasitaemia is the primary cause of anaemia in very young children in 
Africa (Kitua et al. 1997). As a result, anaemia is very frequent in young children in high 
transmission areas since malarial infections are the norm. Assessment of the impact of 
chemoprophylaxis in Tanzanian infants indicated that over 60% of the anaemia could be 
due to malaria in this age group (Menendez et al. 1997). The emergence and spread of 
parasite resistance to commonly used antimalarials has exacerbated the problem of 
anaemia in Sub-Saharan Africa (Bloland et al. 1993). 
 
Hopes for malaria and malarial anaemia control have recently been revitalised by the 
demonstration that insecticide treated nets can reduce morbidity and mortality. A summary 
of randomised controlled trials showed an average protective effect of about 50% on mild 
malaria episodes in stable malaria areas. Moreover, protective effects were shown on the 
prevalence of high parasitaemia (31%) and overall mortality (19%). A modest improvement 
in packed cell volume (2%) and weight gain was also observed in children sleeping under 
treated nets (Lengeler, 1998). Large scale implementation of ITNs is underway in a 
number of African countries (Anonymous, 1999). 
 
It is not known whether the impressive impact of treated nets in the frame of well controlled 
randomised controlled trials can be replicated under programme conditions (Lengeler & 
Snow, 1996). We report the first impact assessment of a large scale treated net social 
marketing (an approach using marketing techniques to promote and distribute socially 
beneficial interventions rather than a commercial product) programme on morbidity 
indicators in children under two years of age in a highly endemic area of Tanzania. 
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Methods 
Study area and population 
Social marketing of treated nets started in the frame of Kilombero Net Project (KINET) 
(Schellenberg et al. 1999a) in 1997, covering the Kilombero and Ulanga Districts 
(population 350,000) in Southwestern Tanzania. Nets and insecticide (branded “Zuia 
Mbu”) are now being promoted, distributed and sold using public and private outlets, and a 
system of community door-to-door distributors. The retail price of the treated nets was 5.0 
US Dollars. While this amount was a non-negligible part of the average annual income in 
this community, experience shows that a majority of the residents were both willing and 
able to pay this amount (Schellenberg et al. 1999a). The impact of the programme on 
morbidity and mortality indicators is being monitored in 18 villages under demographic 
surveillance (DSS). Population characteristics of this area of very high perennial malaria 
transmission have been described elsewhere (Tanner et al. 1991). Moderate anaemia 
(PCV< 25%) and severe anaemia occur in 61% and 14% of children under five years 
admitted at the local St Francis District Hospital (Schellenberg et al. 1999b). Chloroquine 
resistance is common: 65% of malaria infections do not clear within one week of 
chloroquine treatment (Hatz et al. 1998).  
 
Design 
Three annual cross-sectional surveys where conducted in a sample of children under two 
years of age living in the DSS area (Schellenberg et al. 1999a). The first survey was done at 
the time of launching the social marketing campaign in June 1997, and two other surveys 
were carried out at the same period (June to August) in the subsequent two years. A simple 
random sample was selected from the DSS database for the first survey, and a two-stage 
random sampling (sampling 6 villages then sampling children from these) was done for the 
subsequent surveys. A different sample was selected for each survey. 
 
Procedures 
The selected children were visited at home and a verbal consent obtained from the parent or 
guardian. A questionnaire was applied to assess treated net use and other potential risk 
factors. A physical examination was performed, and temperature, weight and height 
measurements were also taken. A finger prick blood sample for haemoglobin estimation and 
parasitological assessment was then taken.  Haemoglobin was measured using the portable 
HemoCueÒ (HemoCue AB, Ängelholm, Sweden) kit. Slides were stained in Giemsa and 
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reading was done (without the microscopists knowing the net status) using standard 
procedures as described elsewhere (Schellenberg et al. 1999b). An inspection of the 
children’s sleeping places to assess net use was only done in 1999 because this was 
strongly perceived as an intrusion in their privacy. 
 
Anaemia was classified as haemoglobin level below 8.0 g/dl since this is the level that has 
been associated with increased mortality (Stoltzfus, 1997) and is consistent with earlier 
studies in the area (Menendez et al. 1997). Parasitaemia and splenomegaly were classified 
as either present or absent. Use of treated nets was categorised based on the respondent’s 
answers on ownership and if they were “ever treated” or “not treated”. There are currently no 
simple ways to assess insecticide content on the nets in the field.  
 
Data analysis 
Analysis was done for all the three cross-sectional surveys combined. The impact of the nets 
on haemoglobin level, anaemia, parasitaemia and splenomegaly was estimated using 
multiple linear and logistic regression models taking into account the village cluster sampling 
for year 2 and 3, using robust regression approaches in STATA® (STATA Corp.). The effect 
of different time points of observation (surveys) was included as one of the explanatory 
variables.  
 
Other factors considered in the multivariate models included use of the net, condition of 
the net, age, sex, ethnicity, religion, nutritional status, access to the dispensary, shops and 
covered wells. Treatment history and attitudes toward health seeking were also included, 
as were factors related to the family size and income. 
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Results 
We identified 985 eligible children. 16 mothers refused consent and 142 could not be 
traced at their homes. Therefore, mothers and guardians of 827 children were interviewed 
during the three cross-sectional surveys. 68 children were over twenty four months old at 
the time of sampling, and the net status was not known for 11 children, and therefore only 
748 (91%) children were included in the analysis. Children analysed and those not 
analysed had similar proportions of anaemia and reported ownership of nets (data not 
shown).  
 
We observed an increase in the mean haemoglobin level from 8.0 to 8.9 g/dl and a decline 
in the proportion of children with anaemia (49% to 26%), any parasitaemia (63% to 38%) 
and splenomegaly (86% to 49%), during the successive surveys (Table 1). The proportion 
of children having any net increased from 58% to 83% and those having treated nets 
increased dramatically during the 3 years (from 10% to 61%) indicating a rapid uptake of 
the socially marketed treated nets, especially in the first year of the implementation 
(Table1).  
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Table 1: Characteristics of children surveyed in the 3 cross-sectional surveys (1997 -1999) 
Year 1997 1998 1999 Overall 
Selected 325 330 330 985 
Interviewed* 269 (82.8) 291 (88.1) 267 (80.9) 827 (84.0) 
Analysed* 240 (73.9) 269 (81.5) 239 (72.4) 748 (75.9) 
Mean age in months‡ 14.2 ( 3.3 to  26.4 ) 13.5(3.0 to 24.7)   15.4 (2.4 to 25.5) 14.4 (2.4 to 26.4) 
Males 122 (50.8) 137 (50.9) 113 (47.3) 372 (49.7) 
Mean haemoglobin§ 8.0 (0.12)  8.9 (0.10) 8.9 (0.10) 8.6 (0.07) 
Anaemia (< 8 g/dl)¶ 118 (49.2) 83 (31.0) 62 (26.1) 263 (35.3) 
Parasitaemia** 151(62.9) 126(46.8) 90 (37.8) 367(49.1) 
Splenomegaly** 207(86.3) 144 (53.5) 117 (49.0) 468 (62.6) 
     
No net 100 (41.8) 49 (18.2) 40 (16.7) 189 (25.3) 
Untreated net 116 (48.3) 64 (23.8) 53 (22.2) 233 (31.1) 
Treated net 24 (10.0) 156 (58.0) 146 (61.1) 326 (43.6) 
 
Percentages in brackets except where indicated 
*  Percentage of the total selected 
‡  Range in brackets 
§  Standard errors in brackets 
¶  Classified as Hb £ 8 g/dl 
** Classified as present or absent 
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Table 2: Predictors of bed nets ownership (Logistic regression analysis: The final model also included ethnic origin of the child) 
Variable numbers with nets 
(%) 
 Adjusted odd ratio 
(95% CI) 
LRT-c2 a 
(r-value) 
Income categories (quantiles of total family income) 
1st quantile of income 125 (66.8)  1*   
2nd quantile of income 130 (70.7)  1.25 (0.59 to 2.66)   
3rd quantile of income  143 (73.3)  1.13 (0.74 to 1.72)   
4th quantile of income  164 (89.1)  2.74 (1.58 to 4.75) 8.89 (0.031) 
No access to covered wells ‡ 191 (78.0)  0.61 (0.41 to 0.90) 3.90 (0.048) 
Advice care at health facility§  387 (83.4)  2.27 (1.38 to 3.72) 3.90 (0.048) 
Advice care at traditional healer§ 1 (33.3)  0.12 (0.01 to 1.07) 2.97 (0.085) 
Immunised 376 (84.1)  1.92 (0.86 to 4.29) 3.38 (0.066) 
Mother educated 395 (79.0)  1.59 (0.85 to 3.00) 3.15 (0.076) 
a Likelihood ratio test c2 
*  Comparison group 
‡  piped clean water classified under covered wells 
§  place where guardian of study child advises neighbour to sent child sick with fever 
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Net ownership and use 
Predictors of net ownership (Table 2) included family income, those with high income 
(fourth quartile) being about 3 times more likely to have a bed net than those with low 
income (first quartile). This was expected as the treated nets were being sold. By the end of 
the 2nd year of implementation only 16% of the children were without a net. Children with no 
access to piped or covered wells i.e. not at the centre of the villages, were less likely to 
have nets (Table 2). Mothers that mentioned that they would advise their neighbours to 
send their sick children to a formal health facility were more likely to have nets for their 
own children (OR=2.3 Likelihood Ratio Test-c2, p value=0.048). This might reflect an 
association between health seeking patterns or perceptions about the value of the formal 
health system and the decision to have a net or not. 
 
Observation of sleeping places for 171 children in 1999 revealed that, among those who 
claimed to be using nets, 92.9% (117/126) had a net hanging at the sleeping place. For all 
9 children who had a missing net at the sleeping place, we were shown a net claimed to 
be used.  Among those that claimed not to be using nets, 17% (8/45) had a net hanging at 
the sleeping place. These observations indicated that reported ownership and use 
provided a reasonable basis for defining bed net status. 
 
Health impact of treated nets 
We observed a protective efficacy (defined as 1-odds ratio × 100) on the prevalence of 
parasitaemia of 63% (95% CI:38 to 77%) and 51% (95% CI: 0 to 76) for treated and 
untreated nets respectively, when compared with children without nets (Table 3). Parasite 
prevalence was also related to ethnic group, religious affiliation, use of the net in the 
previous month and age of the child, with the prevalence in those more than 1 year of age 
being four times higher than those below 7 months. This is consistent with earlier studies 
in the same area, which demonstrated that prevalence of parasitaemia increased with age 
(Kitua et al. 1996; Smith et al. 1999).    
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Table 3: Impact of nets on prevalence of any parasitaemia (Logistic regression analysis: The final model also included stunting, no 
access to covered wells and sex). 
Variable Numbers with 
parasitaemia 
(%) 
Geometric mean 
parasite density  
Adjusted odd ratio 
(95% CI) 
LRT-c2 a 
(r-value) 
No net 132 (69.8) 4404 1*   
Untreated nets 115 (49.6) 2890 0.49 (0.24 to 1.00)   
Treated nets 120 (36.9) 2745 0.38 (0.23 to 0.62) 8.75 (0.013) 
Use of net in the last 
month 
107 (34.0) 3291 0.53 (0.35 to 0.79) 6.69 (0.010) 
Ethnic group      
Ndamba 49 (36.0) 3901 1*   
Pogoro 76 (66.7) 3423 3.78 (1.62 to 8.87)   
Hehe 42 (43.3) 4315 1.53 (0.74 to 3.16)   
Others 209 (51.1) 3070 2.48 (1.27 to 4.84) 14.63 (0.002) 
Age category      
0 – 6     months 17 (28.3) 2040 1*   
7 – 12   months 106 (43.3) 2710 3.00 (0.95 to 9.44)   
13 – 18 months 114 (55.9) 4111 3.64 (1.31 to 10.14)   
> 18     months 140 (56.5) 3622 4.85 (1.57 to 14.96) 13.4 (0.004) 
Religion      
Other religion 52 (40.9) 4434 1*   
Muslim 157 (58.8) 2967 2.40 (1.32 to 4.35)   
Catholic 159 (45.3) 3404 1.54 (1.00 to 2.37) 8.85 (0.012) 
      
a  Likelihood ratio test c2 
*  Comparison group  
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Table 4: Impact of treated bed nets on prevalence of anaemia (Hb £ 8 g/dl) (Logistic regression analysis:  
The final model also included distance to a shop, use of the net in previous month, immunisation status, age and sex of the child) 
Variable Numbers with 
anaemia (%) 
 Adjusted odd ratio 
(95% CI) 
LRTc2 a 
(r-value) 
No net 103 (54.5)  1*   
Untreated nets 90 (38.8)  0.63 (0.27 to 1.46)   
Treated nets 70 (21.5)  0.37 (0.19 to 0.73) 9.58 (0.008) 
      
Stunted(Z-score£ -3) 109 (51.2)  2.53 (1.66 to 3.84) 12.95 (< 0.001) 
No access to covered wells 
‡ 
87 (35.5)  1.95 (1.24 to 3.07) 7.64 (0.006) 
Religion      
Other religion 40 (31.5)  1*   
Muslim 112 (42.0)  1.80 (0.97 to 3.36)   
Catholic 113 (32.2)  0.96 (0.58 to 1.58) 7.31 (0.026) 
Advice care at health 
facility§  
125 (26.9)  0.45 (0.19 to 1.11) 4.12 (0.042) 
Mother educated 179 (35.7)  1.53 (0.87 to 2.68)  2.93 (0.087) 
a  Likelihood ratio test c2 
*  Comparison group 
‡  piped clean water classified under covered wells 
§  advice neighbour to sent child sick with fever to a formal health facility 
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The mean haemoglobin level was 7.7 g/dl (95% CI:7.4 to 7.9) for those without nets, 8.6 
g/dl (95% CI:8.3 to 8.8) for untreated nets and 9.2 g/dl (95% CI: 9.0 to 9.3) for treated nets. 
Multiple regression analysis showed that there was an increase of haemoglobin of 1.3 g/dl 
(95% CI: 0.8 to 1.7) for those with treated nets and 1.1 g/dl (95% CI: 0.5 to 1.7) for those 
with untreated nets compared to those with no nets. Considering the classification of 
anaemia, a protective efficacy of 37% (95% CI:-46 to 73%) for untreated nets and 63% 
(95% CI:27 to 82%) for treated nets was observed. Those classified as stunted or as 
having no access to covered wells were more likely to be anaemic (Table 4). If the cut-off 
level for anaemia was set at 11g/dl, untreated nets had a protective efficacy of 78% (95% 
CI:29 to 93%) and treated nets of 82% (95% CI:42 to 94%). Paras itaemia was associated 
with anaemia: children with high parasitaemia had lower mean haemoglobin compared to 
those who had no or few parasites (c2-trend, p<0.001). Lastly, nets had also a high impact 
on prevalence of splenomegaly with a protective efficacy of 71% (95% CI:39 to 87%) for 
untreated nets and 76% (95% CI:52 to 88%) for treated nets.   
 
For children without nets, their prevalence of anaemia remained relatively stable over the 
study period (between 49% and 58%) and this was also the case for the prevalence of 
parasitaemia (between 68% and 71%). This suggests that there were no major changes in 
the malaria situation during the period under evaluation. 
 
Discussion 
These results have demonstrated that the social marketing approach of distributing 
insecticide treated nets was very successful and resulted quickly in more than 80% of 
children under two years of age having access to a net. Our results suggest an overall impact 
of social marketing of treated nets on health outcomes in the community, with an 
improvement of mean haemoglobin levels (from 8.0 to 8.9 g/dl) and a decline in the total 
proportion of children with anaemia (from 49% to 26%), parasitaemia or splenomegaly. The 
treated nets had an apparent individual protective efficacy of over 60% on the prevalence of 
anaemia, parasitaemia and splenomegaly. In this study untreated nets were also found to be 
protective. Overall, most of the changes occurred in the first year of implementation.  
 
These efficacy estimates are higher than those from most controlled trials (Table 5). It is 
therefore pertinent to question whether this finding may be the result of residual confounding 
despite the effort made to control for it. This is especially so because our comparison group 
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was made up of children who did not own nets (non-adopters) in the same community. The 
tools used to measure confounding factors like social-economic status and health seeking 
may not be sensitive enough to allow for proper control of confounding. However, factors 
related to the dynamics of the malaria infection and the associated disease presentation may 
also explain this finding. For example, it has been observed that variations in transmission 
strongly affect the estimates of morbidity and mortality in very young children (Marsh & Snow, 
1999). Therefore at a given transmission intensity the age of the study participants may be 
crucial in determining the level of protection. Our finding of high impact in children under two 
years is in line with other studies that included very young children (Table 5).   
 
Lower impact estimates than ours were observed in a randomised study near Ifakara in a 
similar age group (Fraser-Hurt et al. 1999). This may be due to fact that our study covered a 
larger geographical area and included study children with a lower average haemoglobin 
(average haemoglobin of those without nets 7.7 g/dl vs. 8.7 g/dl , t-test =3.9:  p=0.0001). It is 
probable that more anaemic children are more likely to benefit from the intervention.  
 
We conclude that treated nets distributed through a social marketing programme setting were 
effective and produced a rapid and high impact on parasitaemia and anaemia prevalence in 
children under two years of age. This strategy has high potential in the control of malaria in 
Sub-Saharan Africa.   
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Table 5: Impact of treated net materials on anaemia in controlled trials in Sub-Saharan Africa  
Country : Year of  Publication Entomological 
inoculation ratea 
Age 
(months) 
Impact on anaemia  
   Mean 
difference b  
Protective 
efficacy 
 
Control: with untreated nets      
Gambia: (D’Alessandro et al. 1995) 1 to 10 12 to 48 0.1   
Gambia: (Snow et al. 1988) 1 to 10 12 to 108 0.9   
Gambia: (Snow et al. 1987) 1 to 10 12 to 108 0.2   
Gambia: (Alonso et al. 1991) * 10 6  to 72 0.5   
      
Control : Without nets      
Sierra Leone: (Marbiah et al. 1998) 35 3 to 72 1.8   
Ghana: (Binka et al. 1996) 100 to 1000 6 to 59 0.4   
Kenya: (Sexton et al. 1990) 300     
Burkina Faso:(Habluetzel et al. 1997) 300 to 500 6 to 59 0.5   
Tanzania: (Premji et al. 1995)*(<33 pcv) 300 to 700 6 to 40 0.7 49.1  
Tanzania: (Njunwa et al. 1996)*‡(<32 pcv) >300 0 to 108  69.7  
Tanzania: (Fraser-Hurt et al. 1999) >300  5 to 24 0.4   
Tanzania : This study (<24 pcv) 300§ 2 to 26 1.5 73.2  
a  Estimate applicable to the period before insecticide treated nets were introduced or the control group in the trial 
b  Mean haemoglobin difference in g/dl 
*  Non-randomized controlled trials 
‡  Impact estimate of the peak transmission season 
§  Description of malaria situation provided in reference 7 
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Abstract: 
Background: 
Case-control studies have been proposed as an appropriate tool for health impact 
evaluation of insecticide treated nets (ITNs) programmes.   
 
Methods: 
A dispensary based case-control study was carried out in one village in Tanzania. Each 
case of fever and parasitaemia in a child under five years was paired with one community 
and one dispensary control without fever and parasitaemia. Cases and controls were 
compared with regard to ITNs ownership and other factors assessed by a questionnaire. A 
cross-sectional survey of factors associated with parasitaemia, including ITN use, was 
carried out during the study. Dispensary attendance rates of the study children were 
calculated using the passive case detection data. 
 
Results: 
Cases and dispensary controls had higher dispensary attendance rates compared to 
community controls and children with nets attended more for most of the illness events. A 
comparison of cases and community controls showed a strong and statistically significant 
association between untreated net use and being a case (OR 2.1: 95%CI 1.3, 3.4). For 
those with ITNs there was a smaller and weaker association between risk of being a case 
and ITN use (OR 1.4: 95%CI 0.9, 2.2). Comparison of cases and dispensary controls 
showed no association between untreated or treated nets and the risk of being a case (for 
treated nets OR 0.9 : 95%CI 0.5, 1.4 and for untreated nets OR 1.2: 95%CI 0.7, 2.0). 
These results are contrary to those from the cross-sectional assessment, where children 
with ITNs had a lower  prevalence of parasitaemia than those with no nets (OR 0.5: 95%CI 
0.3 – 0.9), and also contrary to other assessments of the health impact of ITNs in this 
population. 
 
Conclusion: 
The positive association between mild malaria and net ownership is counter-intuitive and 
best explained by attendance bias, since children with nets attended more frequently for all 
curative and preventive services at the dispensary than those without nets. Dispensary-
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based case-control studies may not be appropriate for assessing impact of treated nets on 
clinical malaria. 
Introduction:  
Intervention programmes for community health problems in developing countries have 
usually been implemented after their efficacy was demonstrated in randomised controlled 
field trials. Recently more emphasis has been put in assessing the performance of such 
interventions under programme conditions before wide-scale use (Habicht et al. 1999). 
These evaluations aim to test whether the benefits of the interventions observed under trial 
conditions are retained in a programme setting. Positive results will encourage allocation 
of resources to sustain and expand the programmes to cover whole populations in 
endemic countries (Lengeler & Snow, 1996) .  
 
Experience in the impact evaluation of health intervention programmes is limited (Lengeler 
& Snow, 1996). These Phase IV assessments are complicated by the absence of 
appropriate control populations and biased access to interventions and health services. 
Also, there is usually a limited opportunity for establishing an elaborate evaluation system 
that may be required to accurately assess exposure and outcome events in the target 
population (Habicht et al. 1999; Mohr, 2000).  Therefore, inexpensive, simple and non-
intrusive evaluation tools are required.  
 
Case-control studies have been proposed as the most convenient and appropriate tools in 
the evaluation of insecticide treated nets (ITNs) programmes (Lengeler & Snow, 1996). 
This was further advocated after the first ITNs programme evaluation in the Gambia 
(D'Alessandro et al. 1997). Case-control studies are attractive because they can be 
performed relatively cheaply and quickly after the initiation of the intervention (Habicht et 
al. 1999). But they also face well-described problems of bias and confounding, as with all 
observational studies (Schlesselman, 1982).  
 
The use of “passive case detection” through clinics rather than through active surveillance 
simplifies a case-control study (Rowland et al. 1997) and may improve classification of 
disease status (Kirkwood et al. 1997). However, this increases the difficulty of selecting 
appropriate controls.  
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Alternatively, cross-sectional surveys can be done. These assess prevalence and lack the 
time sequence between exposure and disease events if a single survey is carried out 
(Kirkwood et al. 1997). However, repeated cross-sectional studies have been used to 
assess impact of ITNs programmes (Barutwanayo et al. 1991; D'Alessandro et al. 1995; 
Van Bortel et al. 1996; Abdulla et al. 2001). 
 
Here we describe a case control study relying on passive case detection in an area of 
Tanzania where other studies have reported a positive impact of an ITNs social marketing 
programme on child health and survival (Abdulla et al. 2001; Schellenberg et al. 2001). 
The programme utilised marketing techniques to promote, distribute and sell pre-treated 
bed nets and insecticide kits for re-treatment (Schellenberg et al. 1999).  
 
 
Methods: 
Study site and population:  
The study was conducted in Idete village (08o 5’ S; 36o 30’ E), Kilombero District, 
Southeast Tanzania.  The village is one of 18 in the Kilombero Valley within a 
demographic surveillance system (DSS) (Schellenberg et al. 1999). The area has intense 
year-round malaria transmission (Charlwood et al. 1998). Prompt diagnosis and treatment 
of clinical cases is the main control strategy and resistance to chloroquine, the first line 
antimalarial at the time of the study, was  high (Mshinda et al. 1996). Children under five 
years of age living in all the hamlets (vitongoji) of Idete village were included in the study.   
 
Case-control study: 
All children in the DSS database who were under the age of five on 1st February 1998 
were  assigned a study number and given a special card bearing the name, date of birth, 
the area of residence and DSS identifiers.  This list was updated every 6 months to include 
new-borns and  children who had migrated into the village. A passive case detection 
system (PCD) operated  at the only local dispensary between February 1998 and August 
1999 and all children under five years who attended the dispensary for any complaints 
were eligible. A standard form was filled out and a blood sample was taken on all children 
who had a history of fever in the previous 48 hours, or a presumptive diagnosis of malaria. 
Haemoglobin (Hb) was measured using the Hemocue® (HemoCue AB, Ängelholm, 
Sweden) system and thick and thin films were prepared for microscopy. Records were also 
kept for all children who were not sick and had attended for preventive reasons, such as 
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growth monitoring. Children with a temperature of more than 37.4 OC and any 
parasitaemia were classified as cases.  
 
For each case, one age matched dispensary control was chosen among the children who 
had come for growth monitoring or attended for being sick for another cause than malaria, 
within two weeks of the attendance of the case. An additional community control was 
chosen from the DSS database matched for age and area of residence (hamlet). If a 
suitable control could not be found then a child of an adjacent hamlet was chosen. Both 
cases and controls were then visited at home, individual verbal consent was asked from 
the guardian and a questionnaire applied. A blood sample was taken from controls who 
had not given a blood sample at the dispensary in the two weeks prior to the day of the 
interview. Controls with temperature more than 37.4 and any parasitaemia were excluded 
in the analysis. Cases and controls were not eligible for recruitment again as either cases 
or controls for a period of one month.  
 
Cross-sectional survey:  
In June-August 1998, all children under five years of age on 1st February 1998 were visited 
at home and a questionnaire applied to assess their use of ITNs and other risk factors for 
malaria infection and anaemia (using a similar approach to the case-control study). A 
blood sample (for malaria parasites and Hb estimation) was taken for children who had not 
given a blood sample at the dispensary in the two weeks prior the day of the interview. The 
position of all houses with children under five and the dispensary were also determined 
using a portable Global Positioning System device (Garmin International, Kansas City, 
USA). The geo-referenced points were then used to calculate the distance from each 
child’s house to the dispensary.  
 
Dispensary attendance rates: 
The PCD data were linked to the DSS data to estimate dispensary attendance rates for 
different illnesses among study children. Attendance for malaria as well as for growth 
monitoring and other non-malaria related illnesses (including injuries, burns, fungal 
infestations, conjunctivitis, abscesses, etc.) was done.  Mosquito net ownership was 
ascribed from the cross-sectional data. 
 
Chapter 6: Assessment of impact on Malar ia morbidity, case-control study 
85 
 
Analysis: 
In the case-control assessment, cases of mild malaria were compared with controls 
primarily with regard to their exposure to ITNs. Both unmatched and matched pairs 
multivariate analysis using logistic regression was carried out using Stata version 6 (Stata 
Corporation, Texas USA). The risk or confounding factors considered included the number 
of people in the room where the child slept , sex of the child, age category, time to the 
nearest shop, access to clean water source, tribe, if the mother or guardian would advise 
neighbour to send a child sick with fever to a formal health facility, religious affiliation, 
nutritional status, vaccination status, antimalarial and antipyretic use, mother/guardian’s 
literacy and the condition of the net in terms of the number of holes and its use in the 
previous month. Family income (quantiles of total family income), which was assessed by 
asking on the average monthly income from various activities of the family, was also 
considered. Significance testing was done using the likelihood ratio test. For the cross-
sectional assessment, the parasitaemia and anaemia were compared between users and 
non-users of ITNs, after controlling for confounding using logistic regression.  
 
 
Results: 
Case-control study: 
Idete village had a total of 881 children under five in the DSS database on 1st February 
1998. A total of 3389 visits of children under five years of age were recorded at the 
dispensary between February 1998 and August 1999. A total of 587 mild malaria cases 
were identified which were individually matched with 424 dispensary and 555 community 
controls. For some cases we could not identify a suitable control from the database and 
not all of the identified cases and controls could be traced at their homes because of either 
travelling or moving to farm houses that could not be located. Those available for interview 
were 461 cases (78.5%), 333 (78.5%) dispensary controls and 423 (76.2 %) community 
controls. 7 community controls and 8 dispensary controls had fever and parasitaemia and 
were excluded in the analysis. 40 cases, 45 community and 17 dispensary controls were 
excluded due to missing information on actual distance to the dispensary.  
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Interviewed children had an average age of 26 months (95%CI: 24 , 27) for cases, 26 
months (95%CI: 25 , 27) for community and 25 months (95%CI: 23 , 26) for dispensary 
controls. The mean Hb was 9.2 g/dl (95%CI: 9.0 , 9.5) for cases, 10.2 (95%CI: 10.0 , 10.4) 
for community controls and 10.1 (95%CI: 9.9 , 10.4) for dispensary controls. The Hb 
difference between cases and either controls reached statistical significance (Wilcoxon 
rank-sum tests: p<0.001).  
 
Important risk factors for becoming a case compared to community controls included 
having a net and living far away from the dispensary. In the unmatched analysis, those 
with untreated nets were about twice as likely to be cases than those without nets (OR 2.1: 
95%CI 1.3, 3.4).  Those with ITNs also appeared to be more likely to be cases (OR 1.4: 
95%CI 0.9, 2.2) but the relationship was not statistically significant (Table 1a). When 
comparison was made using dispensary controls, there was no apparent protective effect 
of either untreated nets nets (OR 1.2: 95%CI 0.7, 2.0)  (Table1b) and only a small effect of 
treated nets, which did not reach statistical significance (OR 0.9: 95%CI 0.5, 1.4). Similar 
results were observed with matched analysis (data not shown). 
 
Distance to the dispensary was a significant predictor of being a case compared to both 
types of controls. Those living more than 3 kilometres away were twice more likely to be 
cases (community controls (OR 1.9: 95%CI 1.1, 3.1) and dispensary controls (OR 2.6: 
95%CI 1.5, 4.7). There were no other risk factors associated with being a case.  
 
Dispensary Attendance: 
 Cases and dispensary controls had dispensary attendance rates of 12.5 per thousand 
while the rate was only 10.7 per thousand for community controls. Children with nets 
attended more for most of the illness events (Table 2). Distance from the dispensary was a 
limiting factor for attendance observed by the decrease in overall attendance with 
increasing distance to the dispensary (chi-square for trend p<0.001). Ownership of ITNs 
was an indicator for higher utilisation of the dispensary for those living between 0.5 and 3 
kilometres but not for those living very close or very far from the dispensary (Table 2).  
 
Cross-sectional study: 
In total 652 children were interviewed in the cross-sectional assessment. The analysis 
included 629 (96.5%) children for whom we had information on both the net and Hb status. 
The characteristics of the children included in the analysis of the cross-sectional survey 
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showed that those without nets had a higher prevalence of parasitaemia, anaemia and 
splenomegaly (Table 3). Comparison of those with ITNs and with no nets in a multivariate 
analysis showed that those with ITNs had a lower prevalence of any parasitaemia (OR 0.5: 
95%CI 0.3 – 0.9). Age of the child and distance to the dispensary were other important 
factors (Table 4). Positive effects of treated nets were also shown for prevalence of 
anaemia.  
 
 
Discussion: 
We found a positive association between risk of clinical malaria and ownership of mosquito 
nets using a case-control design. This finding is counter -intuitive and contradicts the 
results of the cross-sectional assessment the same village and a repeated cross-sectional 
assessment conducted in the surrounding villages, which suggested an impact of the ITNs 
in reducing the prevalence of anaemia and parasitaemia by 60% (Abdulla et al. 2001). An 
estimated 27% reduction in childhood deaths associated with treated nets has also been 
shown in the same area (Schellenberg et al. 2001). The discrepancy is likely to be a 
consequence of attendance bias in the Idete case-control study. Children with nets 
attended more frequently for all the services at the dispensary, which may be explained by 
the higher awareness of health issues or as a consequence of the dispensary being one of 
the ITN sales outlets. Hence, the exposure of interest pre-determined to some extent the 
recruitment, resulting in analysis and estimation of impact to be done on an already 
selected group of individuals. Those with nets would be included as cases if they became 
sick. But those without nets were less likely to attend the health facility so although they 
were eligible to be community controls they were not likely to be seen as cases if they 
became sick with malaria. Thus, the community controls were not comparable with cases 
and both cases and dispensary controls were not comparable with the general population 
in the area. The lack of a statistically significant association between ITN ownership and 
being a case when considering dispensary controls may be due to a lack of power or to 
the fact that the exposure of interest also determined the likelihood of being a dispensary 
control. Attendance bias is neither easily measured nor can it be corrected for in the 
analysis (Sackett, 1979). 
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Table 1a: Risk factors for being a case of malaria at the Idete dispensary (unmatched analysis using community controls) 
Variable Cases Community 
controls 
Crude odds ratio 
(95% CI)* 
Adjusted odds ratio 
(95% CI) 
LRT –c2  
(r-value) 
Number 421 371    
Net ownership      
No net 52 (12.3) 63 (17.0) 1 1  
Untreated net 125 (29.7) 77 (20.7) 1.97 (1.24, 3.13)  2.10 (1.31 , 3.38)  
Treated net 244 (58.0) 231 (62.3) 1.29 (0.85 , 1.93) 1.42 (0.93 , 2.17) 10.33  (0.006) 
Distance to the Dispensary      
Below  500 meters 45 (10.7) 60 (16.2) 1 1  
500 – 1500 meters 197 (46.8) 185 (49.9) 1.42 (0.92 , 2.20) 1.39 (0.90 , 2.15)  
1500 – 3000 meters 86 (20.4) 61 (16.4) 1.88 (1.13 , 3.12) 1.97 (1.18 , 3.30)  
Above  3000 meters  93 (22.1) 65 (17.5) 1.91 (1.16 , 3.15) 1.89 (1.14 , 3.13) 9.19  (0.027) 
      
      
Table 1b: Risk factors for being a case of malaria at the Idete dispensary (unmatched analysis using dispensary controls) 
Variable Cases Hospital 
controls 
Crude odds ratio 
(95% CI)* 
Adjusted odds ratio 
(95% CI) 
LRT –c2  
(r-value) 
Number 421 308    
Net ownership      
No net 52 (12.3) 34 (11.0) 1 1  
Untreated net 125 (29.7) 69 (22.4) 1.19 (0.70 , 2.00)  1.19 (0.70 , 2.03)  
Treated net 244 (58.0) 205 (66.6) 0.79 (0.49 , 1.25) 0.86 (0.53 , 1.39) 3.39  (0.184) 
Distance to the Dispensary      
Below  500 meters 45 (10.7) 46 (14.9) 1 1  
500 – 1500 meters 197 (46.8) 172 (55.9) 1.17 (0.74 , 1.85) 1.15 (0.73 , 1.83)  
1500 – 3000 meters 86 (20.4) 56 (18.2) 1.57 (0.92 , 2.67) 1.54 (0.91 , 2.63)  
Above  3000 meters  93 (22.1) 34 (11.0) 2.80 (1.58 , 4.94) 2.62 (1.48 , 4.65) 16.39  (<0.001) 
Note: The multivariate models were built from variables that included number of people in the room where the child is sleeping, sex of the 
child, age category, time to the nearest shop, access to clean water source, tribe, stunting (height for age Z-scores £-3), family income 
category (quantiles of total family income), if the mother or guardian would advise neighbour to send a child sick with fever to a formal 
health facility, mother/guardian’s literacy and the condition of the net in terms of the number of holes. All these variables were dropped as 
their log-likelihood ratio test p value was more than 0.05. 
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Table 2: Attendance rates for different reasons at Idete dispensary for children with and without treated nets 
Attribute No nets  Untreated nets  Treated nets 
 Number Rate§  Number Rate§ RR‡  Number Rate§ RR‡ 
Total number of children in the cohort 134   140    304   
Total days of follow up 52310   59769    132442   
           
Attendance for growth monitoring 90 1.7  178 3.0 1.7 (1.3,2.3)  401 3.0 1.8 (1.4,2.2) 
           
Total attendance for any illness 295 5.6  392 6.6 1.2 (1.0,1.4)  1221 9.2 1.6 (1.4,1.9) 
           
Attendance rate sick with anaemia 28 0.5  38 0.6 1.2 (0.7,2.0)  112 0.9 1.6 (1.0,2.5) 
           
Attendance rate sick and malaria slide positive 120 2.3  147 2.5 1.1 (0.8,1.4)  423 3.2 1.4 (1.1,1.7) 
           
Attendance rate sick with diarrhoea 67 1.3  91 1.5 1.2 (0.9,1.7)  316 2.4 1.9 (1.4,2.5) 
           
Attendance rate sick with non malaria-related illness 56 1.1  77 1.3 1.2 (0.8,1.7)  210 1.6 1.5 (1.1,2.0) 
           
Attendance rate for *:           
Those living within 0.5 kilometers 42 11.9  59 8.0 0.7 (0.5,1.0)  179 11.2 1.0 (0.7,1.4) 
           
Those living between 0.5 - 1.5 kilometers 137 5.8  147 6.6 1.1 (0.9,1.5)  647 11.9 2.0 (1.7,2.5) 
           
Those living between 1.5 - 3 kilometers 37 4.2  90 8.0 1.9 (1.3,2.9)  147 7.9 1.9 (1.3,2.8) 
           
Those living more than 3 kilometers 67 4.6  78 4.7 1.0 (0.7,1.4)  147 4.4 1.0 (0.7,1.3) 
           
§: Rate per 1000 person days 
‡: Relative rate comparing with those with no nets and 95% confidence intervals in brackets  
*: Calculated based on specific total person days of follow up for each distance category 
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Table 3: Characteristics of the children in Idete village from the cross-sectional assessment 
Attribute No nets (%) Untreated nets (%) Treated nets (%) Overall 
Children analysed  140 (22.2) 159 (25.3) 330 (52.5) 629 
Mean age in months * 36.4 (33.4  , 39.3 ) 32.2 (30.4  ,  36.1 ) 28.6 (26.6 , 30.8) 31.5 (30.0 , 33.0) 
Males  74 (52.9) 76 (47.8) 162 (49.1) 312 (49.6) 
Mean Haemoglobin * 9.5 (9.2 , 9.8) 10.0 (9.7 , 10.3) 9.9 (9.7 , 10.1) 9.8 (9.7 , 10.0) 
Moderate severe anaemia 17 (12.1) 14 (8.8) 31 (9.4) 62 (9.9) 
Mild anaemia 98 (70.0) 101 (63.5) 199 (60.3) 398 (63.3) 
Parasitaemia (P. falciparum)# 98 (70.0) 92 (58.2) 155 (47.3) 345 (55.1) 
Splenomegaly   59 (42.1) 41 (25.8) 68 (20.7) 168 (26.8) 
Distance to the dispensary 
less than 1500 meters § 
62 (49.2) 75 (52.8) 180 (60.8) 317 (56.2) 
* :   95% confidence interval in brackets 
# : Children assessed for parasitaemia were 626 
§ : Children assessed for distance to the dispensary were 564 
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Table 4: Risk factors for parasitaemia in the cross-sectional survey 
Variable Numbers with 
parasitaemia (%) 
Crude odd ratio 
(95% CI) 
Adjusted odd ratio 
(95% CI) 
LRT –c2  (r-value) 
      
Net ownership      
No net 89 (28.3) 1 1   
Untreated net 82 (26.1) 0.57 (0.34 , 0.94) 0.67 (0.39 , 1.15)   
Treated net 143 (45.6) 0.39 (0.24 , 0.60) 0.53 (0.33 , 0.85) 7.09  (0.029) 
      
Age  category      
Below 1 year 25 (8.0) 1 1   
1 - 2 years 50 (15.9) 2.95 (1.64 , 5.30) 2.87 (1.58 , 5.25)   
2 - 3 years 77 (24.5) 6.81 (3.77 , 12.31) 6.47 (3.53 , 11.84)   
3 – 4 years 60 (19.1) 6.11 (3.30 , 11.31) 5.33 (2.83 , 10.04)   
Above 4 years 102 (32.5) 8.79 (4.92 , 15.68) 8.58 ( 4.72 , 15.59) 68.88  (<0.001) 
      
Distance to the Dispensary      
Below  500 meters 26 (8.3) 1 1   
500 – 1500 meters 140 (44.6) 2.29 (1.33 , 3.94) 2.39 (1.33 , 4.30)   
1500 – 3000 meters 60 (19.1) 3.46 (1.80 , 6.64) 3.65 (1.80 , 7.42)   
Above  3000 meters  88 (28.0) 2.18 (1.22 , 3.87) 2.14 (1.15 , 3.98) 14.01  (0.003) 
      
Note: The multivariate model was built from variables that included sex of the child, time to the nearest shop, access to clean water 
source, religious affiliation, antimalarial use in the last illness, family income category (quantiles of total family income), if the mother or 
guardian would advise a neighbour to send a child sick with fever to a formal health facility, mother/guardian’s literacy, the history of use 
of the net in the previous month and the condition of the net in terms of the number of holes. All these variables were dropped as their 
log-likelihood ratio test p value was more than 0.05. 
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Case-control studies for the evaluation of an intervention, usually compares the risk of 
being diagnosed with the disease among the adopters and non-adopters of the 
intervention, which will be similar to assessments using either longitudinal or cross-
sectional studies (Kirkwood et al. 1997). For all these approaches, the adopters of the 
intervention are likely to differ from non-adopters in subtle but important ways that cannot 
be assessed or controlled for in the analysis. The comparison of adopters vs. non-
adopters answers a different type of question from intervention vs. control, with the former 
measuring the health benefit of those who adopt rather than health impact per se 
(Kirkwood et al. 1997). Therefore the results of these two comparisons cannot be directly 
compared. In an ITNs programme, a randomly allocated contemporaneous control group 
(Lengeler & Snow, 1996) would no longer be ethically acceptable or feasible, as this 
involves withholding nets from some groups given their proven impact on mortality.  
 
The comparisons of adopters vs. non-adopters in our studies illustrate an particular 
difficulty of assessing ITNs programme impact where ITNs use is very high. It may then be 
impossible to make this comparison because of the small numbers of non-adopters, who 
will represent a highly selected group. Furthermore, the likelihood that there is a “mass 
effect” of the ITNs (Howard et al. 2000) may give some protection to non-adopters and this 
reduces differences in the malaria disease burden between adopters and non-adopters.  
 
The logistical difficulty of obtaining enough cases and controls adds to the complexity of 
such studies. In our study the recruitment extended over 18 months and had a high rate of 
non-interviewed cases and controls. In the previous study in the Gambia a difference in 
the timing and recruitment pattern of the community and health facility controls was 
thought to be the source of discrepancy in the study results (D'Alessandro et al. 1997). 
Together, these observations call into question the usefulness of health facility based 
case-control studies for evaluating the morbidity impact of ITNs programmes. An 
alternative study design would have been to use active case detection in the community. 
All children in the village could be visited at home every week, temperature taken from all 
and blood slides from those with fever. The cases would then those with fever and 
parasitaemia and the controls would be a random sample of those without. However, this 
is logistically more complex and expensive, and hence usually unrealistic in the frame of a 
programme evaluation.  
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The lack of a simple test to check for insecticide content of the nets (Drakeley C.J. et al. 
1999) meant that exposure to ITNs could not be accurately ascertained as suggested by 
work in The Gambia (Muller et al. 1994; D'Alessandro et al. 1997). Reported ownership of 
ITNs may have led to some misclassification of exposure in our studies and reduced the 
power. 
 
The finding that distance to the dispensary is an important predictor of attendance is in line 
with findings elsewhere (Stock et al. 1983). However, it is unclear if the observation of 
more cases from those living far from the dispensary indicates a true occurrence of more 
disease in the periphery of the village, or if it is just a reflection of patterns of dispensary 
attendance and self-medication for malaria episodes in the village. Furthermore, the odds 
ratios need to be interpreted with caution as cases and controls were matched on area of 
residence.  
 
Every health programme implementing interventions shown to be effective in randomised 
controlled trials aims to demonstrate that the desired health impact is also achieved under 
large-scale implementation – and if not, then why. However, given that (1) programme 
staff are unlikely to be familiar with epidemiological studies and (2) most programmes wish 
to invest more of their resources in implementation rather than monitoring, a compromise 
with regard to the optimal study design will have to be made.  The use of simple cross-
sectional surveys seems to be an attractive option, if suitable health outcomes can be 
identified and relevant exposure measures are feasible. 
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Abstract: 
 
Randomised controlled trials have shown that Insecticide Treated Nets (ITNs) have an 
impact on both malaria morbidity and mortality. Uniform high coverage of ITNs 
characterised these trials and this resulted in some protection of nearby non-users of ITNs. 
We have now assessed the coverage, distribution pattern and resultant spatial effects in 
one village in Tanzania where ITNs were distributed in a social marketing programme. The 
prevalence of parasitaemia, mild anaemia (Hb < 11 g/dl) and moderate/severe anaemia 
(Hb < 8 g/dl) in children under five was assessed cross-sectionally. Data on ownership of 
ITNs were collected and inhabitants’ houses were mapped.  
 
One year after the start of the social marketing programme, 52% of the children were 
using a net which had been treated at least once. The ITNs were rather homogeneously 
distributed throughout the village at an average density of about 118 ITNs per thousand 
population. There was no evidence of a pattern in the distribution of parasitaemia and 
anaemia cases, but children living in areas of moderately high ITNs coverage were about 
half less likely to have moderate/severe anaemia (OR 0.5, 95%CI: 0.2 , 0.9) and had lower 
prevalence of splenomegaly, irrespective of their net use. No protective effects of 
coverage were found for prevalence of mild anaemia nor for parasitaemia. The use of 
untreated nets had neither coverage nor short distance effects. More efforts should be 
made to ensure high coverage in ITNs programmes to achieve maximum benefit. 
  
 
Chapter 7: Spatial effects of ITNs 
99 
Introduction: 
There is growing interest on insecticide treated bed nets (ITNs) as a tool for malaria 
control, after randomised controlled trials showed that they reduce morbidity and mortality 
from malaria (Lengeler, 1998) . Large scale implementation programmes are underway 
focusing mainly on operational issues of delivery and distribution of ITNs in a sustainable 
manner (Anonymous, 1999) .   
 
The ITNs act by both being a physical barrier protecting those sleeping under them and by 
killing and repelling mosquitoes hence reducing the survival and infection rates (Lines, 
1996). Hence those with the ITNs and who use them properly have a reduced exposure to 
malaria infecting mosquitoes and consequently reduced malaria disease burden. The 
distribution pattern and coverage levels attained in implementation programmes may 
determine the level of protection observed in those who use them (D'Alessandro et al. 
1995; Binka et al. 1998; Howard et al. 2000). Protection is highest among persons with 
ITNs living in areas with high ITN coverage and use. There are indications that people 
without nets sleeping nearby ITNs are also protected. Earlier work showed some short 
range (within the same room) protective effects of ITNs (Lines et al. 1987) while other 
studies did not show such protection (Rowland et al. 1996). Work conducted in Ghana 
supports the claims of short distance protective effects (those near ITNs are also 
protected) on those without bed nets. Among non-users the mortality risk increased by 
6.7% with every 100 meters shift away from the nearest compound with treated bed nets 
(Binka et al. 1998). In the Kenyan coast those living up to 0.5 kilometers away had also 
lower hospital attendance rates for severe disease (Howard et al. 2000).  
 
In the randomised studies ITNs were distributed free to all the intervention groups and 
uniformly high coverage was ensured (Binka et al. 1998;Habluetzel et al. 1997;Nevill et al. 
1996), while in the programme setting the pattern of distribution is dependent on the many 
factors that determine the uptake of the ITNs intervention. These include social economic 
factors, distribution channels and local perceptions about ITNs (Fraser-Hurt & Lyimo. 
1998; Snow et al. 1999; Minja et al. 2001). This has lead to speculation on what might 
happen when ITNs are distributed in a programme setting.   
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It is not clear what patterns of spatial distribution of ITNs will occur in social marketing 
schemes. Conceivably, market mechanisms may lead to ITNs being widely but thinly 
distributed, with thus a relatively low coverage. This may  be a more efficient way of 
conferring protection for those without ITNs (Binka et al. 1998). Alternatively, ITNs might 
end up being concentrated where the wealthiest people are whilemalaria transmission and 
disease is more likely to be concentrated on the poorest segment of the population, who 
tend live on the edges of the villages and may be less likely to have nets (Bonilla & 
Rodriguez. 1993; Smith et al. 1995; Charlwood et al. 1998; Abdulla et al 2001). Therefore, 
spatial effects of ITNs may be important in the understanding and interpretation of the 
results of impact assessments of ITNs programmes for malaria control.  
 
We report the investigation of the spatial pattern of ITNs in one village covered by a large 
scale ITNs social marketing programme and the consequent effects on malaria morbidity 
indicators in children under five years of age.  
 
Methods: 
Study population and design.  
The study was conducted in Idete village, South Western Tanzania (08o 5’ S; 36o 30’ E). 
The residents are mainly subsistence farmers and the main crop is rain fed rice. This is an 
area of intense year-round malaria transmission. The main vectors are Anopheles 
gambiae ss, Anopheles arabiensis and Anopheles funestus  (Smith et al. 1993; Charlwood 
et al. 1998).  A social marketing programme for ITNs has been implemented in this area 
since May 1997 (Schellenberg et al. 1999).  
 
A cross-sectional assessment of all children under five living in all the hamlets (‘vitongoji’) 
of Idete was done at the end of the main rainy season June – August 1998. Details of the 
survey are described elsewhere (Abdulla et al. 2002). In summary, children were visited at 
home and a questionnaire was applied to assess use of ITNs and other risk factors for 
malaria infection and anaemia. A physical examination was carried out and a blood 
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sample was taken. The sample was screened for malaria parasites and haemoglobin level 
(Hb) was assessed using HemocueÒ (Angelholm, Sweden). 
 
Age and sex data for the community were available from a Demographic Surveillance 
System (DSS) established to allow the evaluation of impact of the social marketing 
programme (Schellenberg et al. 1999). ITNs ownership was also assessed in the 4 
monthly cycles within the framework of the DSS. 
 
Mapping: 
The position of the houses and other important service outlets including the dispensary, 
were determined using a portable Global Positioning System (Garmin, Thousand oaks, 
USA). The geo-referenced points were then used to calculate distance between houses 
and between the houses and the dispensary. Coverage of ITNs and untreated nets were 
calculated for each individual child in the cross-sectional survey. The number of nets per 
1000 population living in houses other than the index child and within specific radii were 
calculated. Radii of 50m (R50), 100m (R100), 200m (R200) and 400m (R400) were chosen, on 
the basis of the findings of other studies (Binka et al. 1998;Hii et al. 2001). Coverage was 
categorised as low (0 ITNs/1000 persons), moderate (1-300 ITNs/1000 persons) and high 
(>300 ITNs /1000 persons). 
 
Analysis: 
The outcomes of mild anaemia ( Hb <11 g/dl), moderate/severe anaemia (Hb<8g/dl) and 
any parasitaemia in the cross-sectional assessment were compared between users and 
non-users of ITNs, after controlling for confounding using logistic regression analysis. The 
explanatory variables also included ITNs coverage and distance to the dispensary (Abdulla 
et al. 2002). Logistic models were also used to assess the effects of different risk factors 
on mild and moderate/severe anaemia. Random effects were added on the logit scale of 
these models to take into account the spatial structure of the data, that is, 
   log(pi / 1- pi) = b t Ci  + ei 
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where pi is the outcome probability, b the vector of coefficients and Ci the vector of 
covariates for individual i. Spatial correlation was incorporated in the random effects ei, by 
parameterising their covariance matrix , such that: 
Cov(ei, ej) = s 2  f(dij) 
 where dij measures the Euclidean distance between location si and sj. We modeled an 
exponential decrease of spatial correlation with distance by adopting: 
f(dij) = exp(-r dij) 
but also compared the fit of this model with others, considering different choices of spatial 
covariance types using the Akaike’s information criterion (AIC). Explanatory variables, 
such as age, distance to dispensary etc., were discretizised into several categories. The 
analysis was done using the SAS GLIMMIX macro, which uses iteratively reweighted 
likelihoods (Wolfinger & O'Connell 1993) to fit the models. The likelihood ratio test was 
used to assess the significance of the explanatory variables on the outcomes. 
 
 
Results: 
652 children were examined in the cross-sectional survey. Details of their characteristics 
and the assessment of the impact of ITNs on occurrence of anaemia and parasitaemia 
have been described elsewhere (Abdulla et al. 2002). In short, those children using ITNs 
had lower risk of anaemia (OR 0.47 ,95%CI: 0.30 – 0.75) and moderate/severe anaemia 
(OR 0.66,95%CI: 0.32, 1.37) compared to those without nets at all. The relationship did 
not reach statistical significance for moderate/severe anaemia. A statistically significant 
difference was also observed on the prevalence of any parasitaemia (OR 0.53,95%CI: 
0.33 – 0.85). Other risk factors identified included distance to the dispensary, which was 
positively correlated to the prevalence of moderate/severe anaemia, and any 
parasitaemia. 
 
Coverage effects: 
The DSS database had 941 households in Idete at the time of the cross-sectional 
assessment. 708 (75.2 %) were present in the village and their houses mapped at the time 
of mapping exercise. The mapped houses had significantly more members on average, a 
higher proportion with children under five and fewer single member households than those 
not mapped (Table 1).  
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Table 1: Characteristics of the mapped and un-mapped households in Idete village 
Attribute Mapped (%) Not Mapped (%) c2  (P-value) ‡ 
DSS – Households  708 (75.2) 233 (24.8)  
Average number of persons * 5.2 (5.0  , 5.3) 3.6 (3.3  ,  3.9) 8.160 (<0.001) 
Households with children under five years  495 (69.9) 89 (38.2) 74.904 (<0.001) 
Households with a single adult member only 68 (9.6) 63 (27.0) 44.465 (<0.001) 
    
Households with known net status 620 (87.6) 146 (62.7) 71.854 (<0.001) 
Households with no net 176 (28.4) 44 (30.1)  
Households with at least one untreated net 227 (36.6) 57 (39.1)  
Households with at least one treated net 217 (35.0) 45 (30.8) 0.917 (0.632) 
Average treated net per 100 persons 13.3 (11.6 , 15.1) 17.4 (12.1 , 22.6) 0.03 (0.978) 
Average untreated net per 100 persons 13.3 (11.5 , 15.1) 20.9 (15.8 , 26.1) 1.827 (0.068) 
* :   95% confidence interval in brackets and Wilcoxon rank sum test statistic 
‡ : Pearsons c2 with Yates continuity correction 
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There were 626 children under five years of age included in the cross-sectional survey. 
Analysis presented here was restricted to 564 (90.1%) children classified as DSS 
members and who had information available on geo-location, bed net and anaemia status. 
The mean ITN coverage in the study area was 118.8 per 1000 inhabitants (range 0 – 
1000). As defined by coverage at 100 meters (C100), 259 (45.1%) children lived in low, 256 
(44.5%) moderate and 60 (10.4%) in high ITNs coverage areas (Table 2). Children living in 
the different 3 coverage levels had similar average age, average haemoglobin level, 
proportions with mild anaemia and parasitaemia (Table 2).  But those living in moderate 
and high coverage had significantly lower proportions of moderate/severe anaemia and 
splenomegaly than those living in low coverage areas (9% vs 16.2 and 22.8% vs. 33.6% 
respectively). Significantly higher proportions of children in the moderate and high 
coverage groups were living within one and a half kilometers of the dispensary (Table 2). 
Similar proportions of children with ITNs were observed in the three areas, indicating that 
coverage did not predict children’s net ownership. However, those living further from the 
centre of the village had a lower proportion of ITNs (173 versus 93 per thousand 
population for those living within 500 meters and those living over 3 kilometers 
respectively: extended Kruskal-Wallis test for trend, p < 0.01)      
 
The model used to explore the effects of different risk factors on having moderate/severe 
anaemia (Abdulla et al. 2002) was adjusted to investigate the effect of coverage. The 
results indicate that coverage was an important factor for predicting the risk of having 
anaemia even after controlling for the other already identified factors (Table 3). There was 
less moderate/severe anaemia among those living in moderate (OR 0.46, 95%CI: 0.23, 
0.91) and high (OR 0.33, 95%CI: 0.09, 1.16) ITNs coverage area compared to those living 
in low coverage areas. This indicates that coverage is independently associated with the 
occurrence of moderate/severe anaemia in the study area.  
 
Analysis using other radii did not show significant results for moderate/severe anaemia nor 
other outcome variables assessed. Furthermore no coverage effects were observed for 
untreated nets for any radii or morbidity indicators. 
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Table 2: Characteristics of children living within the different coverage areas (C100) in Idete village 
Attribute No other ITNs per 1000 
persons (%) 
1 – 300 other ITNs  
per 1000 persons (%) 
301 – 1000 other ITNs  
per 1000 persons (%) 
c2  (P-value) ‡  
Children analysed * 255 (45.2) 249 (44.2) 60 (10.6)  
Mean age in months ** 32.3 (30.0  , 34.6) 31.7 (29.4   ,  34.1) 32.3 (27.7 , 36.9) 0.17 (0.921) 
Mean Haemoglobin ** 9.6 (9.4 , 9.9) 10.0 (9.8 , 10.2) 9.8 (9.4 , 10.2) 4.85 (0.089) 
Moderate severe anaemia 38 (14.9) 16 (6.4) 3 (5.0) 11.89  (0.003) 
Mild anaemia 163 (63.9) 151 (60.6) 42 (70.0) 1.95 (0.378) 
Parasitaemia (p. falciparum)# 152 (59.8) 126 (50.8) 35 (59.3) 4.49 (0.106) 
Splenomegaly  § 86 (33.7) 56 (22.6) 12 (20.0) 9.69 (0.008) 
Living within 1500m of the 
Dispensary 
100 (39.2) 182 (73.1) 35 (58.3) 58.86 (<0.001) 
Owning an ITN 139 (54.7) 112 (45.0) 30 (50.0) 4.78 (0.092) 
     
* Percentage of total children in brackets 
** :   95% confidence interval in brackets and Kruskal-Wallis Statistic    
# : The total of children assessed for parasitaemia was 561 
§ : The total of children assessed for splenomegaly was 563 
‡ : Pearsons c2 with Yates continuity correction 
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Table 3: Risk factors for anaemia (Hb< 8 g/dl) in children in Idete village 
Variable Numbers with 
anaemia (%) 
Crude odd ratio 
(95% CI) 
Adjusted odd ratio 
(95% CI) 
LRT –c2  (P-value) 
Net ownership      
       No net 15 (28.3) 1 1   
       Untreated net 12 (22.6) 0.72 (0.32 , 1.61) 0.67 (0.28 , 1.59)   
       Treated net 26 (49.1) 0.72 (0.36 , 1.42) 0.64 (0.31 , 1.31) 1.51  (0.470) 
      
Mother literate 20 (37.7) 0.39 (0.21 , 0.69) 0.38 (0.20 , 0.70) 9.84  (0.002) 
Given an antipyretic in the 
last illness 
44 (83.0) 3.42 (1.63 , 7.19) 5.13 (2.31 , 11.35) 20.36  (<0.001) 
Distance to the Disp.      
     Less than 500 M 2 (3.8) 1 1   
     500 - 1500 meters 23 (43.4) 3.37 (0.77 , 14.74) 3.26 (0.71 , 14.93)   
   1500 – 3000 meters 7 (13.2) 3.02 (0.60 , 15.11) 1.83 (0.34 , 10.02)  
    More than 3000 m  21 (39.6) 4.98 (1.13 , 22.00) 5.47 (1.15 , 26.00) 9.28 (0.026) 
Coverage of other ITNs 
within 100m distance  
     
    Low (No ITNs ) 34 (64.2) 1 1   
    Moderate (1 – 300) 16 (30.2) 0.43 (0.23 , 0.80) 0.46 (0.23 , 0.91)   
    High  (301 – 1000)  3 (5.6) 0.34 (0.10 , 1.16) 0.33 (0.09 , 1.16) 7.09  (0.029) 
LRT: Likelihood ratio test 
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Neighbourhood or short-distance effects: 
Neither the ownership of ITNs, nor having malaria parasites, or mild or moderate/severe 
anaemia seemed to have any particular spatial distribution (Fig 1a-c). Logistic regression 
without covariates and including or excluding a spatial adjustment, also did not show any 
difference in the residuals. The conclusion was confirmed by testing the effects of different 
spatial correlations structures and by variogram analysis of the residuals from the non 
spatial model. Multivariate logistic models incorporating spatial (exponential) effects 
estimated slightly larger standard errors for the fixed effects parameter estimates but this 
did not reduced the number of significant covariates (data not shown). 
 
 
Discussion: 
Relatively good coverage of ITNs in the target group (children and expectant mothers) was 
achieved in the social marketing programme. About 61% of children under two years 
(Abdulla et al. 2001) and 52% of children under five years (Abdulla et al. 2002) slept under 
a net treated at least once. This is similar to findings of an earlier exploratory study in the 
same area using a similar delivery mechanism (Fraser-Hurt & Lyimo 1998) and in Burundi 
(Van Bortel et al. 1996). Assessment of coverage effects show that children who lived in 
areas with high ITNs coverage had significantly lower anaemia levels when coverage 
within 100 meters was considered, indicating that the prevalence of anaemia is better 
explained by nearby ITN coverage than by personal protection alone.  
 
This was similar to effects of ITN coverage on malaria exposure (Lines et al. 1987), on 
severe disease (Howard et al. 2000) and on mortality (Binka et al. 1998). However, unlike 
the studies in Papua New Guniea (PNG) (Hii et al. 2001) and in Burundi (Van Bortel et al. 
1996), we did not find any effect of bed net coverage on prevalence of parasitaemia. This 
may be because the prevalence of  parasitaemia is not very closely linked to transmission 
intensity in areas of high endemicity (Thomas & Lindsay 2000) .   
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Figure 1A: Spatial distribution of houses in Idete village 
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Figure 1B: Spatial distribution of  ITNs in Idete village 
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Figure 1C: Spatial distribution of parasitaemia in Idete village 
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Figure 1D: Spatial distribution of anaemia in Idete village 
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Unlike the work in PNG (Hii et al. 2001), the coverage effects in our study were significant 
only when considering C100. It may be that at lower radii the coverage effects are higher 
but we had wider confidence intervals. While at higher radii, the coverage effects are close 
to zero. It may also be that the effects of the other ITNs around out-weigh the effects of 
ITNs of the index child at this range, beyond which the coverage effects gets smaller. Or it 
may be that only at this distance the existing distribution structure of the ITNs makes a 
difference. Lastly, although some attempt has been made to control for differences in 
confounding factors like soc-economic status (Abdulla et al. 2002), it is still possible that 
some of the coverage effects that we have observed are mainly a reflection of residual 
confounding effects. All these issues allow us to make only crude statements about the 
relationship between coverage effects and morbidity indicators in children.  
 
Allowance for spatial structure with the generalised linear mixed model did not 
substantially alter the point estimates from the fixed effects logistic regression and there 
was no residual spatial pattern detectable in the models including distance to the 
dispensary. Hence the fixed effects models adequately described the relationship of the 
effects of ITNs on anaemia. The finding that the malaria indicators are related to measured 
distance from the household to the dispensary (Abdulla et al. 2002) presumably reflects 
the importance of the health seeking behaviour and treatment of malaria on these 
indicators. Demonstration of diversion or no diversion of mosquitoes (through 
entomological assessment) might have given some insights to the effects of ITNs that are 
not easily detectable using morbidity parameters. 
 
The lack of spatial patterns in the distribution of ITNs and morbidity parameters may be a 
result of imprecision in our tools and methods. Errors in ascertainment of geo-positions 
with non-differential GPS (Hightower et al. 1998) and net treatment with reliance on 
histories provide by relatives contribute to the limitations of the study. The area studied 
may have been too small to detect any spatial patterns. Work conducted in a wider 
geographical area indicated that children living on the fringes of the populated area had 
more disease (Abdulla et al. 2001). A further investigation of the spatial effects in a larger 
geographical area is therefore required.  
 
The results indicate that the social marketing campaign has managed to make the ITNs 
widely available even to those who live on the edge of the inhabited areas, where the risk 
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of malaria disease is likely to be concentrated (Binka et al. 1998). This may have led to 
some protection being conferred to those without nets and those with untreated nets. In 
Kenya, a lower risk of admission to hospital for malaria has been observed in children not 
using ITNs but living in areas with high ITNs coverage compared to those in areas without 
ITNs (Howard et al. 2000). This phenomenon has bearing on the estimated effectiveness 
of the ITNs observed in programme evaluations. The reduced risk for those near the ITNs 
will bias the measured effect toward zero if a simple comparison is made of users and 
non-users. Hence, estimates of effectiveness made by our program (Abdulla et al. 2001, 
Schellenberg et al. 2001) are likely to be conservative. Data was too sparse in our study to 
observe any increase or decrease of disease in those without nets, or examine the effects 
of those without nets living within different coverage levels or non users living in houses 
with treated or untreated nets. The cross-sectional survey conducted in a larger 
geographical area did not show any change in the prevalence of anaemia nor 
parasitaemia in those without nets in the three years of observation (Abdulla et al. 2001).  
However, a comparison of the age specific parasitaemia prevalence rates with historical 
values show that the children both those with and those without ITNs had much less 
malaria in current studies than a decade ago (Fig 2). This trend indicates that a substantial 
reduction in malaria endemicity has occurred in the last decade. This may well represent a 
further beneficial effect of the social marketing program which has not been accounted for 
in evaluations to date. 
 
We conclude that the social marketing of ITNs resulted in a relatively homogenous 
distribution of ITNs in the village. There are indications that coverage of ITNs was 
important in determining the prevalence of anaemia in children and high coverage 
produces higher impact of ITNs. Hence, efforts should be made to achieve high coverage 
in ITN programmes. In order to explore this important aspect further, analyses should be 
done in a larger geographical area together with entomological assessment. 
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Figure 2 : Age specific malaria parasite prevalence in the Kilombero valley
1991 and 1997-99 
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Abstract 
A randomized, open trial involving 260 Tanzanian children, aged 1-5 years, with acute 
Plasmodium falciparum malaria was conducted to evaluate the efficacy of the combination 
antimalarial CGP 56697 (artemether and benflumetol), and to compare it with chloroquine, 
the standard drug used for malaria treatment in the Kilombero area. Children who had 
received rescue medication within the first 48 h or had a negative slide at the same time 
were excluded. Seven-day parasitological cure rates were 94% (95% Cl 88-97.5) for CGP 
56697 and 35.4% (95% Cl 25.9-45.8) for chloroquine. Using the same definition, the 14-
day parasitological cure rates were 86.4% (95% Cl 78.5-92.2) for CGP 56697 and 10.3% 
(95% Cl 5.1-18.1) for chloroquine. Gametocytes were more effectively suppressed by CGP 
56697 than by chloroquine. There were no major adverse events with either drug. CGP 
56697 is highly efficacious against P. falciparum in this area of Tanzania. The study 
contributes to the discussion on treatment strategies, particularly whether chloroquine may 
still fulfil its role as first-Iine drug in an area of high malaria transmission and very high 
levels of chloroquine resistance. 
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Introduction 
The development of Plasmodium falciparum parasites resistant to currently available 
antimalarial drugs is a main concern and problem confronting governments and health 
authorities. Whereas resistance of this parasite against quinine, mefloquine, halofantrine 
and other antimalarials exists in South-east Asia, the situation in Africa is also alarming 
despite susceptibility to the newer antimalarials. The efficacy of chloroquine, the most 
affordable drug on the continent with the highest morbidity and mortality due to malaria, is 
decreasing. The 7-day cure rate of a standard dose of 25 mg/kg of chloroquine given over 
3 days was recently reported to be at 80% in the Kilombero area (Mshinda et al. 1996). 
Quinine resistance is also reported from some African countries (Adagu et al. 1996). lt is 
estimated that the annual worldwide death rate from malaria will rise to 7 million if quinine-
resistance reaches the same levels in Africa as it does in South-east Asia (Day 1996). 
Thus, a situation is approaching in many African countries where chloroquine can no 
longer be the recommended treatment for uncomplicated malaria, and where clinicians 
may encounter problems in treating small children with acute P. falciparum malaria with 3-
days regimens of quinine (Kremsner et al. 1994). Alternative drugs must be evaluated for 
the potential challenges of treating this life-threatening disease in the most vulnerable 
groups of the African population. 
 
CGP 56697 (artemether and benflumetol) is an oral, fixed dose combination of artemether, 
a semisynthetic derivative of arternisinin, and benflumetol, a synthetic racemic fluorene 
derivative developed by the Academy of Military Medical Sciences in Beijing. This 
combination was developed in China for the treatment of P. falciparum malaria (Olliaro & 
Trigg 1995). Artemether is of proven benefit in the treatment of Malaria, but recrudescence 
is common when it is used as a single agent (Bunnag et al. 1995). Benflumetol is also an 
effective antimalarial with a high cure rate, but is slower in action. The rationale for the 
combination of the two drugs is to combine the benefits of the fast onset of action provided 
by artemether with the advantage of the high cure rate associated with benflumetol, given 
as a short course of four doses over 48 h to foster compliance (unpublished observation). 
Studies with CGP 56697 on 196 Chinese adults achieved 4-week cure rates of 97.4% 
(unpublished observation). A similar trial in Thailand on 252 patients which compared CGP 
56697 with mefloquine gave 4-weck cure rates of 69% and 82%, respectively (unpublished 
observation). CPG 56697, however, had a statistically significantly better parasite 
clearance time (43 h vs. 66 h), a faster fever clearance time (32 h vs. 54 h), and was more 
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than twice as rapid in gametocyte clearance (152 h vs. 331 h), the latter considered to be 
of importance in relation to containing malaria transmissibility. Limited data on the efficacy 
of CGP 56697 among 100 children aged 5-14 years are available from China. A 4-week 
cure rate of 93% was obtained with a reduced adult dose according to the children's age 
and weight. Oral CGP 56697 was well tolerated and no serious adverse events were 
reported. A pilot study of CGP 56697 in West African children aged 1-6 years with 
uncomplicated falciparum malaria showed a good tolerance of the drug (von Seidlein et al. 
1997). 
 
This communication reports on the first experience on CGIP 56697 in East Africa. Its 
potential as a reliable addition to the future armoury of antimalarial drugs was tested 
against chloroquine, the current first-Iine drug according to Tanzanian policy. 
 
Study population and methods 
Population 
The trial population comprised boys and girls aged 1-5 years (body weight > 5 kg) with 
acute falciparum malaria. They were recruited from the 'mother-and-child' out-patient clinic 
at St Francis District Designated Hospital, Ifakara, Tanzania. A species prevalence of 93% 
for P. falciparum infections and a malaria related fever prevalence of 5% are reported in 
this area of permanent transmission among this age group (Smith et al. 1993). Inclusion 
criteria for selection were: age 1-5 years; body weight > 5 kg; microscopically confirmed 
P.falciparum infection, parasitaemia > 5,OOO/ml blood; fever (axillary temp 37.5 oC); living 
within 5 km of trial site; feasibility of participation and informed consent; not participating in 
any other trial. Ethical clearance was obtained from ethical committees of the Tanzania 
Commission for Science and Technology and from Basel University. 
 
Exclusion criteria were parasitaemia < 5,000/ml; absence of fever; intolerance of oral 
medication; signs or symptoms of severe or complicated malaria; severe malnutrition or 
kwashiorkor; history of other antimalarial drugs within 48 h; known sensitivity to 
chloroquine; any known chronic underlying disease. 
 
Each child eligible for the trial had a general medical examination and a medical history 
taken. The purpose and details of the trial were fully explained to the parent or guardian 
Chapter 8: Efficacy of artemether & benflumentol 
124 
and consent forms signed or fingerprinted. 260 children were randomized equally to the 
CGP 56697 or chloroquine treatment groups (130 to each). 
 
Medication 
The children in the CGP 56697 treatment group received 4 doses of paediatric tablets at 0, 
8, 24 and 48 h, respectively. Each paediatric CGP 56697 tablet contained 10 mg 
artemether + 60 mg benflumetol (½ the adult tablet level) 
and 1, 2, 3 or 4 tablets were given at the 4 dosage times according to body weight (5-10 
kg body weight, 4 doses of 1 tablet; 10-15 kg, 4 doses of 2 tablets; 15-20 kg, 4 doses of 3 
tablets; 20-25 kg, 4 doses of 4 tablets). 
Children in the chloroquine treatment group similarly received 4 doses over 3 days, 
relating to body weight at 25 mg total per kg body weight (10, 5, 5 & 5 mg/kg) as follows: 
5-10 kg, ½ tablet, followed by ¼ tablet at each of the next 3 doses; 10-15 kg, ¾ tablet,  ½ 
tablet each dose; 15-20 kg, 1 tablet, ½ tablet each dose; 20-25 kg, 1½ tablets: ¾ tablet 
each dose (each tablet contains 150 mg chloroquine base). 
 
The trial medication for each child was contained in an individually numbered blister pack. 
The contents (chloroquine or CGP 56697) were allocated randomly in blocks of 6. 
Medication was given whenever possible between meals. Mothers still breast feeding were 
encouraged to continue. Children who had rescue medication or had negative slides within 
48 h after admission were excluded from evaluation. However, they were included in the 
ITT evaluation (Table 2). 
 
 
Trial procedure 
The trial was a randomized, open, parallel group, comparative, single centre investigation. 
Children were assigned treatment upon presentation by allocating the blister pack with the 
lowest available number. On entry (day 0), each child at the out-patient department (OPD) 
was screened for eligibility criteria and, following parental/guardian informed consent, the 
first dose was administered, with the child observed in the hospital over 2 h to check for 
vomiting. Eight hours after treatment started, a field worker (FW) visited the child at home 
and supervised the administration of the second dose, checked the axillary temperature 
(T) and completed an adverse events (AE) questionnaire. On Days 1 and 2 (24 and 48 h) 
the FW visited the patient at home, administered the third and fourth doses, checked T, 
took finger prick blood for microscopy and completed the AE questionnaire. On Day 3 (72 
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h), the FW went to see the patient, checked T, took fingerprick blood for microscopy, 
haematology and PCR and documented any AEs. On Day 7, the child attended OPD for 
neurological examination, T was checked and fingerprick blood for microscopy, 
haematology and PCR was taken; AEs were also recorded. On Day 14 a further follow-up 
was done at OPD, and investigations were done as on Day 7. A similar examination was 
conducted at OPD on Day 28. 
 
Techniques 
Giernsa-stained thick films were used to examine and assess levels of parasitaemia (thin 
films were only used to confirm presence of other Plasmodium species). Prior to patients’ 
inclusion in the trial 20 thick film fields were examined; absence of P. falciparum excluded 
them from the trial. lf asexual forms of P. falciparum were found, then 200 thick film fields 
were screened for the presence of malarial parasite species. Identification of P. falciparum 
was followed by a tally counter count of asexual forms and leucocytes. Present 
gametocytes were counted similarly. 
 
All blood films were read twice, independently, and a third time if the ratio of densities from 
the first 2 exceeded 1.3 or was less than 0.67, or if one was positive and the other 
negative. A definitive result was based on a majority verdict for positivity and the geometric 
mean of the 2 closest positive density counts. A peer review of 282 slides was done. There 
was a 87% agreement in terms of negative/positive results between the 2 counts. 
 
Urine samples were tested for chloroquine at baseline. Blood samples were taken for 
haemoglobin, haematocrit, WBC (total and differential) platelets and PCR confirmation of 
parasitaemia. 
 
Casagrande's method was used for calculation of the sample size (George 1984). 
Assuming a 7-day parasitological cure rate of 95% for CGP 56697 and 80% for 
chloroquine, this gave a minimum requirement of 113 for each treatment group (a = 5%, b 
= 10%). The primary endpoint for the 7-day cure rate (evaluable patients) was defined as 
the proportion cleared of asexual parasitaemia within 7 days of drug initiation, without 
reappearance on Day 7. Failures were defined as those patients in whom (a) parasites 
were present on Day 7, or (b) rescue therapy was given after day 1, but within the first 
week, when parasites were still present. The primary end point for the 14- day cure rate 
was the proportion of patients cleared of asexual parasitaemia by Day 7 and without any 
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reappearance by Day 14. Secondary end points were defined as parasite reductions on 
Days 1, 2 and 3 and the proportion of children with a negative slide result. 
 
The 95% confidence intervals (C1) for cure rates were calculated by using Pearson-
Clopper limits. The 95% Cl for the difference in rates (p1 – p2) between CGP 56697 and 
chloroquine was calculated as: 
(p1 – p2) ± u1-a/2Ö[p1(1 - p1)/n1] + [p2(1 – p2)/n2] 
together with the c2 test. For the parasite reductions on Days 1, 2 and 3, the median, 25th 
and 75th percentiles were calculated and treatment effects tested using the nonparametric 
Wilcoxon rank-sum test (Woolson 1987). 
 
Results 
Demographic and baseline data 
During the recruitment phase, 1132 mothers were approached for screening the blood of 
their febrile children. Two mothers refused to participate in the trial. 454 children had 
negative slides and 81 children had already been given chloroquine within 48 h. 335 
children had either a parasitaemia lower than stated in the inclusion criteria or were living 
more than 5 kilometers from the MCH clinic. Table 1 summarizes the baseline data of the 
260 patients enrolled. None of the children died during the trial period. 21 patients were 
admitted during the period of the trial (CGP 56697: 7; chloroquine: 14). Premature 
discontinuations: 118 children were discontinued prematurely during the trial. 
Unsatisfactory therapeutic effect (96) was the main reason, followed by adverse reactions 
(8), lost to 'follow-up' (6) and withdrawal of consent (3). 5 had P. falciparum counts < 
5,000/ml at enrolment and were excluded from analysis. In the CGP 56697 group 18.5% 
(24) discontinued compared with 72.3% (94) in the chloroquine group. 
  
8 children did not receive the complete CGP 56697 course and only 108/130 completed 
the chloroquine course. 118 children (CGP, 25; chloroquine, 93) were treated with other 
antimalarials over the 28 day observation period. 7 in each group were treated for adverse 
events. All children received an antipyretic (paracetamol), 250 mg, twice daily, over the 
first 3-4 days. In addition, 183/260 (70.4%) received other medications as follows: 
ampicillin for bronchopneumonia; iron and folate for anaemia; erythromycin for ulcers or 
rashes. Co-trimoxazole was given to 2 children on chloroquine. 
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Efficacy of treatments 
Seven-day parasitological cure rates are shown in Table 2. Forty-eight of the total ITT 
(Intention To Treat) patients had been discontinued from the trial by Day 7, most of them 
due to unsatisfactory treatment response, leaving 116 evaluable patients in the CGP 
56697 group and 96 in the chloroquine group. Of the former, 109 (94%, 95 % CI 88-97.5]) 
were regarded as cured in terms of the primary end point of parasite clearance, as 6 
patients had a positive slide on day 7 and 1 patient received rescue medication 3 days 
after treatment was started. 6 of the 7 children had parasites only on day 7 and were 
subsequently found to be negative, thus not becoming new illnesses. In the chloroquine 
group only 34/96 (35.4%, 95% CI 26-46) were free of parasites by Day 7. The 95% CI for 
the difference was [48.0, 69.1] (P < 0.001). 
 
The related parasite reduction percentages and number of patients with negative blood 
film slides over Days 1, 2 and 3 are shown in Table 3 and Figure 1. These data relate to 
the secondary end points. Thus, by day 1, 121 of the CGP 56697 group had achieved 
97.8% parasite reduction, rising to 100% by Day 3 (117 patients), compared to a 59% 
reduction in the chloroquine group on Day 1 (118 patients) to 95.9% (96 patients) on Day 
3. The related negative/positive slide relationship is shown in Figure 1. 14-day 
parasitological cure rates are shown in Table 2. 95/110 (86.4%) of the evaluable CGP 
56697 patients had no detectable parasites, compared with 10/97 (10.3%) of the evaluable 
chloroquine patients. 
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Table 1: Demographic and baseline data 
 CGP 56697 
(n=130) 
Chloroquine 
(n=130) 
Female/male ratio 1.03 0.61 
Age (years) Median (range) 2 (1-5) 2 (1-4) 
Weight   
Median 10.6 11.1 
Range 6 – 20 7.5 – 18.3 
Haematocrit  (%)   
Median 31 29.4 
Range 17 - 42 14 – 41 
   
Previous malaria infection within  3 months (%) 48 41 
Temperature   
Median 38.9 38.3 
Range 37.3 – 40.9 36.8 – 40.9 
Parasite density (/ml)   
Geometric mean 55017 53575 
Range* 5644 - 674933 5124 – 373547 
*excluding the  5 children with less than 5000/ml parasites 
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Table 2:  7 Day  and 14 day cure rates 
 CGP 56697 
 
Chloroquine 
 
ITT patients   
7 day cure rate (%)  83.8% 26.2% 
 (109/130) (34/130) 
   
Evaluable patients   
7 day cure rate 94% (109/116) 35.4% (34/96) 
95% CI* 88 – 97.5 25.9 – 45.8 
   
14 day cure rate 86.4% (95/110) 10.3% (10/97) 
95% CI* 78.5 – 92.2 5.1 – 18.1 
*using Perasons Clopper limits 
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Table 3 : Percentage parasite reduction on days 1,2 and 3 (ITT,using all available slides) 
 CGP 56697 Chloroquine Wilcoxon rank test 
Day 1 (n = *) 121 118  
Median 97.8% 59% P < 0.001 
25 – 75th percentiles 88.7 – 99.8% -1.9 – 79.8%  
    
Day 2 (n = *) 120 106  
Median 100% 81.8% P < 0.001 
25 – 75th percentiles 100% 45.3 – 96.8%  
    
Day 3 (n = *) 117 96  
Median 100% 95.9% P < 0.001 
25 – 75th percentiles 100% 81.6 – 99.9%  
    
(n = *) slides available for analysis 
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Table 4: Gametocytes on days 0,1,2,3,7 
  CGP 56697 Chloroquine 
Day (Hours) Gametocytes n % n % 
0 Not detected 128 98.5 121 93.1 
(6 h) Detected 2 1.5 6 4.6 
 Missing data   3 2.3 
      
1 Not detected 114 87.7 112 86.2 
(24 h) Detected 7 5.4 6 4.6 
 Missing data 9 6.9 12 9.2 
      
2 Not detected 113 86.9 98 75.4 
(48 h) Detected 7 5.4 8 6.2 
 Missing data 10 7.7 24 18.5 
      
3 Not detected 111 85.4 89 68.5 
(72 h) Detected 6 4.6 7 5.4 
 Missing data 13 10.0 34 26.2 
      
7 Not detected 115 88.5 80 61.5 
 Detected 2 1.5 8 6.2 
 Missing data 13 10.0 42 32.3 
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Table 5: Haemoglobin levels 
 % patients (n)    
 CGP 56697 Chloroquine 
 <8.0 g/dl <6.5 g/dl <8.0 g/dl <6.5 g/dl 
Day 0 16.3 (21/129) 6.2 (8/129) 23.4 (30/128) 10.2 (13/128) 
     
Day 3 23.7 (28/118) 14.4 (17/118) 33.3 (32/96) 16.7 (16/96) 
     
Day 7 19.8 (23/116) 3.4 (4/116) 31.5 (28/89) 6.7 (6/89) 
     
Day 14 8.3 (9/108) 0.9 (1/108) 16.9 (12/71) 4.2 (3/71) 
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20 of the CGP 56697 patients were not evaluable for the 14- day cure rate. Those 
additional to the non-evaluables for Day 7 were patients who did not have a slide taken at 
the two week follow-up. Of the evaluable 110 patients of the CGP 56697 patients, 7 were 
recorded as failures from the first week, with another 8 failures by day 14. Of these 8 new 
cases, 3 had only one positive slide on this visit, but were subsequently negative without 
rescue medication. Thus only 5 children on CGP 56697, i.e. less than 5%, had early 
recrudescence. Four of the 8 children tested by PCR had confirmed new infections (Irion 
et al. 1998). For the chloroquine group the 62 failures from the first week had increased by 
a further 25 by Day 14. 
 
Gametocyte counts are summarized in Table 4. Twelve patients (9.2%) on CGP 56697 
and 15 (11.5%) on chloroquine had gametocytes detected within the first 72 h (Days 0-2). 
By Day 7 the figures were 2 (1.7%) and 8 (9.1 %), respectively. The high drop-out rate for 
those on chloroquine made comparisons unreliable beyond Day 7. 
 
Clinical features and adverse events: 48 h after treatment started, the temperature was still 
above 39 oC in 4 children from the chloroquine group, whereas all children treated with 
CGP 56697 had a temperature below 38 oC. The most frequent signs and symptoms 
reported at any time during the trial were unspecific signs and symptoms (abdominal pain, 
headache, rigors). 37% presented with coughing and 18% with diarrhoea. Sleep disorders 
occurred in 39% (CGP 56697) and 37% (chloroquine). 
 
These signs and symptoms tended to disappear with treatment in both groups and 
resolved faster in the CGP 56697 group. No serious drug-related adverse events were 
recorded in either group of patients. There were no significant differences in the incidence 
of abdominal pain, fatigue, headache, vomiting, anorexia, diarrhoea or sleeping disorders 
between the 2 regimens, neither at the beginning nor with onset during the observation 
period. The overlap of malaria symptoms with drug-related adverse events was apparent 
as were confounding symptoms due to concomitant diseases. Minor drug-related adverse 
events included rashes in 3.8% (CGP 56697) and 3.9% (chloroquine), and pruritus in 0.8% 
(CGP 56697) and 6.2% (chloroquine). 
 
Several laboratory parameters were affected by the patients' disease status at 
presentation. Table 5 lists the evolution of haemoglobin levels in the two groups. The 
anaemia worsened with the disease resolution, on Days 3-7, but improved thereafter in the 
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CGP 56697 group. Only about 50% of the children on chloroquine were still on study, as 
the other needed rescue medication and had dropped out. 40% of all patients had below 
normal platelet counts at baseline (<150  ´ 109/L), but by day 7, 95% had normal values. 
The laboratory parameters were consistent with the disease status at baseline, improving 
with disease resolution due to a successful response to drug therapy. 
 
Of 157 children tested for chloroquine in urine at baseline, 97 (62%; CGP 56697: 59%; 
chloroquine: 67%; difference between the 2 regimens not significant) were positive, 
indicating recent medication. The presence of chloroquine in the urine at baseline was not 
related to the cure rates at 7 and 14 days in either group. However, it seemed to positively 
affect the 28 days cure rate by as much as 23% in the CGP 56697 group (14/30 children 
without vs. 29 of 42 with detectable chloroquine). The full evaluation of the parasite 
genotype dynamics using PCR technology is presented elsewhere (Irion et al. 1998). 
 
Discussion 
The efficacy of artemether-benflumetol (CGP 56697) in the treatment of acute falciparum 
malaria in young children (age 1-5 years) was compared with that of chloroquine, the 
presently used standard drug in this area. The parasite reduction rate found was 97.8% at 
24 h rising to 100% on Days 2 and 3 (compared to 59% at 24 h rising to 81.8% and 95.9% 
for chloroquine). These results were paralleled by rapid reductions of fever in the CGP 
56697 group, which was slower with chloroquine, with temperature still elevated in some 
patients 24-48 h after treatment started. The 7-day cure rate of 94% and the 14-day cure 
rate of 86.4% (compared to 35.4% and 10.3% % for chloroquine) showed a similar efficacy 
in young Tanzanian children to that in 100 Chinese children, aged 5-14, where a 28-day 
cure rate of 93% was recorded (unpublished data). Taking into account all parasitological 
and PCR findings of the children treated with CGP 56697, the recrudescence rate by day 
14 was found to be below 5%. 
 
Irrespective of the type of drug, the children in this trial suffered a series of mostly mild 
adverse events. One common adverse event not drug-related and noted in 37% of all 
patients was a dry, unproductive cough at baseline, which appears to be a symptom 
associated with the disease. Interestingly, a further 40% of all patients developed this 
symptom after treatment onset: some of them had another episode, some newly reported 
this symptom after baseline. This phenomenon has been reported previously in India 
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(Kulkarni 1996). Its pathogenesis may be related to cytoadherence ligands (Smith et al. 
1996) but the mechanisms are unclear. 
 
The haematological figures were similarin both groups, as was the anaemia at 
presentation. Both are features of the disease which improved with response to successful 
therapy. 
 
Gametocyte reduction levels can be considered a very important feature of antimalarial 
drug therapy. The ability to rapidly suppress gametocyte formation is important in some 
endemic areas in reducing transmissibility. Arternisinin and its derivatives reduced 
gametocytes 8-fold in primary infection and up to 18-fold in reinfection, compared with 
mefloquine (Price et al. 1996). The authors suggested that the 50% drop in malaria on the 
Thai/Burmese border in 1994, coinciding with use of artesunate, reflected its 
antigametocyte activity rather than the benefits of its treatment efficacy on clinical malaria. 
In our study 12 children (9.2%) on CGP 56697 and 15 (11.5%) on chloroquine had 
gametocytes detected over the first 72 h (Days 0-2, Table 4). By Day 7,1.7% of the CGP 
56697 group were positive for gametocytes as against 9.1 % of the chloroquine group, 
emphasizing the beneficial effect of the former in suppressing gametocyte formation. This 
confirms the trend observed in other studies. The epidemiological impact of this 
gametocidal activity remains to be established. It may merit carefully designed intervention 
studies in holoendemic settings in Africa. 
 
The results of this study, in relation to previous investigations (Koella et al. 1990; Mshinda 
et al. 1996) , confirm that chloroquine resistance is of growing concern in this area of 
Tanzania. These papers suggested that resistance may be a reflection of the 
immunological status. This is also supported in this study by the fact that recrudescent 
infections appeared in chloroquine-treated patients who initially showed higher parasite 
densities than patients who cleared parasitaemia (data not shown). In addition, a higher 
drug pressure in the periurban study site, and the higher parasite densities may have 
contributed to the surprisingly higher failure rate than the one found in a rural community of 
the Kilombero area by Mshinda et al. (1996). Hence, chloroquine may not be an 
efficacious first-Iine drug for uncomplicated falciparum malaria in this area of Tanzania. 
In conclusion, the combination therapy of artemether - benflumetoi (CGP 56697) was 
shown to be a highly efficacious antimalarial therapy for young Tanzanian children aged 1-
5. It achieved a 94% cure rate, accompanied by rapid parasite reduction and clearance 
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rates. 6 of the 7 cases with parasites detected on day 7 were positive only on that day and 
had subsequently no parasites. This is an important point when considering the likely span 
of useful therapeutic life of this drug. 
 
CGP 56697 also showed some antigametocyte activity, which may be of some importance 
in limiting malaria transmission. lt is recommended as an efficacious 
antimalarial which may be particularly important to prevent the development of severe 
falciparum malaria. 
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Abstract 
Objective  
To test the efficacy of a new compound drug (CGP 56 697) against acute, uncomplicated 
falciparum malaria. 
 
Method  
Reappearing parasites were analysed by PCR-RFLP within a randomized controlled trial. 
130 patients received chloroquine and 130 patients were treated with CGP 56 697. 
Samples from 96 patients with parasitological failure were tested by PCR-RFLP for MSP2 
of Plasmodium falciparum. Seven days after treatment 32 patients of the chloroquine 
control group with reappearing parasites were tested by PCR and one infection was 
unequivocally determined as a new infection. After 7 days, in the CGP 56 697 group, 6 
samples were tested in which one new infection was identified. Similar observations were 
made one and three weeks later in both groups. 
 
Results  
Although a high multiplicity of infections on admission was observed, there was no 
significant correlation between multiplicity and either recrudescence or new infection. 
Patients in both treatment groups with subsequent recrudescent parasites had higher 
initial mean parasite densities than patients who cleared. Those of the patients with 
recrudescent parasites who were treated with CGP 56 697 had higher initial parasite 
densities than those treated with chloroquine. The rate of re-infection increased with time 
as expected in holoendemic areas and appeared to be higher in chloroquine patients. 
Generally, CGP 56 697 showed a superior clearance rate, successfully cleared higher 
parasite densities and suppressed new infections over a longer period of time. 
 
Conclusion  
The PCR analysis confirmed that reinfections beyond day 7 are significant in areas highly 
endemic for malaria and showed the necessity of excluding these when estimaring 14 day 
clearance rates. Provided new infections are excluded, the 28-day clearance rate can also 
be used to determine the efficacy of antimalarial drugs in highly endemic areas, and adds 
to our knowledge of drug resistance and dynamics of infections in people living in such 
areas. 
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Introduction 
For the last 50 years chloroquine has been an efficient drug with low toxicity for treatment 
of malaria in most tropical countries. Since the first report of chloroquine resistance from 
eastern Africa in 1978, it spread rapidly all over the continent (Henry et al. 1994). Today 
about 50% of African Plasmodium falciparum strains are resistant to chloroquine, but the 
pattern of resistance varies with geographical location (Creasey et al. 1990). In lfakara, 
Tanzania, where this trial took place, 20% of P. falciparum strains were reported to be 
resistant to chloroquine in 1988 (Koella et al. 1990). In the present trial, the 7-day cure rate 
of chloroquine was found to be only 30% (Hatz et al. 1998). 
 
Currently there is general agreement that combination treatment with two differently acting 
drugs should be considered (Peters 1987). One drug should be fast-acting with a short half 
tife to reduce parasite numbers quickly, the other should be slow-acting and possess a 
long half life (White & Olliaro 1996). The use of both drugs in conjunction both provides 
effective treatment and reduces the chance of recrudescence. The data presented here 
derive from an efficacy trial of such a combination drug made of artemether and 
benflumetol (CGP 56 697) (Hatz et al. 1998). 
 
Artemether is a semisynthetic chiral compound derived from the Chinese medical herb 
qing hao (Artemisia annua L.) which had been used as malaria treatment for centuries 
(Qinghaosu Antimalarial Coordinating Research Group 1979). Since the rediscovery of 
artemisinin in 1972 (Klayman 1985), severat studies have been conducted with different 
derivatives in tropical countries (Arnold et al. 1990; White et al. 1992). The common results 
of these studies are shorter parasite clearance times and shorter fever clearance time than 
with any of the other antimalarial drugs. 
 
In addition, artemisinin and its derivatives are effective against chloroquine-resistant 
strains (Qinghaosu Antimalarial Coordinating Research Group 1979; Bunnag 
et al. 1991) and antigametocydal (Price et al. 1996). Since artemisinin and its derivatives 
have a high recrudescence rate (Qinghaosu Antimalarial Coordinating Research Group 
1979), it can only effectively be used when combined with another long-acting drug, in this 
case benflumetol. There is little published data available on benflumetol. It was developed 
by Chinese scientists at the Institute of Microbiology and Epidemiology, Academy of 
Military Medical Sciences (AMMS), Beijing and registered in 1991 (Acaderny of Military 
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Sciences 1993). Antimalarial, blood schizontocidal activity was reported (Wernsdorfer et 
al. 1996). A study in China with CGP 56 697 on 100 children aged 5-14 years reported a 
28-day cure rate of 93% (Liu et al. 1995). A study of 5 to12 year-olds is in progress in 
Thailand, where CGP 56 697 is being tested in cornparison to oral quinine treatment. 
 
The appearance of parasites in peripheral blood after treatment may be taken as proof of 
failure in areas with low transmission, where reinfections are likely. However, in areas of 
high endemicity, appearing parasites may originate from a new infection and presence of 
parasites cannot be taken solely as proof of recrudescence. Microscopy can readily 
determine parasite species and densities, but is not able to distinguish between 
recrudescent or new infections. Hence, for drug trials in highly endemic areas, methods to 
identify individual parasite infections must be developed in order to distinguish between 
true relapses or new infections. Techniques applying PCR restriction fragment length 
polymorphism (RFLP) to a polymorphic locus will allow such identification (Felger et al. 
1993). In this study we applied PCR-RFLP for the MSP2 (Merozoite Surface Protein 2) 
locus, coding for a polymorphic plasmodial membrane protein, to unequivocally identify 
recrudescent or new infections after drug treatment. MSP2 amplification and distinct 
restriction patterns in conjunction with extensive sequence information allow the 
discrimination of almost all different genotypes found (Thomas et al. 1990; Smythe et al. 
1991; Felger et al. 1993, 1997). 
 
Patients and methods 
Study design 
This was a randomized, open, comparative, single centre trial to compare the efficacy and 
safety of a new oral combination, CGP 56 697, with chloroquine, the current treatment in 
Tanzania for uncomplicated acute falciparum malaria. The study was conducted in lfakara, 
Tanzania, a holoendemic area with perennial transmission (Hatz et al. 1998). Patients 
were children aged 1-5 years living within 5 km of the out-patient clinic of St. Francis 
Hospital, lfakara. They were treated either with chloroquine or CGP 56 697. A total of 260 
children were enrolled in the efficacy study (130 in each group). Finger prick blood 
samples for PCR were taken on day 0 (day of treatment), day 3, day 7, day 14, and when 
possible on day 28. 
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At each of the three time points (days 7, 14 and 28) blood samples from a subset of 
parasitological failures were used for PCR analysis. Samples could not be analysed from 
all failures because many had already received rescue medication. Conversely, multiple 
samples were included from patients who were defined as parasitological failures at 
repeated surveys but who remained asymptomatic and hence were not treated. 
 
DNA preparation and PCR 
Five ml of blood were lysed in 50 ml GTC solution (4 M guanidine-isothiocyanate, 25 mM 
Na citrate pH 7.0, 0.5% Na sarcosylsulphate), 5 ml b-mercaptoethanol, and mixed with 50 
ml TE saturated phenol and 50 ml chloroform. The aqueous phase was separated, 
precipitated with isopropanol and DNA redissolved in 30 ml H20. 
 
A nested PCR was performed as described elsewhere (Saiki et al. 1988). Briefly, 5 ml of 
DNA were used for the primary reaction and 2 ml of PCR product for the nested reaction in 
a 100 ml reaction composed as follows: 10 mM Tris pH 8.8, 50 mM KCI, 1.5 mM MgCI2, 
0.25% Tween 20, 0.2 mM each dNTP, 0.5 pM each primer, 1.25 U taq polyrnerase. Primer 
pairs used were S2 and S3 for the primary reaction and S1 and S4 for the nested reaction 
as published by Foley et al. (1992). Both PCR reactions were performed in a Perkin Elmer 
Thermocycler 480 with the following profile: 5 min at 94 oC and 30 cycles: 1 min at 94 oC, 2 
min at 55 oC, 2 min at 70 oC. Negative controls were included with each set of PCR 
reactions. 
 
The different MSP2 alleles were genotyped as previously described (Felger et al. 1993). 
20 ml of nested PCR product were subjected to restriction digests with the restriction 
enzymes Ddel, Rsal, Hinfl, ScrF1, respectively, and tun on a 10% polyacrylamide gel. All 
digests of one restriction enzyme were loaded side by side for all samples of an individual 
patient and sizes were calculated using a standard commercial size marker. RFLP 
patterns were visualized by ethidium bromide staining and documented electronically. All 
gels were analysed by two independent researchers. 
 
Data analysis 
Patients were included in the efficacy analysis as parasitological failures if they were 
parasite-positive by microscopy or if rescue medication (quinine) had been required at or 
before the respective time point. They were included as treatment successes if an 
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aparasitaemic sample (by microscopy) was available for the time point and no other 
parasites had been recorded between completion of treatment and collection of that 
sample. Genotypes found by PCR either in samples from day 0 or day 3 were considered 
to be present initially and considered as baseline. Recrudescence was deemed to have 
occurred if the RFLP pattern of an allele seen at baseline (day 0 and/or day 3) was 
detected by PCR on any consecutive follow-up day. New infections were defined as 
having completely different RFLP patterns in follow-up samples from those seen at 
baseline. Hence, new infections with the same MSP2 genotype would have been 
considered as recrudescences. Estimates of recrudescence and new infection rates were 
made separately for days 7, 14, and 28 (Figure 1). For each day, the recrudescence rate 
was estimated as the proportion of tested samples found by PCR to contain recrudescent 
parasites, multiplied by the failure rate (failures/total patients included) for that day. A 
similar calculation was carried out for patients defined by PCR as being newly infected. 
 
Results 
In the population enrolled for the study in lfakara, the 7-day and 14-day parasitological 
cure rates for chloroquine were 35.4% and 10.3%, respectively, and for CGP 56 697 94% 
and 86.4% (Hatz et al. 1998). Our analyses consider a rather more inclusive group of 
patients (Table 1) than those of Hatz et al. (1998) did: we also included patients whose 
parasitaemia never cleared. The numbers of patients who were thus included in the 
analyses, and the numbers for whom samples were analysed by PCR-RFLP for each time 
point are shown in Table 1. The relative efficacy of chloroquine was even poorer when 
these early failures were included (Table 1), and by day 28 the cure rate was only 5% with 
chloroquine compared to 64% with CGP 56 697. 
 
In 82.5% n = 83) of the samples tested by PCR, multiple infections were detected 
throughout the observation time. 
Chapter 9:Distinction of recrudescences by PCR 
 
147 
 
 
Table 1: Patients with microscopically detectable parasites on follow-up days, PCR                
results, and estimated cumulative recrudescence- and new infection-rates 
 
Drug 
 
CGP 56 697 
 
Chloroquine 
 
 
Day 
 
 
7 
 
 
14 
 
 
28 
 
 
7 
 
 
14 
 
 
28 
 
 
number of patients included 
 
 
118 
 
 
113 
 
 
118 
 
 
115 
 
 
116 
 
 
119 
 
 
n failures (%) 
 
 
9 (7.6) 
 
 
18 (15.9) 
 
 
43 (36.4) 
 
 
81 (70.4) 
 
 
106 (91.4) 
 
 
113 (95.0) 
 
 
n failures tested by PCR 
 
 
6 
 
 
7 
 
 
23 
 
 
32 
 
 
52 
 
 
44 
 
 
n with recrudescences only 
 
 
2 
 
 
2 
 
 
3 
 
 
21 
 
 
20 
 
 
17 
 
n with recrudescences and 
new infections 
 
 
0 
 
 
1 
 
 
7 
 
 
10 
 
 
27 
 
 
20 
 
 
n with new infections only 
 
 
1 
 
 
4 
 
 
12 
 
 
1 
 
 
5 
 
 
6 
 
 
n PCR negative 
 
 
3 
 
 
0 
 
 
1 
 
 
0 
 
 
0 
 
 
1 
 
% of tested patients with 
recrudescences 
 
 
33.3 
 
 
42.9 
 
 
43.5 
 
 
96.9 
 
 
90.4 
 
 
84.1 
 
estimated % all patients with 
recrudescences 
 
 
2.5 
 
 
6.8 
 
 
15.8 
 
 
68.2 
 
 
82.6 
 
 
79.9 
 
% of tested patients with new 
infections  
 
 
16.7 
 
 
71.4 
 
 
82.6 
 
 
34.4 
 
 
61.5 
 
 
59.1 
 
estimated % of all patients 
with new infections 
 
 
1.3 
 
 
11.4 
 
 
30.1 
 
 
24.2 
 
 
56.2 
 
 
56.1 
 
* Patients were counted as failures for the 7- (14-, 28-) day cure rate if parasites were present at 
any time point after day 3, or if rescue medication was given before the respective observation 
period. For further details see patients and methods part. 
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Table 2: Mean multiplicity1) of initial infections in patients with recrudescent or new          
parasites by treatment group. 
 
 
 
 
 
CGP 56 697 
 
Chloroquine 
 
 
 
 
 
 
 
 
n 
 
 
mean 
multiplicity 
 
 
std err 
 
 
n 
 
 
mean 
multiplicity 
 
 
std err 
 
 
p=2) 
 
 
new infections 
 
 
17 
 
 
2.5 
 
 
0.3 
 
 
2 
 
 
1.5 
 
 
1 
 
 
0.27 
 
 
recrudescent 
 
 
13 
 
 
3.3 
 
 
0.3 
 
 
56 
 
 
3.0 
 
 
0 
 
 
0.28 
 
 
Wilcoxon p=3) 
 
 
 
 
 
0.11 
 
 
 
 
 
 
 
 
0.14 
 
 
 
 
 
 
 
1) multiplicity refers to the number of different genotype pattern identified in one sample. 
2) Wilcoxon's test compares between treatment groups within patients with new infections 
or with recrudescent infections. 
3) Wilcoxon's test compares between new infections and recrudescences within treatment 
group. 
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Table 3: Representative examples of infection dynamics with recrudescent and new 
infections after Chloroquine or CGP 56 697 treatment 
 
 
 
Patient # 
 
 
day 0 
 
 
day 3 
 
 
Day 7 
 
 
day 14 
 
 
day 28 
 
 
Infectio
n 
(R/N) 
 
 
patient 
(R/N) 
 
 
drug 
(CGP/CQ) 
 
 
85 
 
 
Wos6 
Wos34 
Wos12 
 
 
Ifa34 
 
 
3D7(330) 
 
 
Wos6 
 
 
 
K1 
 
 
 
Wos34 
Wos12 
 
 
 
 
 
Wos34 
 
Wos3 
K1 
 
 
 
Wos6 
Wos34 
Wos12 
Wos3 
K1 
 
3D7(250) 
3D7(320) 
 
 
 
R 
R 
R 
N 
R 
C 
N 
N 
C 
 
 
R 
 
 
CQ 
 
 
68 
 
 
K1 
Wos12 
3D7(340) 
 
 
K1 
Wos12 
 
 
3D7(410) 
 
 
 
 
 
K1 
Wos12 
3D7(340) 
 
 
K1 
Wos12 
 
3D7(390) 
3D7(410) 
3D7(500) 
 
 
R 
R 
R 
N 
R 
N 
 
 
R 
 
 
CGP 
 
 
230 
 
 
 
 
 
 
 
 
 
 
 
3D7(380) 
 
 
 
 
 
 
 
3D7(380) 
 
 
 
 
 
D10 
 
3D7(330) 
 
 
3D7(480) 
 
 
D10 
Wos12 
3D7(330) 
3D7(370) 
 
 
 
N 
N 
N 
N 
C 
N 
N 
 
 
N 
 
 
CQ 
 
 
181 
 
 
 
Ifa30 
3D7(430) 
 
 
 
 
3D7(430) 
 
 
 
 
 
K1 
 
 
K1 
 
 
N 
C 
C 
 
 
N 
 
 
CGP 
 
3D7 infections (except sequenced genotypes) were defined by their fragment size after 
Hinf I digest. Genotypes printed in bold face appeared as comparatively dominant PCR 
products and underlined genotypes with strong PCR products, the remaining genotypes 
were comparatively weak. (R=recrudescence, N=new infection, C=cleared infection, 
CQ=Chloroquine, CGP=CGP 56 697) shaded=microcopy negative=clearance of parasites 
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Table 4: Initial geometric mean density in patients with recrudescent or new parasites by 
treatment group. 
 
 
 
 
 
CGP 56 697 
 
Chloroquine 
 
 
 
 
 
 
 
geom. mean 
density 
(parasites/ml 
blood) 
 
95 % confidence 
limits 
 
 
geom. mean 
density 
(parasites/ml 
blood) 
 
95 % confidence 
limits 
 
 
 
 
 
 
 
 
 
lower 
 
 
upper 
 
 
 
 
lower 
 
upper 
 
p=1) 
 
Cleared or 
new infections 
 
49000 
 
39000 
 
61000 
 
22000 
 
10000 
 
47000 
 
0.08 
 
Recrudescent 
 
73000 
 
49000 
 
108000 
 
50000 
 
39000 
 
66000 
 
0.31 
 
Wilcoxon p=2) 
 
0.06 
 
 
 
 
 
0.05 
 
 
 
 
 
 
  
1) Wilcoxon's test compares between treatment groups within patients with new infections 
or with recrudescent infections. 
2) Wilcoxon's test compares between new infections and recrudescences within treatment 
group. 
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Mean multiplicity of infection (number of allele types detected) at baseline and on follow-up 
days in the two comparison groups is shown in Table 2. In agreement with other studies 
(Feiger et al. 1994; Contamin et al. 1995, 1996; Ntoumi et al. 1995; Robert et al. 1996; 
Beck et al. 1997) there was extensive MSP2 allelic diversity. 54 different genotypes of 
MSP2 could be identified by PCR-RFLP at baseline. The most frequent of these were Wos 
12 (14%), Wos 6 (6.6%), 3D7(340) (5.8%), 3D7(330) (5.6%), and KI (5.3%). Five additional 
genotypes were found only in follow-up samples. 
 
In two patients, a genotype which was subsequently found recrudescent, was found on 
day 3 but not on day 0. In all other cases, recrudescent parasites were already found on 
day 0. Four representative examples of the dynamics of infection are shown in Table 3. 
The genotype pattern specific for the recrudescent parasite persisted in 66% of patients 
with recrudescent parasites until day 28 (often as the most dominant PCR band). In 4% 
and 9%, RFLP patterns persisted until day 25 or 20, respectively. In only 7% and 13% of 
the patients the RFLP pattern disappeared without rescue treatment after day 7 or 14, 
respectively. However, besides recrudescent parasites, new genotypes appeared 
additionally during the follow-up period (new infections). The sample of these patients had 
to be defined as recrudescent due to the persistence of one genotype found at enrolment. 
Table 1 lists the number of samples with microscopically detectable parasites, 
recrudescences and new infections, for both groups on each day. From these results, the 
estimated recrudescence and new infection rates are given in Figure 1. Initial mean 
parasite densities in both treatment groups were higher in patients with subsequently 
recrudescent parasites (Table 4). Mean parasite density at admission in patients with 
subsequent recrudescences was higher in patients treated with CGP 56 697 than in 
patients treated with chloroquine(Table 4). 
 
Discussion 
An analysis of the infection dynamics after drug treatment was performed using parasite 
genotype date in a comparison trial of chloroquine and CGP 56 697 treatment for 
nonsevere malaria. In areas with high endemicity for Plasmodium falciparum, such as in 
the Kilombero valley, Tanzania, where individuals receive > 300 infective bites per year 
(Smith et al. 1993), re-appearance of parasites alone after treatment cannot be taken as 
indicator of recrudescence. Both drugs used in the trial are known to be inactive against 
hepatocytic parasite stages, therefore they would not affect the development of new blood 
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stage infections immediately after drug concentration decreases. Thus techniques to 
unequivocally identify individual parasite infections are needed. We used MSP2-RFLP 
genotyping which has been proven to have sufficient discrimination power to identify most 
individual infections (Beck et al. 1997). In areas, where multiple infections are frequent, 
this technique proved to be equal to multiloci analyses (Snounou & Beck 1998). We are 
aware that PCR analysis could miss some genotypes, if single samples were used to 
characterize each episode. This could happen either because of suppression of concurrent 
low density infections by a superimposed high density infection, or because of 
sequestration of infected erythrocytes at the time of sampling. We decided to use as 
baseline both day 0 and day 3. Although in many samples genotypes appeared at day 3 
which were not seen at day 0, these genotypes recurred in only two patients and were 
defined as recrudescence. In all other cases, the genotypes of recrudescent parasites 
were already contained in the day 0 RFLP pattern. The extent of resistance against a 
given drug can only be estimated if re- infections can be excluded. In this trial, after 
chloroquine treatment only 3.3% of all parasites appearing up to 28 days were new 
infections, indicating the inability of chloroquine to clear parasites completely. But 
recrudescent parasites, especially those with high allele frequencies, could also be 
reinfections with the same parasite genotype. In contrast to chloroquine treatment, 45.5% 
of parasites appear ing after CGP 56 697 treatment were new infections. 
The usefulness of analysing 28-day cure rates has often been disputed, in particular in 
areas of high endemicity, where new infections are very likely to occur within 28 days. But 
in this study, only 22% of the observed parasites were shown to be new. The remainder 
still comprised recrudescent parasites and must be considered as late failures, hence 
making the 28-day cure rates a useful outcome measurement. 
 
The dynamics of individual infections, with persisting genotypes, disappearing genotypes, 
and new genotypes all appearing within one sample, raises the question whether the 
persistent or the new infection is clinically significant. Since in multiple infections, 
quantification of PCR products may not be correct, we can only speculate that the 
dominant infection would result in a dominant PCR product. In all but 8 cases, the 
dominant PCR product at recrudescence was already contained within the baseline 
samples. With caution, this may imply that in most cases the recrudescent infection might 
be responsible for the major parasitaemia and perhaps for the clinical presentation. 
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Initial parasite genotypes able to persist after treatment might be explained by the fact that 
any drug, in particular artemisinin derivates, only reduce the parasite load (White & Olliaro 
1996) and remaining parasites might undergo a quiescent stage (Kyle & Webster 1996). In 
case of recrudescence, it has to be assumed that benflumetol, the slow-acting component 
of CGP 56 697, was not able to eliminate those quiescent stages completely It has been 
debated whether true resistant parasites against a given drug must exist (Nakazawa et al. 
1995), but the above hypothesis would allow recrudescences without genetically 
manifested resistance against the drug. The mode of action of benflumetol is not yet 
understood, as it is not known for how long quiescent parasites can survive in the host. 
Nevertheless, the high cure rate and comparatively low recrudescence rate of CGP 56 697 
give strong suppor t to the notion of using compound drugs in the treatment of falciparum 
malaria. This is supported by the fact that the mean density of initial infections was much 
higher in recrudescences seen in the CGP 56 697 group than in the chloroquine group. 
Also, the higher initial parasite density between those who experienced recrudescences 
and those who cleared the infection in the CGP 56 697 group adds to the argument that 
CGP 56 697 can eliminate larger numbers of parasites, but apparently fails to clear very 
high densities, resulting in recrudescence of the remaining parasites. It may be speculated 
that the slow-acting compound of CGP 56 697 (benflumetol) suppresses new infections for 
much longer than chloroquine, as can be seen in Figure 1, where the rate of new 
infections is much higher in the chloroquine group. 
 
The fact that multiplicity of initial infections has no influence on whether a patient 
experienced a recrudescence, clearance or new infection, would also support the above 
hypothesis. The failure to observe any association might be due to the small size of the 
comparison group, since few patients had new infections only. No samples were tested 
from patients who were parasite-negative over the full observation period. High initial 
parasite densities do predict recrudescence. This is quite compatible with the absence of a 
correlation between multiplicity and recrudescence because densities were not correlated 
with multiplicity. Sometimes many parasite genotypes simultaneously persisted, so 
persistence cannot merely be a consequence of high load of a single parasite genotype. 
These recrudescences might be due to insufficient resorption of the drug or drug 
consumption by parasites, and not to true genetic resistance. In conclusion, identification 
of recrudescent parasites after drug treatment may not only help to estimate drug 
efficacies more precisely, it also adds to our knowledge of drug resistance and dynamics 
of infections in people living in highly endemic areas. 
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Introduction 
Early and effective treatment is one of the main pillars of malaria control, and is the most 
widely implemented strategy to control the disease in tropical Africa. However, the 
worsening problems of drug resistance in many parts of the world have led to increasing 
difficulty in making decisions on the choice of antimalarial drugs to be used in 
implementing the early treatment strategy. In Tanzania, the Ministry of Health is currently 
in the process of reviewing the national malaria treatment policy. This paper discusses 
some of the challenges of developing such a treatment policy. It focuses on chloroquine 
(CQ) and sulphadoxine/pyrimethamine (SP) which are the main antimalarials currently 
being discussed in Tanzania. However, the issues raised are also relevant to other types 
of antimalarials. 
 
Conceptual framework 
Few publications are available on the issue of policy-making for malaria control. A few 
countries in Africa have already reviewed their policies  (Schapira 1989, Fevre & Barnish 
1999). The World Health Organisation Regional Office for Africa, (WHO-AFRO) is in the 
process of developing a framework for changing malaria treatment policy, highlighting the 
issues to be considered for the policy review process in a country.  The issues identified 
include the objective of malaria treatment, efficacy of antimalarials assessed at the 
national sentinel sites, treatment-seeking behaviour for malaria, and cost-effectiveness 
analysis (WHO-AFRO 1999).  
 
To simplify the understanding and the description of the reasoning behind the decisions in 
the process of changing a malaria treatment policy, we propose a triangular interactive 
framework (Fig 1), which has clinical, epidemiological, and economic and health system 
dimensions. The clinical dimension incorporates all the factors that influence the 
occurrence of the disease and its complications. It also encompasses the choice of 
antimalarials used to treat cases of disease, and issues concerning their efficacy and 
safety in different populations. The epidemiological dimension refers to the question of the 
prevalence of different Plasmodium strains, and the status, development and spread of 
resistance to antimalarials. It also includes consideration of the geographical distribution of 
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malaria transmission and the resultant burden of disease in a population. The economic 
and health system dimension comprises intrinsically intertwined factors, which include 
health-seeking behaviour patterns, costs and cost-effectiveness, levels of health care, the 
infrastructure of the health system, structures for decision-making, and the decision 
making processes. The following paper reviews information on all three dimensions that 
could assist the policy review process in Tanzania. 
 
Clinical dimension  
Objective of malaria treatment 
The goal of most of the national malaria control programmes in Africa is to reduce 
morbidity and mortality associated with malaria.  But most programmes have not yet 
defined the objective of malaria treatment precisely. This poses some problems during the 
review of treatment policy (Bloland & Ettling,1999). Defining the objectives of treatment will 
assist in determining whether the recommended drugs reach the goal of therapy, and will 
also help to establish criteria for deciding what levels of resistance or failure can be 
tolerated.  
 
It has been suggested that the objective of malaria treatment may vary according to the 
level of malaria endemic ity. In this view, parasitological clearance is considered to be 
essential only in areas of low transmission, whereas in areas of intense transmission the 
aim should be clinical cure; that is, clearance of signs and symptoms and prevention of 
clinical recrudescence 14 days after treatment  (WHO 1994). The underlying assumption 
is that in areas of intense transmission, clearance of acute symptoms can prevent the bulk 
of severe disease and mortality even without parasitological cure (Hoffman et al 1984, 
Brandling-Bennet et al 1988).  
 
The problem with this view is that it underestimates the contribution of persisting 
parasitaemia to morbidity (for example anaemia) and mortality. Studies in the Kilombero 
district, Tanzania, an area of intense malaria transmission, have shown that the clearance 
of peripheral parasitaemia during treatment of children under five years is beneficial, as it 
reduces the risk of developing a further clinical episode (Kitua et al 1996). Kitua et al. also 
demonstrated the importance of low level parasitaemia for the occurrence of anaemia in 
children (Kitua et al 1997). In Bagamoyo, an area where the clinical treatment failure rate 
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is 50%, not only was there a severe fall in haemoglobin concentration in children who had 
early treatment failure (Ekvall et al 1998), but even in children successfully treated with 
CQ there was no improvement in haemoglobin concentration. Similar observations on the 
failure of CQ to produce haematological recovery were recorded in Kenya and Malawi 
(Bloland et al.,1993, Verhoeff et al., 1997, Brabin & Ganley 1997).  
 
Severe anaemia contributes directly to mortality in women and children (Stoltzfus et al 
1997), though it is hard to assess the magnitude of the problem, since anaemia is not 
widely recognised in the community as a life-threatening disease (Mwenesi et al 1995) and 
most childhood deaths occur at home, so the causes are not easy to clarify (Tanner et al 
1991, Slutsker et al., 1996). The hospital case fatality rate for severe anaemia for children 
under five years of age was estimated to be 6% (Schellenberg D et al., 1999). Community 
case fatality figures are not available, but are expected to be higher, as the majority of 
children with severe anaemia in Tanzania live beyond the reach of facilities which can 
manage the condition, for example by providing blood transfusion. 
 
Therefore, even in areas of intense transmission, it is important that the treatment offered 
should also prevent the occurrence of complications of the disease such as severe 
anaemia. Hence, we suggest that in Tanzania the objective of treatment should be 
clearance of symptoms and prevention of recrudescence of symptoms within 14 days, 
and also the clearance of peripheral parasitaemia. 
 
Choice of an alternative drug 
The useful life of the current first line drug in Tanzania (CQ) is coming to an end because 
of high parasite resistance. About 52% of children treated with a standard dose of CQ 
(25mg/kg) are not cured within 14 days (MOH 1999). In several countries in Southern 
Africa (White 1999), SP was considered to be the most appropriate drug to replace CQ. 
Studies have shown that SP is efficacious in Tanzania, with an average clinical failure rate 
of 10-15% (MOH 1999). Amodiaquine (AQ) is another possible candidate. It seems 
currently to be more efficacious than SP, but its acceptability has been a problem among 
health workers due to fears of side effects (Nevill et al 1994, MOH 1999) - although a 
review of studies on safety and efficacy of AQ concluded that the drug is safe provided its 
use is monitored (Olliaro et al 1996). There is also concern that the effectiveness of AQ 
may be reduced by cross-resistance between it and CQ (Olliaro et al 1996). In Tanzania, 
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it has already been observed that in an area of very high CQ resistance there is also a 
relatively high AQ resistance (Abdulla S. et al, personal communication) (Table 1). 
 
 
Malaria diagnosis 
Malaria diagnosis in areas of high endemicity poses a significant challenge during  
assesment of efficacy of antimalarial drugs and  in routine  practice.   Presence of parasite 
in blood with or without sign and symptoms are not definitive indication of  malaria disease.  
 
Epidemiological dimension 
Antimalarial treatment policy is formulated at the national level. A sentinel monitoring 
system has been established, with 8 sentinel sites, in order to generate data that is 
representative of the whole country. The efficacy of CQ, SP and AQ has been evaluated 
using a modified WHO 14-day test (EANMAT 1999). CQ failure rates were high in all the 8 
sentinel sites, with an average of 52%, indicating that resistance is widespread in 
Tanzania. For SP, in contrast, failure rates below 10% were observed except at one focus 
(Muheza District in north-eastern Tanzania) where there was a high failure rate of 30% 
(MOH 1999). 
 
There are several factors that contribute to the development and spread of resistance to 
antimalarials. These range from host population factors such as appropriate use of the 
drugs, amount of use, duration of use, and time for clearance of the drug, to parasite 
population factors like the biomass of parasite exposed to the drug, the duration of 
exposure, and the mechanism of resistance. This mechanism may affect the speed with 
which resistance can develop. For example, resistance to SP is apparently due to the 
stepwise accumulation of point mutations in the genes controlling the drug-target enzymes 
dihydrofolate reductase and dihydropterate synthetase. This may explain why resistance 
can develop rapidly.  Resistance to CQ, on the other hand, involves changes in the 
process of drug uptake and transport through the cell, which may require a more complex 
series of mutations. This may explain why CQ resistance only appeared after the drug had 
been in use for a long time. 
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Table 1: Comparison of advantages and disadvantages of three commonly-used antimalarials 
 
 
 CHLOROQUINE SULPHADOXINE 
/PYRIMETHAMINE 
AMODIAQUINE 
Efficacy    47% (28% - 72%) 90.5% (66%-93.6%) 95.4% (94%-96.5%) 
Cost of treatment one episode (with tablets 
in children) 
  US $ 0.01 US $ 0.01 US $ 0.03 
Availability +++ ++ + 
Side effect + ++ ++ 
Cross resistance with Chlorquine Not Applicable No Yes 
Selection for resistance Not applicable Rapidly Slowly 
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There is, however, a lack of concrete information on the rate of growth of resistance to SP 
(or any other drug) in various epidemiological settings. This makes it difficult to predict the 
useful life of any antimalarial.  In Thailand, SP became useless after about 10 years of 
widespread use (WHO 1994). So far, the experience in Africa is not so bleak. Clinical 
treatment failures in Malawi are still less than 10%, though the change was introduced 7 
years ago.  (Macheso A. personal communication).   
 
Resistance to the drug most commonly used can be expected to increase mortality rates. 
Assessments from West Africa show that this is indeed the case for CQ resistance (Trape 
et al., 1998). In Tanzania, the magnitude of the effect of chloroquine resistance on 
mortality is not known, but it is expected to be substantial in view of the widespread high 
levels of CQ resistance, and the high number of people who develop malaria. Anecdotal 
reports indicate that most deaths associated with febrile illness occurred at home, after 
attending a formal health facility (AMMP/TEHIP, unpublished data).   
 
Interestingly, most of the information collected so far is on children under five years old. 
Little is known about the contribution of older children and adults either in terms of the 
dynamics of resistance or of the burden of disease. Information from an Adult Morbidity 
and Mortality Project (AMMP) suggests that malaria is also among the important causes of 
mortality in those above 15 years of age (Kitange et al 1996). Work at sites with 
continuous demographic surveillance will provide more information in the future. 
 
 
Economic and health systems dimension 
Malaria treatment-seeking behaviour 
Even the best drug policy will be ineffective unless consumers and providers comply with 
it. Their behaviour must be considered if a rational policy is to be implemented and have a 
substantial impact on the reduction of morbidity and mortality. In East Africa, shops and 
drug stores rather than health facilities are the main source of antimalarials. Most people 
who fall sick with malaria-like symptoms are given antimalarial drugs stored at home. The 
course of treatment given is usually incorrect and the drugs often sub-optimal. (Mwenesi et 
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al 1995, Nyamongo 1999, Nsimba et al 1999). Many factors contribute to the preference 
for shops and drug stores. These include lack of drugs in public sector facilities, and 
convenience. There are more shops and drug stores than health facilities, and they may 
be more easily accessible, in terms of time to reach them, time spent waiting for service, 
and opening times. Public facilities are often closed at weekends or at night. The financial 
cost of an illness episode can also appear to be less when drugs are bought from a shop, 
since shops will even sell 1/3 of a dose (Table 2). 
 
Table 2: Sources of antimalarials among 1263 interviewed people from different parts of 
Tanzania 
 
Drug Sources Chamwino 
Central-TZ 
Kyela 
Southwest-TZ 
Mlimba 
Southeast-TZ 
Total 
 N=446 N=411 N=406 N=1263 
Government health facility 96.7% 22.9% 13.1% 51.0% 
Private health facility 1.6% 4.2% 13.1% 5.4% 
Drug store/shops 1.7% 79.9% 68.4% 42.2% 
Other 0% 0% 5.3% 1.46% 
TZ: Tanzania 
 
 
When treatment is not successful, patients often look for alternatives. For malaria, 
treatment-seeking behaviour patterns vary a great deal, with constant interchange 
between formal and traditional providers.  Studies in Ifakara and Rufiji, found that if there 
was no improvement after treatment from a formal health facility, only a quarter of the 
mothers and caretakers came back for re-treatment (Muela- Hausmann et al. 1998, 
Bjorkman 1991). Alternative sources of care included private health care or visits to 
traditional healers. If the response to treatment is poor, complicated malaria may develop, 
leading to convulsive episodes in children. These are often regarded as a separate 
disease, degedege, for which traditional healers are considered more competent than 
hospitals (Makemba A.M et al. 1996, Mwenesi et al. 1995).  
 
Thus, in cases where the first-line drug is not effective, a significant proportion of patients 
do not return to health facilities where they might obtain treatment with second-line drugs. 
Even for those who do return to the health facilities for further treatment, clinicians tend to 
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repeat the same treatment unless the patient has severe malaria. Therefore, the drug used 
as first line therapy in Tanzania needs to be very efficacious. 
 
Up to now, national Malaria Control Programmes have not paid enough attention to the 
way that malaria and its complications are managed at household level, the importance of 
self-treatment and the role of shops and drug stores in the provision of malaria treatment. 
The challenge for a national programme is to ensure that effective antimalarial drugs are 
available easily to all (Brugha R et al. 1999, Tanner and Vlassoff 1995). Encouraging 
home treatment may even facilitate early treatment (Deming et al. 1989). Hence, a policy 
need to be developed that addresses this level of care.  
 
Costs and cost-effectiveness assessments  
Drug-resistant malaria and the related deaths and treatment failure will carry a cost in 
terms of disability and loss of life. A model was developed that balanced the cost caused 
by drug resistant malaria and related deaths under different drug regimens in a fixed time 
period (Schapira et al. 1993). It was then used to find the optimum time to change the drug 
regimen, and the point where CQ treatment failure reaches between 15% and 25% was 
proposed. Other workers used decision analysis models to compare the cost and 
effectiveness of CQ, AQ and SP treatments (Sudre et al. 1992). SP was the most cost-
effective treatment when the prevalence of chloroquine resistance in Plasmodium 
falciparum at the RIII level was greater than 14-31%, depending on compliance. A similar 
decision tree analysis model was developed that takes into account  changes over time 
(Goodman et al. 1999). This was later applied to Tanzania- specific data, and clearly 
demonstrates that at current levels of resistance to CQ, a policy of using SP as the first 
line drug is more cost effective. This was the case over a 10-year projection. Considering 
changes in outpatient drug costs only, using the SP regimen rather than the CQ regimen 
over the 10 year period would cost US$ 0.46 per operational failure averted, or US$33 per 
death averted (Abdulla S. et al.. 2000). This seems to be less cost-effective. 
 
The actual choice of what strategy to implement is determined more by the ability of 
individuals and communities to pay the absolute costs than by assessments of cost-
effectiveness. The use of a more expensive drug than chloroquine may be assessed to be 
more cost-effective, but the absolute cost of implementing the treatment strategy may be 
beyond what the community can afford.  
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In Tanzania, calculations of economic benefits must also take into account the fact that the 
government health services do not pay for all the uncomplicated malaria cases that occur 
in the community, since many people buy drugs privately and treat patients at home. The 
little money there is must be allocated to competing priorities in health care, of which 
malaria is only one. Hence what  is important is to have a policy which will use the small 
amount of money that can be invested in reducing the problem of malaria as effectively as 
possible. An optimal policy will be harmonised with what individuals in the community can 
do to help themselves. 
 
Acceptable levels of resistance: when should the drug be changed? 
Various attempts have been made to establish resistance levels for changing malaria 
treatment policy. Some were based on parasitological resistance levels and others on 
treatment failure rates. Estimation parameters that included the cost of drugs, compliance 
and levels of parasitological resistance had the greatest effect on generating cost-
effectiveness ratios. For CQ, parasitological resistance (RIII) levels of 14- 31% have been 
suggested. (Sudre et al. 1992), while for treatment failures a cut-off of between 15% and 
25% was proposed for the switch from CQ to SP (Schapira et al. 1993). Others have 
proposed that a change should be made when the median duration of clinical response is 
no longer below 14 days and /or when haematological recovery is not optimal even with  
clearance of parasitaemia (Bloland et al. 1993). The WHO, while leaving the national 
programmes to establish an “acceptable level” based on the available options and financial 
position of the country, has proposed an upper limit of 25% failure as an indication for 
change (WHO 1994).  
 
Many questions remain. How should Tanzania set a cut- off level? Should the prevalence 
of RII or RIII resistance be considered, or the proportion of early clinical failures or of 
failures on day 14, or the use of cost-effectiveness assessments? The dynamic nature of 
the problem of resistance, and of the factors that contribute to its increase or decline, calls 
for a more dynamic assessment, taking into account all the factors that we have described 
above. Hence, the upper limit for changing policy should not simply be one number, but 
consider the efficacy of second and third-line antimalarials, together with other factors like 
treatment-seeking behaviour, public health impact, cost-effectiveness and the perceptions 
of health workers and policy makers. Decisions about limits should take into consideration 
the public health impact of resistance in terms of subsequent clinical episodes, effects of 
chronic infection like anaemia, severe disease and mortality. The availability of health and 
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demographic information systems in several African countries offers an opportunity to 
evaluate more rational approaches for setting upper limits in different epidemiological 
settings. A decision could be made to change the treatment policy for all the population, or 
different guidelines could be established for specific groups, for example women and 
children only. Such a policy would have its own unique implementation demands and must 
be considered in the light of the existing health infrastructure. In Tanzania, it would be 
logistically simpler to have a policy for all the population. 
 
The decision-making process 
 The decision-making processes involved in changing policies for malaria treatment do not 
show a uniform pattern. There are big differences from country to country in the structure 
of health systems, and in the levels at which decisions on malaria control are made. 
Furthermore, changes in policy and policy implementation rarely result from a linear 
process of generating research, laying out policy options, choosing between alternatives, 
and finally  evaluating the implementation of the selected option. Rather, changes come 
about through a process of iterative interactions among three “streams” of activity: defining 
the problem, suggesting solutions, and obtaining political consensus (Porter R.W.1995). 
After the generation of technical information, like data on efficacy, treatment-seeking 
behaviour, costs and cost-effectiveness, advocacy of the results to the stakeholders and  
those responsible for making decisions at various levels is required.  
 
In Tanzania, a harmonious system for the transmission of research findings to policy 
makers is still lacking. Researchers complain that their findings are not considered in the 
decision-making process, while policy makers complain that they do not get a simple, 
understandable version of the results to translate into action. A decision to change drug 
policy has important implications for the Ministry of Health, the pharmaceutical sector, both 
public and private, public and private health practitioners, and the general population.  
Therefore, it is vital that the interests and concerns of all stakeholders are taken into 
consideration by all those involved in the process.  
 
Case-studies - and the way forward  
In Thailand, chloroquine (CQ) was replaced with sulphadoxine/pyrimethamine  (SP) as 
first-line antimalarial in 1973. About ten years later, the efficacy of SP diminished, and a 
combination of quinine and tetracycline temporarily became the first-line treatment. Later, 
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this was replaced by a mefloquine-SP combination.  These changes were made when 
parasitological resistance at RI level was 15%-20% (WHO 1994). In Africa, CQ has been 
the drug of choice for more than forty years. However, in 1994 Malawi became the first 
country to replace CQ with SP, and it was later followed by  several other countries in 
Southern Africa, namely Botswana, Swaziland, South Africa and Kenya (White 1999).  
 
The decision to change the malaria treatment policy in Malawi was based on a comparison 
of the efficacy of CQ and SP.  In one study, 30% and 60% of children treated with CQ 
became symptomatic again by days 14 and 28 after treatment, but none of the children 
treated with SP were symptomatic during follow up. The improvement of haematological 
symptoms was significantly better in SP-treated than in CQ-treated children, and the RIII 
resistance level to CQ was 33%  (Bloland et al. 1993).  These data, together with others 
collected in 6 sentinel sites, formed the basis for changing the treatment policy.  The main 
parameters considered were the reduction of clinical response in a 14-day period, poor 
haematological recovery, and a high level of in vivo parasitological resistance to CQ. In 
Malawi, CQ was replaced with SP at all levels of care, and the use of chloroquine 
restricted to sales on prescription only. 
 
In Zambia in the 1990s, CQ clinical failure rate in six sentinel sites range from 31% to 48% 
with in vivo parasitological failure of 34% - 70% (using the 14 Day test, WHO 1996. SP 
tested in 2 sites indicate RII and RIII failures in 3% and 17% and only one case of clinical 
failure in at each site.  Based on these results it was decided to maintain CQ as firstline 
drug and promote the use of SP for all cases not responding to CQ.  SP was made 
available in all health facilities, whereas before it was available only on prescription and in 
hospitals (Barat et al. 1998).    
 
There is consensus among Tanzanians that the problem of the high morbidity and 
mortality associated with the use of CQ as first line therapy needs to be addressed as 
soon as possible. The epidemiological and other information gathered so far also supports 
the view that Tanzania is long overdue in changing its antimalarial treatment policy (Kitua 
A 2000). So  the question is not whether to change or not, but what the new standard 
treatment should be. In addition, clear guidelines need to be developed for deciding when 
the next change is necessary.  
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On the basis of the information currently available, an immediate switch from CQ to SP 
would be appropriate. Other drug options are not suitable either because of their costs 
(mefloquine, Halofantrine etc), or because only limited information is yet available on 
safety, cost benefit, ease of implementation and impact on epidemiological parameters of 
resistance (e.g Combination Therapy). It is certainly possible that the wide introduction and 
use of SP as a first-line treatment may compromise future strategies which are under 
development (Winstanley et al. 2000), and are dependent on antifolate compounds. These 
include the use of combinations of chlorproguanil and dapsone  (Lapdap) or SP with 
artemesinin derivatives. But the high morbidity and mortality now means that delay 
because of possible future implications is not warranted. Furthermore, there is hope that a 
different range of options will be available in the future. New, cheaper efficacious 
compounds may be developed by initiatives like Medicines for Malaria Venture, and under 
the Roll Back Malaria initiative there may be a drop in prices of available compounds, and 
new strategies for funding malaria control.  
 
Further work is needed on guidelines for malaria prophylaxis in children and expectant  
mothers in the new policy. The preparations for future policy revisions need to start now by 
developing new tools for assessments and decision making and refining available ones. 
For example, there is still room to improve on the costs and effects models and to validate 
them with the results of actual experience after the change of policy in Tanzania. New 
aspects of the health systems also need to be explored, for instance, the role of diagnostic 
and treatment strategies. For example, Integrated Management of Childhood Illness (IMCI) 
or the improvement of laboratory diagnosis of malaria. Improvement in diagnostic and 
treatment procedures may reduce unnecessary treatment and hence drug pressure.  
 
Further developments are required in identifying molecular markers of resistance, and 
developing the necessary technology (e.g. DNA micro-array techniques) to allow the 
monitoring of the development and spread of resistance in large epidemiological studies. 
Mechanisms need to be developed for the advocacy of the concerns of policy makers to 
scientists,  and the integration of these concerns in the research that is done. Ways must 
be found to identify solutions, and to create in all the stakeholders the political will to put 
them into practice. New strategies (e.g. combination therapy) need to be tested in the field. 
Lastly, training is needed to ensure that a “critical mass” of skilled personnel will be 
available to co-ordinate implementation, and maintain continuous monitoring of changes in 
all three dimensions – clinical, economic, epidemiological and health systems - over time.  
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It must also be remembered that as most malaria treatment is done at home, changing the 
first-line drug in the public health sector alone may not have a substantial impact. 
Promotion of SP alone at home, and restricting the use of CQ, might even be counter- 
productive because it might result in many cases of malaria not being treated at all. This 
might happen if SP is not perceived as efficacious, because although it is actually more 
effective than CQ its antipyretic effect is slower (Nyomongo 1999, Williams et al. 1999). 
Furthermore, though SP is commonly available in urban areas, it is not yet widely in 
available in rural areas (Nsimba 1999, Masele et al. 1998). However, if a new SP policy is 
implemented, the private sector can be expected to respond by making SP accessible 
even in rural areas. Information on SP and its appropriate use must be disseminated in the 
community and the private sector. 
 
Fears of  the inappropriate use of the drug on a wide scale, and an acceleration of the  
development and spread of resistance as a consequence, should not be ignored. Hence, a 
policy for home management and a suitable drug for use at home need to be developed.  
Ideally, the drug recommended for home use should be different from the ones used in the 
public sector. We propose that research be conducted to identify suitable compounds as a 
basis for home treatment. They should act rapidly, with high efficacy, low frequency of side 
effects and low potential for toxicity. The products would then be promoted and distributed 
mainly in the private sector using social marketing strategies. The distribution channels for 
home products should be investigated to enhance availability and correct use. Simple 
technology like blister packaging of the antimalarials may offer some solutions to the 
problem of incorrect use (WHO 1998). 
 
Having a different drug for home use would reduce the potential of development of 
resistance to the drugs that are used in health facilities. Furthermore, if the drugs used in 
health facilities were not available on the home market, people would feel it was 
worthwhile to attend health facilities. Mothers and guardians do not want to waste a lot of 
time and money at the formal health facility, only to be given a drug (e.g. chloroquine) 
which they can easily get from a shop (Minja H. personal communication). 
 
Chapter 10: Development of antimalarial policy 
173 
New treatment policies in practice 
Malawi and Zambia used different approaches for changing malaria treatment policy.  
Malawi has replaced CQ by SP as the first-line drug in all health facilities, and restricts the 
use of CQ by making available on prescription only.  Zambia has decided to maintain CQ 
as the first-line drug, and promote the use of SP for all CQ clinical failures. The Malawi 
approach has the advantage that operationally it is much easier; uniform health messages 
and information are disseminated to both the general public and clinicians. The approach 
is likely to cost about the same, and br ing a substantial public health gain. However, the 
widespread use of  SP may lead to a rapid spread of resistance 
 
The Zambia approach may cost less in terms of SP costs to the provider. This will depend 
on the proportion of patients who come for retreatment. It may cost more for the patient in 
terms of financial and opportunity costs, and the public health gain may be lower. It may 
be difficult for patients to comply with health messages, as it will not be easy for individuals 
or staff of primary health facilities decide when to change to SP. Furthermore, considering 
that the CQ failure rate is high in Zambia - more than 31%- 48% (Barat et al. 1998) -  so 
many patients will be treated with SP that in effect it will become the first-line drug. 
However, if CQ does continue to be used as well as SP, resistance to SP may spread at 
slower rate than in Malawi.  
 
Conclusion 
We have described a dynamic web of factors that need to be considered when reviewing 
policy. They are all interrelated. For example, changes in the health system and the 
economic situation may influence epidemiological pattern of the disease in a country, and 
the frequency of different forms of clinical presentation.  
 
Considering all the options available, replacing CQ with SP in all health facilities, and the  
promotion of SP with proper health message to improve compliance, is the most 
appropriate policy for Tanzania at present. However, the change should be regarded as 
temporary, and preparations for further changes should be made. The main challenge of 
the National Programme is to ensure that effective malaria treatment and protective 
measures like insecticide-impregnated nets are widely available to all the people. Only by 
using all the measures available to us can we hope to reach the goal of  “Roll Back 
Malaria”, of reducing malaria mortality by half by 2010. 
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CHAPTER 11 
 
Discussion 
 
Morbidity and mortality in the Kilombero Valley 
The studies described in this thesis confirm that malaria is a major public health problem in 
the study area. This is an area of very high perennial malaria transmission. Moderately 
severe anaemia was highly prevalent in young children before the start of the ITNs social 
marketing programme, with about half of all children found to be anaemic. Malaria 
parasitaemia prevalence was also high with 60% of children being parasitaemic. Initial 
mortality assessment in 1997 indicated that the children in the Kilombero valley had higher 
infant (95 per 1000) and childhood (14.3 per 1000) mortality rates (Schellenberg et al. 
1999) compared to the Tanzania National average in 1996 (Demographic Health Surveys 
1996).  These findings made it essential that better preventive and curative malaria 
strategies be implemented. 
 
Availability of treated nets 
The use of untreated bed nets mainly for protection against nuisance mosquito was not 
uncommon before the start of the project. Initial work done 1996 indicated that 37% of all 
households had at least one net. A few ITNs were also available from initial short-term 
projects and programmes including the Rotary project (Fraser-Hurt & Lyimo 1998), and the  
UNICEF Child Survival Protection & Development (CSPD) programme. But most of the 
nets that were in use in 1996 were old and some were badly damaged, thus they provided 
little protection. The initiation of the social marketing programme resulted in a replacement 
of the untreated net nets with treated nets and increased overall ownership of nets. 
Relatively good coverage of ITNs in the main target group (children and expectant 
mothers) was achieved in this programme. About 61% of children under two years 
(Abdulla et al. 2000a) and 52% of children under five years (Abdulla et al. 2000b) slept 
regularly under a treated net. Among pregnant women 53% were using ITNs in 1998-1999 
(Marchant et al. unpublished data). These findings are similar to results of earlier 
exploratory studies in same area, using similar delivery mechanisms (Fraser-Hurt & Lyimo, 
1998) and in neighbouring Burundi (Van Bortel et al. 1996).  
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The sales figures of “Zuia Mbu” products indicated a seasonal pattern that can be 
explained by both the abundance of mosquitoes and the availability of spare resources. 
The figures indicated high sales at the start of the main rainy season and at the end of 
harvest in September to October. A total of 65,000 ITNs and 25,000 insecticide sachets for 
retreatment were sold between mid-1997 and mid-2000 (Mponda H. unpublished data).  
The rapid uptake of the treated nets clearly indicates the existence of a substantial market 
for nets. Preliminary assessment of the willingness-to-pay and ability-to-pay for the socially 
marketed products indicated that the majority of the population was both willing and able to 
pay the prices charged (Schellenberg et al. 1999).  At the end of the two years only 17% of 
children under two were without any net. For this small proportion of non-users who can 
probably not afford a net, the existing welfare system could be used for assistance.  
 
Impact of ITNs on malaria morbidity in children 
The social marketing approach for distributing treated nets had a rapid overall impact on 
health outcomes in the community. The increase in the level of net ownership was 
accompanied by a decreasing prevalence of anaemia and malaria parasitaemia in the 
community. Overall, there was an improvement in mean haemoglobin levels in children 
under two years from 8.0 to 8.9 g/dl, and a reduction in the proportion of children who had 
haemoglobin of less than 8 g/dl  from 49% to 26%. A decline was also seen in the 
proportion of children with parasitaemia or splenomegaly. The treated nets had an 
apparent protective efficacy of over 60% on the prevalence of anaemia, parasitaemia and 
splenomegaly (Abdulla et al. 2000a). Furthermore, there was a gradient in protection with 
those owning ITNs having less anaemia compared with those with untreated nets. When 
age-specific malaria parasite prevalence rates in children under two years of age observed 
in the cross-sectional surveys in 1997-1999 were compared with historical data from 1991 
or 1993, it was clearly seen that children in 1997-99 had lower prevalences in all age 
categories, while not much difference was observed between 1991 and 1993. Hence it is 
likely that what was observed was a real decline in parasite prevalence and malaria 
disease, and not a difference due to long-term secular trends. These results over a decade 
increase the plausibility that the observed changes may be attributed to the intervention. 
The finding of an impact of ITNs on malaria morbidity in our studies further support the 
introduction and expansion of ITNs programmes to national level in Tanzania. 
 
There are indications that the social marketing campaign has managed to make ITNs 
widely available even to those who live on the edge of the inhabited areas, where it has 
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been suggested that the risk of malaria disease is concentrated. The lack of significant 
spatial structure in the distribution of ITNs in Idete village is likely to indicate a 
homogeneous spread of ITNs in this village (Abdulla et al. 2000c). However this 
assessment was done in a small area with a small population, and a repetition of the 
evaluation on a larger scale with a larger population is required. This was also suggested 
by the larger cross-sectional survey we conducted, which indicated that children living far 
from the centre of villages had a significantly lower proportion of bed net ownership 
(Abdulla et al. 2000a).   
 
ITNs in high transmission areas 
Our studies have shown an impact of ITNs in an area of very high year-round malaria 
transmission. Concerns were raised by some authors that the ITNs will reduce 
transmission, and in doing so delay the acquisition of functional protective immunity in 
children living in high transmission areas. Theoretically, this could then increase the 
frequency of occurrence of cerebral malaria as severe form of disease, and hence not 
change the overall mortality burden in these areas in the long-term (Trape & Rogier 1996, 
Snow et al. 1997, Marsh & Snow 1999). However, following the discontinuation of malaria 
control trials in the past, no evidence for a delay or a "rebound" in mortality was found 
(Molineaux and Gramiccia 1980, Bradley 1991, Greenwood  1997). Data from Burkina 
Faso also did not show such effects in children under five followed up for four years after 
the intervention (Diallo 1998). Further, the indirect evidence presented to support the idea 
of a delay in child mortality in areas of high transmission has been questioned (Molineaux 
1997, D'Alessandro and Coosemans 1997, Lengeler et al. 1997, Lines 1997). Recent 
analysis of mortality patterns of children under varied transmission intensity indicated that 
the long-term mortality burden in children living in high transmission areas is likely to be 
reduced by lowering transmission intensity, especially because of the reductions in infant 
mortality (Smith et al. 2001). It should also be recognised that transmission reduction 
through interventions will not necessarily result in a situation identical to naturally low 
transmission areas. The introduction of other measures for combating malaria and other 
public health problems will inevitably alter the environment within which the new and lower 
malaria transmission level exists.  
 
Although the current debate does not warrant delaying the implementation of ITNs 
programmes this issue needs to be addressed scientifically and monitored. To address 
this concern a long-term follow-up (over 5 years) of children protected under ITNs is 
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currently on going in several settings including in the Kilombero Valley (Schellenberg et al. 
1999, Smith et al. 2001). 
 
Treatment of uncomplicated malaria  
Antimalarial drug resistance is growing and spreading at an alarming rate. There are 
indications that the use of antimalarials for which resistance is wide spread increases 
mortality (Trape 1998). In Tanzania after reports of initial cases of resistance in 1978, an 
increase of admissions due to malaria but not other infectious diseases was observed in 
hospitals (Kilama and Kihamia 1991). Increasing chloroquine resistance in our study area 
was reported in 1980’s and early 1990’s (Koella et al. 1990, Mshinda et al. 1996). The 
results of our clinical study confirm the worry that chloroquine is no longer useful for the 
treatment of uncomplicated malaria in the study area, with only 35% of children having 
parasitological cure within 7 days of treatment (Hatz et al. 1998). Further work in Mlimba, 
an area 180 km away from Ifakara where the initial study was done, also showed similar 
levels of resistance (MOH 1999). This indicated that the problem of chloroquine resistance 
is wide spread and hence the need of an alternative antimalarial drug. 
Sulphadoxine/pyrimethamine (SP) was proposed as an alternative although resistance to 
this drug has also started to be reported in several places in Tanzania, with an average 
estimate of 14% treatment failures within 14 days (MOH 1999).  
 
The mechanisms of P. falciparum resistance to antimalarials are still not clearly elucidated. It 
is known that the resistant parasites accumulate chloroquine less avidly and it is now thought 
that the phenomenon is conferred by changes in p-glycoprotein pumps that are coded by 
genes in chromosome 7 of P. falciparum. Resistance to SP is highly associated with 
mutations in the genes that code for enzymes dihydrofolate reductase (DHFR) and 
dihydropteroate synthetase (DHPS) (Winstanley 2000). The development of resistance is an 
evolutionary adaptive process in the parasites which is related to the spontaneous mutations 
in the parasites and selection of parasites with resistance genotypes by antimalarials. The 
importance of drug pressure (related to the parasite biomass exposed to a particular drug) in 
the mechanisms of resistance is further illustrated by experiments comparing rate of 
resistance development for SP, which has a long half-life, and chlorproguanil-dapsone which 
has a short half-life. More rapid development of resistance was observed with the long half-
life drug (Nzila et al. 2000).  
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Lastly there is still a need for developing new compounds that have varied mechanisms of 
action, as the current armoury of antimalarials exploits very few targets in the parasite 
(Wistanley 2000). This leads to a high frequency of cross-resistance example between 
chloroquine and amodiaquine, or between pyrimethamine  and chlorproguanil. Most of the 
new compounds (such as chlorproguanil-dapsone) are old products that are put together.  
 
The focus of early diagnosis and treatment is to get the treatment initiated as quickly as 
possible after the malaria attack. Studies have shown that those children treated early in the 
attack have a better prognosis. Furthermore wide availability of antimalarials even at home 
was associated with low mortality in children (Trape et al. 1987). However wide-scale 
availability of drugs encourages the appearance of resistant parasites, by increasing the 
biomass of parasites exposed to the drug. For most of Sub-Saharan Africa a trade-off must 
be reached between wide spread use that meets the enormous need for antimalarial 
treatment with rational appropriate use that safeguards the useful life of the products.  
 
Several more efficacious alternatives than chloroquine exist, for example the fast acting 
artemisinins. The cost of these compounds is high at present but it is envisaged that the 
costs could be reduced, especially with local production (for example: Tanzanian 
plantations of the Africa Artemesia Company). The main limitation of these compounds is 
the high recrudescence rates that have been reported with short treatment regimens (for 
example 3 days). The use of combination therapy for malaria (CT), which entails combining 
an antimalarial with an artemisinin derivative, reduces the chances of this happening. The 
artemisinin will lower the parasite biomass and hence reduce the bulk of spontaneous 
mutations in the parasites that are exposed to the selection pressure of the second drug. The 
ideal situation is to combine two drugs with (1) a short half-life, (2) different mechanisms of 
action, and (3) which have synergistic effect and matching pharmacokinetic profiles (White 
1999). These CT treatments are usually more effective and are believed to have the 
additional advantage of delaying occurrence of resistance or even reducing transmission 
(White et al. 1999). Our results indicate that the combination of Artemether and 
Benflumetol (Co-artemâ) was very effective in treating uncomplicated malaria with about 
94% children having good clinical response within 7 days (Hatz et al. 1998). This 
combination was also found to be very safe and well tolerated in all the studies conducted 
so far (Bakshi et al. 2000). Other new compounds that are under development include 
chlorproguanil-dapsone which promises to be relatively cheap and has very short half-life 
and hence is unlikely to select for resistance (Winstanley 2000).   
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The decision on the choice of drug to be used for a particular country depends on a 
number of clinical, epidemiological, social economical factors, including also the health 
infrastructure. Consideration of all these factors allowed the identification of SP as an 
interim drug to be used as the first line therapy at health facilities in Tanzania (Mshinda et 
al. 2000). However, there is a worry that resistance to SP will rapidly develop as was seen 
in South-east Asia (White et al. 1999). Furthermore, compared to chloroquine it has no 
antipyretic activity, a factor which may give patients a feeling of poor response to 
treatment. Therefore, evaluation of other compounds and strategies including CT are in 
progress to get a long-term solution for the treatment of malaria in the formal health 
facilities.  
 
 
The assessment of care at the household level, however has not been adequately looked 
into. This will entail having a product that is safe enough to be used repeatedly, with a 
rapid mode of action and a short half-life such that it induce have limited resistance 
selection. It will be wise to select a particular type of compound to be used at home and a 
different type with a different mode of action to be used at formal health facilities. Firstly, 
this will help to prevent the rapid selection of resistance to compounds used in the formal 
facilities, and secondly mothers will be encouraged to visit health facilities, if they know 
that the facilities provide medications that are not usually found at home. The 
implementation of such a home treatment strategy could then use social marketing 
techniques and organisational structures similar to what has been described for ITNs. The 
identification of a suitable branded product that will be promoted at home can be done with 
involvement of both the private and public sectors, including the national malaria control 
programme (NMCP). 
 
ITNs and efficacious drugs for malaria control in Tanzania 
Control of malaria in Tanzania requires a multi-sectorial and multi-disciplinary approach. 
Similarly, a combination of control strategies will be required to contain the problem of 
malaria. It is recognised that the use of ITNs confers only a risk reduction and not a risk 
elimination and effective treatment of cases of malaria is still required. Unfortunately, we don’t 
have a better protective measure to-date. Candidate malaria vaccines are still a long way 
from being ready for wide-scale use. The overall transmission impact of the ITNs 
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programmes combined with appropriate use of an effective antimalarial may be dramatic if 
drugs such as artemisinin are used, as they may have an effect on transmission through their 
anti-gametocyte activity (White & Olliaro, 1998). Furthermore, ITNs may help in the effort of 
reducing the rate of development of antimalarial resistance by limiting the spread of the 
parasite, and therefore further enhance malaria control (Molyneux et al. 1999). 
 
Evaluation of control tools 
Studies described in this thesis give a good overview of the issues and approaches involved 
in the evaluation of interventions. The randomised clinical trial of Co-artemâ was a Phase III 
evaluation where the main concern was to assess safety and efficacy under ideal conditions.  
Before this stage of evaluation the drug had been tested in animal models and volunteers to 
establish biological activity and safety for experimentation using human subjects. The high 
efficacy demonstrated in our study indicates that Co-artemâ merits consideration as a 
suitable tool for implementation on a large scale for treatment of uncomplicated malaria. 
However, further Phase IV or implementation programme evaluations are needed before 
wide scale use can be advocated. Such programme evaluations are now being emphasised 
(Habicht et al. 2000), because the results of the phase III can not be easily translated in 
programme settings (Lengeler & Snow 1996). The coverage and compliance to treatment 
may be different in the routine use, and hence limit the effectiveness of the drug. Other 
factors related to the implementation of the intervention may also be markedly different from 
the randomised study. In Tanzania the majority of clinical cases of malaria are treated by 
semi-qualified personnel in dispensaries, using diagnostic algorithms rather than definitive 
diagnosis by microscopy (Massaga et al. 1999). Furthermore, the study population in Phase 
III is too small to be able to detect adverse effects which are rare, or take some time to 
manifest.  Lastly, implications and interactions with other existing strategies is another 
concern that may be important to observe in a programme setting. Hence a careful 
assessment of the effectiveness, cost-efficiency, implementation strategy and the particular 
environment has to be made in order to ensure efficient and appropriate use of the drugs. 
 
The many issues with phase IV evaluations are illustrated with the studies conducted to 
assess impact of ITNs. The ITNs evaluations were mainly aimed at demonstrating that the 
expected benefit of the intervention is retained when the intervention is delivered in a less 
controlled way. These studies highlight important issues for the evaluation of programmes. 
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Two methods of assessment were employed: cross-sectional and case control studies. 
Impact of ITNs was demonstrated using the cross-sectional approach but not the case-
control approach. Attendance bias was the likely explanation for this difference, as those with 
ITNs attended more frequently for all the preventive and curative services offered at the 
dispensary (Abdulla et al. 2000b). It is likely that this observation can be explained by the 
high awareness of health issues and higher tendency to seek care at the dispensary for 
those owning ITNs, rather than more disease in this group.  
 
Furthermore, the case-control approach was thought to be simple in its design and execution 
but in our study it proved to be difficult to implement and took a long period of time (over 18 
months). The advantage of small sample size of the case-control approach is lost when 
evaluating a common disease like malaria. There is also a difficulty of finding suitable 
controls. Therefore, it is unlikely that persons with limited resources and skills in 
epidemiology, computing and database management, can repeat such an investigation. This 
makes the approach unsuitable for recommendation as a tool for routine programme 
evaluation.   
 
The studies also highlight the need of collecting several pieces of information in order to get 
an elaborate picture of the effect of the intervention in the community. Our evaluation of ITNs 
involved repeated cross-sectional surveys and case-control studies. A comparison was also 
made with historical data collected a few years earlier which showed a lowering of 
parasitaemia prevalence after the ITNs social marketing programme was implemented.  
 
The choice of appropriate study subjects is another crucial issue. ITNs work by reducing risk 
of infection and transsmission of malaria. The effects of this reduction are more likely to be 
observed in very young children (McElroy et al. 1994). For example, it has been observed 
that variations in transmission strongly affect the estimates of morbidity and mortality in very 
young children (Molineaux & Gramiccia, 1980). Therefore at a given transmission intensity, 
the age of the study participants is crucial in determining the level of protection. Our finding of 
high impact in children under two years of age is in line with other studies that included very 
young children (see Abdulla et al. 2000a for details).  Hence our studies were mainly focused 
in children for whom the impact was expected to be apparent. Furthermore, in this group the 
burden of malaria anaemia is concentrated, hence they are more likely to benefit from the 
intervention.  
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Prevalence of anaemia as the main indicator in our studies was chosen as this is an area of 
high transmission, and malaria-associated anaemia is a major problem. It has been 
demonstrated that 60% of the anaemia in infants is due to malaria (Menendez et al. 1997). If 
such evaluations were conducted in an area of low transmission prevalence of parasitaemia 
may be more appropriate, as was done in Afghanistan (Rowland et al. 1997) 
 
A decreased risk of admission to hospital for malaria was observed in children not using 
ITNs and living in areas with high ITNs coverage, compared to those in the control areas 
(Howard et al. 2000). This indicated that some protection is being conferred to those 
without nets and those with untreated nets. Therefore, the results of effectiveness 
evaluation in a programme will be reduced toward zero in high coverage rates, and it will 
therefore be very difficult to demonstrate impact (Abdulla et al. 2000b). It is often argued 
that it is essential to achieve very high ITN coverage in order to get the full benefit of ITNs 
(Lines, 1997). In our studies impact was observed even when the coverage was far from 
100%.  We could not assess changes in the observed impact at different coverage levels 
due to the small study population.   
 
Lastly, for both the case-control and the cross-sectional approaches the main comparison 
was between those who have adopted the intervention and those who didn’t. This is because 
of the lack of a contemporaneous control group in this programme setting. In this 
circumstance some control of confounding is performed in the analysis but there may still be 
some residual confounding. The measures used to control for confounding factors like social-
economic status and health seeking behaviour may not be sensitive enough. The lack of a 
simple test to check for insecticide content of the nets (Drakeley et al. 1999) meant that 
this could not be verified as suggested by work in The Gambia (Muller et al. 1994; 
D'Alessandro et al. 1997). The reliance on reported ownership of ITNs meant that some 
misclassification was possible (Abdulla et al. 2000a). It can also be argued that those who 
adopt ITNs differ from those who don’t by some unidentified factors that make their risk of 
getting malaria disease lower, hence causing an overestimation of the impact of ITNs.  
 
It should also be recognised that the comparison of those who adopt versus those who don’t 
essentially estimates the health benefit conferred to those who adopted the intervention, 
rather than how much the health outcomes have improved in a particular setting, estimated in 
control trials (Kirkwood et al. 1997). Therefore, the results of the randomised controlled trials 
can not be directly compared with the results of programme evaluations, unless there is a 
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control group as was the case in the Gambia (D’Allessadro et al. 1997). Inevitably specific 
indicators and programme evaluations approaches will need to be identified for different 
interventions. The results and indicators used in the Phase III trials may be different from 
those used in the Phase IV trials, and a direct comparison of the results of these two levels 
of evaluation cannot always be made. However, estimation and calculation of the cost-
effectiveness or cost-benefit of reducing the burden of disease, especially using anaemia 
as an indicator can be done in both (Goodman et al. 2000).  
 
Theoretically, it would have been advantageous to have a contemporaneous control group 
in our evaluations. One can argue that we could have implemented the ITNs in one district 
and observed the other as control. However, the problems with this design are many. 
Firstly, there would have been a variable uptake of the ITNs in the intervention area and 
possible leakage of nets into the control area. Secondly, it should be considered unethical 
to withhold an intervention with a proven benefit to a population, especially if mortality is 
evaluated. Finally, there are difficulties of comparability in an ‘intention to treat’ analysis of 
one intervention versus one control cluster. In this situation, analysis comparing those with 
ITNs and those without ITNs in the two areas will be similar to what we have done 
comparing adopters and non-adopters in the same area. An extension of such an idea is 
to have several clusters were the intervention is applied and several control clusters hence 
introducing some element of randomisation in the design. This also has the problem of 
variable uptake and possible “contamination” mentioned above. But it also has far larger 
cost and logistic implications since a large enough number of clusters is required for the 
analysis (Kirkwood et al. 1997). Social marketing of ITNs cannot be efficiently done at 
household or village levels and large units are therefore required.  All these alternative 
approaches are less practical and will not usually be possible in many implementation 
programmes. Most programme implementers want to spend their money on implementing 
programmes rather than pay for elaborate evaluations. Therefore more research is required 
on simple methods and tools for programme evaluations. 
 
Improved biomedical monitoring and evaluation tools  
The assessment drug efficacy in clinical trials can also be improved. In areas of high 
transmission, the presence of parasites in peripheral blood cannot be taken as a proof of 
failure of the therapy. Microscopy can readily determine the parasite species and densities 
but can not distinguish between recrudecences and re-infections. The addition of 
molecular aids like polymerase chain reaction with restriction fragment length 
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polymorphism (PCR-RFLP) allows such distinctions and hence improves the evaluation of 
antimalarial drug efficacy (Irion et al. 1998). 
 
More important is the role of such molecular techniques in the evaluation and monitoring of 
treatment strategy in malaria control programmes.  Much work has gone in the delineation 
of the mechanisms by which parasites become resistance to antimalarials. The 
identification of markers of resistance can help in the explanation of problems in therapy 
but also as tools for assessing the performance of treatment strategy at population level. 
Examples are the mapping of the extent of the potential SP resistance problem in 
Tanzania using DHFR and DHPS mutations as markers (Mshinda H. pers. Comm). And 
the use of the same makers to detect the effect of artemisinin derivatives in a combination 
therapy strategy to delay the occurrence of resistance in a programme setting (Bloland P. 
pers. Comm). Additional approaches are still required to get the translation of evaluation 
results into policy. This entails compiling and summarising relevant information, as was 
done by modelling the effectiveness and cost-effectiveness of different malaria treatment 
strategies and drug regimens in Tanzania (Abdulla et al. 2000d).  
 
From research to policy implementation 
The results of all these evaluations are only relevant if the information is received by the end 
users (i.e. policy makers) and relevant policies are formulated. Policy makers need to be 
involved in the whole process of research from formulation of the relevant research questions 
to choosing the appropriate evaluation methods and implementation of the evaluation. Part of 
this is also establishing a good communication between the different stakeholders (Porter & 
Prysor-Jones 1997). The revision of the antimalarial treatment policy in Tanzania illustrates 
these issues. Research scientists had produced data that indicated that chloroquine was no 
longer a useful drug for treatment of uncomplicated malaria in Tanzania already in the 
1980’s. But the information was not well communicated to those who have the mandate to 
revise the National Policy. The review of the antimalarial treatment policy was initiated only 
after the policy makers were involved in the evaluations and provided with information that 
they required: representative antimalarial efficacy data from many parts of Tanzania (MOH 
1999), and data on the cost implications of policy change (Abdulla et al. 2000d).  
 
For the ITNs evaluations the policy makers and health managers both at local  and national 
level were involved in the all the steps of the evaluation. Members of the District Health 
Management teams participated in regular planning meetings of the KINET project 
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implementation. Progress of the implementation was also communicated to the National 
Malaria Control Porgramme. Hence, there was a smooth move towards using the experience 
gained at implementing small district wide projects towards setting a plan for national 
implementation of ITNs (MOH 2000).   
 
The up-scaling of an ITNs implementation strategy inevitably require the presence of other 
partners. Hence a completely different framework is required in which both public, non-
profit, and private institutions participate. The issues of how best to introduce the treated 
nets in a wide scale are then to be discussed and the strategies tailored to the specific 
circumstances of the country or region.  Sustainability of these malaria control initiatives 
make it necessary that they are integrated and recognised within the formal health system, 
resulting in a commitment at all levels of government and non-governmental organisations .  
 
In Tanzania, much experience has been gained with the implementation of small projects. 
They had the dis-advantage of being small and were heavily subsidised. Subsidy allows 
equitable access to the ITNs for the majority of the population in rural areas who are 
generally poor and may not be able to afford the commercial prices of the ITNs. However, 
it introduces dependency on external support and limits the development of the 
commercial market for the ITNs. ITNs can be considered as a public health intervention 
and therefore the Government and its partners and supporters should contribute towards 
the implementation of the strategy. Virtually no other intervention in preventive health is 
entirely self-supporting: if ITN programmes are (1) feasible on a large scale and (2) 
efficient through low delivery cost per net or per treatment, they should be able to attract 
sufficient donor support in the context of the "Roll Back Malaria" initiative (Lengeler 1999). 
There are several ways that can be done to encourage the commercial market despite an 
element of subsidy, especially if it is a subsidy limited to specific target groups. These 
experiences and considerations then broadly categorise the roles of the different 
stakeholders in ITNs implementation. The private and commercial sector produce and 
distribute the ITNs, and the public sector promotes the growth of the market, encourages 
uptake of ITNs in communities, and ensures some level of equity.    
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Conclusion 
Malaria control in the Kilombero Valley and Tanzania as whole requires improvements in 
both preventive and curative strategies. ITNs distributed through a social marketing 
programme setting were effective in reducing malaria morbidity, and plans are under way to 
implement the strategy nation wide. There is an urgent need to implement revised 
antimalarial treatment guidelines using SP as the first line drug. At the same time, continue to 
evaluate new drugs including Co-artemâ in a programme setting, and try out new strategies 
such as combination therapy. The tools and instruments that assist in the monitoring and 
evaluation process, including molecular tools, need to be developed too. 
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